Structural and biochemical studies of PCNA and its molecular interactions by Ludwig, Cornelia
Structural and biochemical studies of PCNA 
and its molecular interactions 
A Thesis 
Submitted for the Degree of 
Doctor of Philosophy 
by 
Cornelia Ludwig, B.Sc. 
0 
Structural Biochemistry Group 
Institute of Structural and Molecular Biology 
University of Edinburgh 
August 2008 
~r~k 
Summary of Contents 
Title j 




List of Abbreviations vii 
Table of Contents viii 
List of Figures xi 
List of Tables xiii 
Chapter 1 Introduction: The structure of PCNA and its homologues 1 
Chapter 2 Crystal structure and biophysical characterization of 
Schizosaccharomyces pombe PCNA unliganded and in complex with a 
human p21 peptide 37 
Chapter 3 A structure-based approach to find inhibitors for PCNA as 
an anti-cancer drug target 95 
Chapter 4 Interaction of PCNA with Gadd45 135 




Proliferating cell nuclear antigen (PCNA) plays a key role in DNA replication and 
repair. It also interacts directly or indirectly with proteins involved in cell-cycle 
control. These proteins include p21, a p53-regulated association control factor with 
check point function, and p53-regulated Gadd45, which plays an important role in 
the cell cycle G2-M checkpoint. There are a number of structures currently available 
for the trimeric ring-forming PCNA family of proteins found in eukaryotes and 
archaea as well as those related PCNA-like sliding clamps in prokaryotes and 
viruses. However, despite the great similarity between the PCNA and sliding clamps 
it is important to increase the understanding about these proteins from other 
organisms, in particular model organisms such as Schizosaccharomyces pombe. 
Structural comparisons highlight a well conserved hydrophobic binding pocket 
involved in protein-protein interactions, which is found in all PCNAs and other 
sliding clamps. Previously this pocket has been identified as a potential druggable 
target for the development of new anti-cancer, drug leads due to the central role of 
PCNA in the cell-cycle. Proteins that bind to this pocket contain all or part of the 
conserved PIP-box motif (Q-x-x-h-x-x-a-a). 
In this thesis I have determined the crystal structure of S. pombe PCNA on its own 
and in complex with a peptide derived from human p21. This peptide was found 
previously to bind to SpPCNA despite there being no homologue of p21 in fission 
yeast. These crystal structures of SpPCNA confirmed structural similarities in 
comparison with human PCNA, but also hints at differences between the two species 
in terms of the hydrophobic pocket and ligand binding modes. 
111 
Using the p21 peptide as a template, chemical libraries were screened for small drug-
like molecules that are able to mimic the protein-protein interaction between human 
PCNA and p21 and were tested for binding using various fluorescence-based 
methods. Binding of selected compounds could not be observed, however, which 
may have been due to poor solubility of the compounds as well as a lack of assays 
sensitive enough to pick up on ligands with low affinity. 
Not all direct PCNA binding proteins bind to the above mentioned pocket and 
PCNAlprotein co-crystal structures of these examples without the PIP-box motif are 
not available so far, so information on the mode of binding in those cases is not 
accessible yet. One objective was, therefore, to narrow down and characterize the 
PCNA binding site of Gadd45. This protein does not contain a PIP-box motif, but 
previously was shown using yeast-two hybrid technology to bind directly to PCNA 
via its C-terminus. In vitro binding of the two full-length proteins could not be 
confirmed, due to the inherent instability of Gadd45, which also has been reported by 
others. GST-tagged truncations of the C-terminus of Gadd45 were expressed and 
purified and binding to PCNA was studied using SPR. These result are at odds with 
the published binding data and suggest that either the interaction between PCNA and 
Gadd45 is not direct and needs to mediated by a third factor. Alternatively, Gadd45 
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CHAPTER 1. Introduction: The structure of PCNA 
and its homologues 
1.1 GENERAL STRUCTURE 
The ring-shaped PCNA (proliferating cell nuclear antigen) is probably best known 
as the processivity factor of the DNA polymerase ö in eukaryotes, however, it is 
involved in a number of processes of DNA metabolism, such as DNA damage repair 
(Maga and Hubscher, 2003; Paunesku et al., 2001). Eukaryotic PCNA encircles 
DNA as a homotrimer. Its ability to slide along DNA explains why it is also called a 
'sliding clamp' (Figure 1-1). However, proteins with related functional and structural 
similarities are also found in prokaryotes and viruses, but are usually only referred to 
as sliding clamps, rather than PCNA (Table 1-1). 
The first evidence for the structure of sliding clamps came from studies in 
Escherichia coli. Stukenberg and colleagues (Stukenberg et al., 1991) carried out 
experiments with 3 sliding clamps on both circular and linear DNA molecules and 
found that the protein bound stably to circular DNA, but dissociated readily from the 
linear form. This finding shed new light on the way the protein binds to DNA by 
encircling the double helix. Further evidence for the overall structure of PCNA-like 
proteins came from T4 phage sliding clamp g45 (Gogol et al., 1992) and electron 
microscope pictures suggested that DNA was threaded through this ring-shaped 
molecule. 
Indirect evidence for the structure of PCNA came from Burgers and Yoder (Burgers 
and Yoder, 1993), who showed that in the absence of Replication Factor C (RFC), 









was used as the substrate. Tinker et al. (Tinker et al., 1994) found that hPCNA could 
only be cross-linked to circular DNA. Previously, Kong et al. (Kong et al., 1992) 
solved the crystal structure of the 13  sliding clamp of E. co/i which proved the validity 
of previous claims about the structure-function relationship in these proteins. Their 
structure showed a homodimeric ring with an inner diameter of-35A, big enough to 
let double stranded DNA pass through. 
LU 
Figure 1-1 Crystal structures of human PCNA and its homologues. 
A) human PCNA, PDB ID: 1VYM (Kontopidis et al., 2005) B) Archaeoglobusfu/gidus PCNA, PDB 
ID: 1RWZ (Chapados et al.. 2004) C) Escherichia co/i 13  subunit of DNA polymerase III, PDB ID: 
2POL (Kong et al., 1992) D) bacteriophage RB69 gene 45 protein, PDB ID: 1B77 (Shamoo and 
Steitz, 1999) Apart from the Escherichia co/i 13 subunit all sliding clamps show the trimeric 
configuration. The overall 3D structure, however, remains similar in all four examples from across all 
domains of life including viruses. 
2 
An alignment of phage, E. coli, archaeal and eukaryotic PCNA secondary structure 
elements showed a high degree of structural conservation (Figure 1-2), but almost no 
similarity in sequence. 
Species PDB 
Number of 
amino acids in Resolution Complexed Code in A with Author monomer  
human 1VYM 261 2.3 naive (Kontopidis et 
al., 2005) 
human 1AXC 2.6 p21(141-160) (Gulbis et al., 
1996) 
human 1U76 2.6 Pol 8 (453- (Bruning and 
465) Shamoo, 2004) 
human 1U7B 1.88 Fen-1 (336- (Bruning and 
348) Shamoo, 2004) 




1PLQ 258 2.3 native 
(Krishna et al., 
cerevisiae  1994) 
Saccharomyces 
1SXJ 2.85 
RFC hetero- (Bowman et 
cerevisiae  pentamer al., 2004) 
Archaeoglobus 
1RWZ 245 2.0 native (Chapados et fulgidus  al., 2004) 
Archaeoglobus 
1RXZ 1.8 Fen-1 (326- (Chapados et fulgidus  336) al., 2004) 
Pyrococcus 
1GE8 249 2.1 native (Matsumiya et furiosus  al., 2001) 
Pyrococcus 
1ISQ 2.3 RFC (469- (Matsumiya et furiosus  476) al., 2002) 
Escherichia 
2POL 366 2.5 native (Kong et al., coli  1992) 
Escherichia 
10K7 1.65 0l 
IV (345- (Burnoufet al., 
coli  351) 2004) 
T4 1CZD 228 2.45 native (Moarefi et al., 
2000) 
RB69 1B77 228 2.1 native hoo and 
Steitz, 1999) 
RB69 1B8H 3.0 pol (893-903) 
(Shamoo and 
Steitz, 1999) 
Table 1-1 List of selected sliding clamp X-ray structures deposited in the PDB till March 2006. 
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C, C-Loop 	D1 
hPCNA 5EAF.LVQiY1L.Y. :DLI 	 - NE C DISSSG 	QsnSSHVrL;QTLRSmFDTyRCDsN 65 
afPCNA VU DVIMTG: 	: -. LV--------- ---RILEKGL{SRAVDPANVA1!JIvDIpK: 	- EVYIDEE- 63 
3subunit -MKFTVEREK ------- 64 
gp45 ----MKLS 	 IN ---------- SGILLSQGKFLMTRAVN --- GT'I'YAEANISDEI-DFD -----  51 
F1 	oB 	 OG , 	OH, b.s.loop 	 IDCL 
hPCNA LMGVN-:: 	ZKCAGN- 	I ITLhAEDNADTLLVFEAmQEKVSDYKLMDLDVEQLGIPEQEYS- 134 
a fPCNA vrrlG 	:FC-- ~- .*~ SISTK-DLVEL IVEDES-TTicvxFG ------- SVEYKVALIDPSAIRKEPRIPELEL 126 
1suburiit ATTVPARKFFDILV TLPEGAEIAVQLEGE-LvFsGR ------  - RFSLSTLPAADFPNLDDWQSE--- 126 
gp45 VALYD:NCFLSILSLVSDDA- -- EISM}!TDGN - :KIADTR------ --WWPAD:TIVFPNKPIQFPV-- 111 
cxA 	 C 2 	 BD2 	b.s.loop 
human VvIQ4P- :FAs: 	i 	IG ---------- DAVVISCAKOGVKFSAS ------- GELGNIKLSQTSNVDK 190 
afPCNA PAKIVMD-\ 	 IS --------- DQVIFRSDKEGFP.IEAK -------  GDVDSIVFHMTETELIEF 183 
csubunit -VEPrLPQA- IM: 	QFSHQDVRYYLNLFETmEELRTVAT -------  DGHRLAVCSMPIGQ- --- 187 
gp45 ASVITEIKAEDL( Ccl -------- DTIAIPNIGIKIVINC.YNKVEDSGLTRpKYsLTLTDyS-- 175 
E, 	F2 	 G2 	 5H2 	I2 
human EEEAVT IEMNEPVQLTFA:::, 	: i(ATPLS- S-TVrLSSADVPL 	EYYIADMGHLKYYLP2KIEDEEGS- 261 
afPcNA NGGE -------- -\SMFSCrrE GsG-D-LLT:HLGpNypvRLvFvGGRAKvsyILApRIEsE--- 245 
Psubunit ---------SLPSHvIvPR 	 LDGGDNPLRV:G-SN--NIRAFiVG----DFIFTSKLVDGRFPDY 245 
gp45 ----------  NNFNF1:N---:MKIQP -----  GNYKVMLWGAGDKVAAKFESSQVSYVIAMEADSTHDF-- -- 228 
1A3 	 3B3 	C3 	 BD3 
human 
afPCNA 
3 subunit RRVLPKNPDKHLEAGCD:LY :Y;.i-AILSNEKFRGVRLYVSQLKI TANNPEQEEAEEILDVrYSGAE 315 
gp45 
3F3 	 G3 	H3 	5,3 
human 
afPCNA 
Psubunit 	 NV 	ALKCET.C'TDSVSSDAASQSA..Y?VMPMRL 	 366 
gp45 
Figure 1-2 Alignment of the sequences of the domains of human PCNA, A. fulgidus PCNA, E. 
coli i subunit and RB69 gene 45 protein. 
Although these proteins come from different domains of life (as well as viruses) and bear no 
significant sequence conservation, the arrangement of secondary structure elements (red = (x helix, 
green = 13 strand) is highly conserved among sliding clamps. The most important loops have been 
labelled in blue, where C-loop = Centre Loop and b.s. loop designates loops placed on the back side of 
PCNA. 
Since then it has been shown by various groups that the structure of sliding clamp 
proteins is indeed highly conserved in all three domains of life as well as viruses. In 
all these different organisms the function is similar and in each case a ring shaped 
trimer (or dimer) formed by smaller monomers provides the structural motif (Figure 
1-1) (Chapados et al., 2004; Kong et al., 1992; Kontopidis et al., 2005; Shamoo and 
Steitz, 1999). In eukaryotes the sliding clamps are homotrimenc doughnut-shaped 
molecules with each subunit in human PCNA weighing about 29kDa. In E. co/i a 
larger gene product leads to the formation of a dimeric ring with each monomer 
contributing 41 kDa. 
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The PCNA family has an overall excess of acidic residues, which gives them a low 
p1 (Kelman and Odonnell, 1995a) (Figure 1-3). The distribution of charge is 
asymmetric, with strong negative potential on the outer surface of the protein, which 
might aid the prevention of non-specific interactions with DNA. There is a net 
positive electrostatic potential at the central cavity (Kong et al., 1992; Krishna et al., 
1994). 
'~ 41 
._I•_ 1r,rw_lrI '.4.. 
Figure 1-3 Surface charge of human PCNA. 
Right: C-side, left: back side. The central cavity is predominantly lined by basic residues, where the 
remaining surface is rather covered in acidic residues. Overall a negative electrostatic potential 
predominates. 
PCNA trimers show an approximate six-fold symmetry like the E. coli dimer. Each 
monomer contains two globular domains which are made up of two 
pseudosymmetric domains following a Papop motif Hence each domain of the 
tnmeric subunit consists of two a helices, which coat the central cavity (Figure 1-1) 
and a continuous layer of nine anti-parallel f3-sheets and leads to the formation of a 
two-layer structure. All together, twelve helices line the central cavity (Figure 1-1), 
which has a diameter of 34A in hPCNA wide enough for B-DNA to fit through 
(Gulbis et al., 1996; Krishna et al., 1994). 
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In a number of DNA binding proteins a helices are placed in such a way as to fit into 
the groves of DNA (Warren, 2002). In PCNA the helices are arranged perpendicular 
to the phosphate back bone, which makes this an unusual recognition mode (Kuriyan 
and Odonnell, 1993; Odonnell et al., 1993), and basic residues on these helices are 
used to recognise and bind DNA (Krishna et al., 1994). The importance of these 
residues has been shown by mutation studies, which showed that removal of any of 
these basic side chains leads to down regulation of DNA synthesis by the appropriate 
polymerase. The proper distribution of positive charge seems to be rather crucial 
(Fukuda et al., 1995). 
Trimeric PCNA forms a stable complex with DNA in solution down to a 
concentration of 20nM. At lower concentrations it dissociates into monomers and 
dimers (Podust et al., 1995). As one can see in Figure 1-1 the basic architecture of 
the sliding clamps is the same, which also holds for bacteriophage clamp gene 45 
protein. In RB69 and T4 the ring is also a trimer with an internal diameter of about 
35A, but has rather a triangular appearance. The structural irregularities make it less 
stable than ScPCNA or the 3 clamp and it only manages to stay bound to DNA in the 
presence of the polymerase in contrast to hPCNA, which independently binds DNA 
once it is loaded (Yao et al., 1996). 
1.2 THE TWO FACES OF PCNA 
As mentioned above PCNA and its homologues are rather acidic proteins with pls of 
4.59 in budding yeast (Krishna et al., 1994), a p1 of 5.38 in the 0 subunit of E. coli 
(Kong et al., 1992) and a p1 of 5.05 in the T4 bacteriophage gp45 (Moarefi et al., 
2000), which has a 77% sequence identity with the closely related bacteriophage 
1 	\ 
A 
D2- E2 fl 
PHr1j 
RB69 gp45 (Shamoo and Steitz, 1999). A colour-coded representation of the surface 
residues in Figure 1-3 shows clearly how both front and back side of the ring are 
covered mainly covered in acidic residues save for the central cavity where a few 
lysines and arginines create the positive charge. Despite the similar charge 
distribution the front and backside are very different in terms of structure due to the 
head-to-tail conformation of the monomers. A number of loops extend from the core 
fold as can be seen in Figure 1-4. The back side has a number of prominent loops 
which connect adjacent anti-parallel 3 strands sticking out into the solvent. The two 
main ones here are D 2-f3E2 and H,-I 1 (Figure 1-2). 




- 	C-terminus  
C-loop 
A) C-side: Highlighted in red are the IDCL, the Centre Loop and the C-terminus on the B) Backside: 
Marked in red are the two long loops in each monomer C) Side view of PCNA: The loops on the 
backside marked in green are protruding into the solvent, while the loops in red on the C-side stay 
fairly close. 
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The other side of PCNA, termed the C-side due to the featured C-terminus, is 
especially marked by the interdomain connector loop (IDCL, residues 121-132 in 
hPCNA). In ScPCNA the 13D2-13E2 loop and IDCL are highly antigenic and already in 
the early nineties were predicted to be involved in interactions with other proteins 
(Brand et al., 1994; Roos et al., 1993). Interestingly, a range of proteins in 
hyperthermophilic archaea like Pyrococcus furiosus and A. fulgidus have been found 
to contain shorter loops in comparison with homologues from eukaryotes (Chapados 
et al., 2004; Jaenicke and Bohm, 1998; Matsumiya et al., 2001; Vogt and Argos, 
1997). 
This difference is thought to increase heat stability of those molecules and is also 
observed in PCNA. In P. furiosus particularly loops 13D 2-f3E2 , 13H1-1311 as well as the 
C-terminus are significantly shorter. 
1.3 THE INTERFACE CONTACT BETWEEN MOLECULES IN THE 
TRIMER 
In sliding clamps the monomers are joined head to tail to form a ring. The internal 
interface consists of two 13-sheets of two domains from different monomers (13D2 and 
1312). Furthermore there is a hydrogen bond network which might be important for the 
orientation of the monomers at appropriate angles. For example, hydrogen bonds in 
hPCNA between G1u109 - Ser183, Vallil - Lysl8l, Asp113 - Asn179, G1u115 - 
Asn177 and Lysi 17 - Leul7 link two anti-parallel 13-sheets of two adjacent 
monomers (Figure 1-5). Between the backbone of analogous residues seven 
(ScPCNA) or eight (hPCNA) clustered hydrogen bonds are formed as can be seen in 
both yeast and human crystal structures (Gulbis et al., 1996; Krishna et al., 1994) 
(Table 1-2). Mutation studies with those residues have shown that they are very 
important for the stability of the trimer (Amin and Holm, 1996; Arroyo et al., 1996; 




Figure 1-5 The intermolecular interface in the PCNAlsliding clamp trimer. 
A) human PCNA (1VYM) (Kontopidis et al., 2005)B) RB69 gp45 (1B77) (Shamoo and Steitz, 1999). 
Two monomers are held together by main chain-main chain hydrogen bonds between f3-strands of 
adjacent monomers, OD,-l3I. The interface of human PCNA is far more extended than in the viral 
sliding clamp and has eight hydrogen bonds. 
Additionally, van der Waals forces within a hydrophobic core at the interface along 
with ion pairs hold the molecules together, although not all interactions are equally 
important as shown in mutation studies (Kelman and Odonnell, 1995a; Krishna et al., 
1994). For example the mutation of a Y 11 4A in hPCNA prevents the formation of 
trimers all together (Jonsson et al., 1995), S  15P in ScPCNA has the same effect 
(Ayyagari et al., 1995), since the Pro residue is not usually found in n-sheets due to 
its conformation. Similarly, the mutation LIO8P in E. co/i also leads to the disruption 
of dimerization (Yao et al., 1996). 
As mentioned above, the T4 sliding clamp is less stable on DNA than is PCNA. This 
is due to the fact that the interface contacts are less exten sive compared to ScPCNA. 
Only four hydrogen bonds link two monomers instead of eight in the eukaryotic 
sliding clamp and the total surface area that is buried at the interface is only about 









in A 2 
_ 
Human PCNA 8 1014 
S. cerevisiae PCNA 7 888 
P. furiosus PCNA 5 1274 
E. coli P subunit 4.5 1285 
RB69 4 692 
T4 4 772 
Table 1-2 Characteristics of the interface in some sliding clamps. 
Distance for donor/acceptor < 3.9A, probe size = 1.4A. 
In E. coli there is a head-to-tail arrangement of the monomers in the dimer. The 
- -- ----average-surface--buried--at-the-interface-is-i-285-A2which-is--sirniiato--the--jffa-
buried at the interface in PfUPCNA. At least four strong hydrogen bonds are formed 
between adjacent f3-sheets of two monomers. At the centre, as in the other structures, 
is a small hydrophobic core consisting of closely packed side chains Phe106 and 
11e278 from one monomer and 11e272 and Leu273 from the other. Positioned around 
this core are six potential intermolecular ion pairs, while only a handful of ion pairs 
are found at the interfaces in the yeast trimer. Interestingly, all positively charged 
residues are contributed by one monomer and all negative ones by the second. This 
electrostatic complementarity might help with the head-to-tail assembly of the dimer. 
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Looking at different domains of life, the archaeon Pyrococcus furiosus grows 
optimally at 100C*. Proteins from thermophiles have been found to share certain 
features like increased numbers of ion pairs as surveys have shown (Jaenicke and 
Bohm, 1998; Vogt and Argos, 1997). Again, main chain amide-to-carbonyl hydrogen 
bonds are formed between anti-parallel f3-strands 0I and PD2 (Matsumiya et al., 
2001). However, the number of bonds is reduced to only four in contrast to the 
eukaryotic clamps. Loops adjacent to Pli and J3D2 are somewhat shorter than in 
human or yeast PCNA as mentioned above, which might cause the differences in the 
hydrogen bond network. On the other hand the buried surface area is even more 
extended than in hPCNA. Additional stability within and between PCNA molecules, 
which is needed for a life in such a hot environment, is probably enhanced by a 
number of short ion pairs found between oppositely charged groups (Matsumiya et 
al., 2001). Ten of those ion pairs are located at a single intermolecular surface of 
PfUPCNA. In contrast to that, the trimeric conformation of hPCNA is supported by 
only five ion pairs per primer and even by fewer in yeast (Gulbis et al., 1996; 
Krishna et al., 1994). 
1.4 THE HYDROPHOBIC POCKET 
1.4.1 The interdomain connector loop and the hydrophobic 
pocket 
The domain topology of each PCNA monomer places the last strand of the N- 
terminal domain remote from the first strand in the C-terminal domain and so a 
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linker strand (residues 121-132 in hPCNA) is an important feature, which 
additionally forms a part of a well defined hydrophobic pocket (Figure 1-1, Figure 
1-2, Figure 1-4). As shown in Figure 1-6 in ScPCNA a number of hydrophobic 
residues from the linker strand reach out towards the hydrophobic pocket underneath 
to maximize van der Waals interactions. Additionall to those hydrophobic 
interactions hydrogen bonds are formed between polar side chains of the linker and 
amino acids in the f3-sheet underneath. But not all the hydrogen bonding potential of 
the backbone is tied up in intramolecular interactions. The remaining hydrogen bond 
capacity is available to the binding of proteins, which is shown by complexes of 
PCNA with peptides of partner proteins. One example for that is the complex of 
PCNA with p21  (141-160) (Figure 1-7 Al and A2). In all structures of sliding 
clamps this linker is found and the conservation of this feature might actually show a 
functional requirement (Figure 1-1). 
r12 2 )7 	 GI 13 
.- 
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Figure 1-6 Intramolecular interactions of the [DCL (121-IDADFLKIEELQ-132) in ScPCNA. 
Acidic (magenta: E130, D200), hydrophobic (white: 1-126. Y133) and polar (yellow: Q38, Q132) side 
chains are involved in four hydrogen bonds. Furthermore a number of hydrophobic residues (e.g. L47, 
L126, 1128, L236, F249) are engaged in van der Waals contacts. 
A number of proteins have been shown to interact with this loop upon complex 
formation with sliding clamps (Eissenberg et al., 1997; Gulbis et al., 1996; Warbrick 
et al., 1995). DNA 
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Figure 1-7 Peptide binding to the hydrophobic pocket in PCNAJsliding clamps is conserved 
throughout the domains of life. 
The surface shown is that of a human PCNA monomer and viewed in A-C from the front/above. All 
peptide sequences are given in Figure 1-8. Al and A2 show human peptides bound human PCNA: 
PL= deep blue (1VYJ) (Kontopidis et al., 2005), Fen-1 = red (1U7B) (Bruning and Shamoo, 2004), 
DNA polymerase 6 = cyan (1U76) (Bruning and Shamoo, 2004), p21 = green (1AXC) (Gulbis et al., 
1996). The cartoon backbone with the a-helical turn is placed at the same position in the pocket. 
Especially the glutamine side chain is fixed in the same position (Q-pocket, red circle in Al), a small 
groove a little further away from the hydrophobic pocket, in all four complexes. The hydrophobic 
residues, on the other hand, that grip into the hydrophobic pocket underneath the IDCL. vary a bit 
more (Figure 1-8). BI and 132: Peptides of non human proteins complexed with the respective sliding 
clamp have been superimposed with hPCNA: A. fulgidus Fen-1 = yellow (1RXZ) (Chapados et al., 
2004), P.furiosus  RFC = lime (1ISQ) (Matsumiya et al., 2002), RB69 polymerase = forest green 
(1B8H) (Shamoo and Steitz, 1999). PL was added for comparison = deep blue. Despite their origin 
from both archaea and virus, the displayed peptides have retained the overall fit to the hydrophobic 
pocket including the a-helical turn. The side chains still grip into the their respective pockets, apart 
from RB69 pol the N-terminal end does not contain a glutamine and it also bend upwards compared to 
the other three peptides. Cl and C2: Peptides from E.coli polymerase DNA polymerase IV (10K7) 
(Burnoufet al., 2004) (light green) and S. cerevisiae RFC (1SXJ) (Bowman et al., 2004) (forest green) 
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are shown with PL (shadow). Neither of them contains the typical a-helical turn, but still place two 
(E.coli p01 IV) or four (ScRFC) residues in the pockets. It should be noted that N398 in ScRFC is 
placed in the appropriate pocket for the usual Q at that position, which can be explained by the similar 
chemical character of the two amino acids. 
Polymerase ö (Eissenberg et al., 1997; Fukuda et al., 1995; Jonsson et al., 1998; .Oku 
et al., 1998; Zhang et al., 1998) binds to this loop as well as to the hydrophobic 
pocket underneath (Figure 1-7 Al and A2). Also for binding of p21 and Fen-1 the 
recognition of the loop is crucial (Eissenberg et al., 1997; Gulbis et al., 1996; 
Jonsson et al., 1998; Oku et al., 1998). It is probably also important for the 
maintenance of the ring structure and adds flexibility at opening of the ring 
(Tsurimoto, 1998). 
Due to its high mobility the IDCL is rather unstructured and often difficult or 
impossible to model in most crystal structures and its conformation depends on the 
ligand binding to that area. However, both the IDCL and the C-terminus, which also 
tends to be flexible in unliganded structures, are rigidified upon complexing with a 
ligand (Kontopidis et al., 2005). 
As the IDCL is conserved among organisms of all three domains of life including 
phages, so is the hydrophobic pocket underneath the loop. Most similar are the 
pockets in eukaryotic PCNA, as not only the fold is conserved but also a substantial 
part of the sequence as can be seen in Figure 1-2. A superimposition of the complex 
structures of RB69 sliding clamp with a DNA polymerase peptide and hPCNA with 
the PL peptide (Figure 1-7 BI and B2, Figure 1-8) (Bruning and Shamoo, 2004; 
Kontopidis et al., 2005; Shamoo and Steitz, 1999) shows that also here the mode of 
interaction is more or less conserved. The PL peptide was designed from sequences 
of human DNA ligase 1 and D. melanogaster Pogo transposase. The aim was to find 
a tight binding peptide which did not contain the cyclin-biriding motif of p21. 
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Among eukaryotes the pockets and hence modes of interactions with peptide are in 
fact so similar, that a peptide from one species like human p21  (141-160) can also 
bind to fission yeast PCNA (Reynolds et al., 2000). 
141 -KRRQTSMTDFYHSKRRL IFS -160 
1- SAVLQKKITJJYFHPKK- 16 
453 -ANRQVSITGFFQR-465 
3 36-TQGRLDDFFKVTG-3 48 
39 6-LDNMSVVGYFKH-407 
469-KQATLFDF--476 
326 -KSTQATLERWF-33 6 
345-RQLVLGL-351 
893-KKASLFDMFDF- 903 
human p21 1AXC 
Pogo/Ligase 	(PL) 1VYJ 
human DNA pol 5 1U76 
human Feni 1U7B 
yeast RFC 1SXJ 
P.fur RFC 1ISQ 
A.ful Fen-1 1RXZ 
E,coli pol 10K7 
RB69 p01 1B8H 
Figure 1-8 Sequence alignment of selected peptides and proteins that bind to sliding clamps in 
crystal structures with PDB codes. 
In red are marked the residues that fit the PIP-box motif. The M in the RB69 polymerase is 
highlighted in green since it is not an aromatic, but does bind into the same pocket as Y, W or F. 
1.4.2 Partner peptides binding to the hydrophobic pocket 
Previously it has been shown that a number of proteins that bind to hPCNA contain a 
certain motif, termed the PIP box. The sequence is Q-x-x-h-x-x-a-a where 'h' stands 
for a moderately hydrophobic residue like methionine or leucine and 'a' means an 
aromatic residue (Warbrick, 2000). These four residues have been found to bind in 
the hydrophobic pocket (Figure 1-7). It is conserved in human Fen-1, DNA 
polymerase 8 and p21 (Figure 1-8); all three of them bind to the hydrophobic pocket 
as well as making connections with the IDCL (Figure 1-7A1 and A2). This binding 
motif seems to be also conserved to some extent among other domains of life (Figure 
1-7 B and Q. The peptide of RB69 DNA polymerase in the complex with the phage 
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sliding clamp has the sequence, KKASLFDMFDF, and even contains a single 
helical turn, just as it is the case in the complex of hPCNA with the human DNA 
polymerase 8 peptide (ANRQVSITGFFQ) (Figure 1-7). Residues L, M and F the 
final F are all found to bind in the pocket, however, the glutamate, which is so 
important for the binding in hPCNA is not present and in its place K is just sticking 
out, not 'making any important contact in or near the pocket. 
1.5 THE C-TERMINUS AND OTHER BINDING SITES FOR 
INTERACTING PROTEINS 
There are two distinct faces on the trimer and there are loops protruding at each side. 
The C-terminus sticks out from the C-side (Jonsson and Hubscher, 1997) and in 
unliganded structures of hPCNA the C-terminal residues 255-261 tend to be 
disordered ( 
Figure 1-9) in the crystal structures. If the C-terminus is then deleted the clamp loader 
protein RFC cannot be stimulated to load PCNA onto DNA (Fukuda et al., 1995). 
C 
N (peptide) 
Figure 1-9 Superimposition of uncomplexed human PCNA and with PL. 
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The C-terminus is more ordered in the complex structure (1VYJ) (Kontopidis et al., 2005) (dark blue 
with peptide in light blue) and two more residues can be modelled compared to the unliganded 
structure (1VYM) (Kontopidis etal., 2005) (green). 
This suggests that the C-terminal region is important for the interaction of RFC with 
the clamp (Naktinis et al., 1996). In E. co/i it has also been shown that the C-
terminus of the sliding clamp interacts with polymerase III (Naktinis et al., 1996), 
which is similar to DNA polymerase E, but not like DNA polymerase 8 in eukaryotes 
(Arroyo et al., 1996; Eissenberg et al., 1997; Fukuda et al., 1995). Different studies 
have also shown that the C-terminus is recognized as well by p21, Fen- 1 and Gadd45 
(Eissenberg et al., 1997; Gulbis et al., 1996; Hall et al., 1995b; Oku et al., 1998). In 
budding yeast residues Asp4l to His43 form the Centre Loop (Figure 1-2, Figure 1-
4) at the C-side between the two domains in a monomer. Asp97 seems to be 
important for the interaction with RFC as mutation studies illustrate (Fukuda et al., 
1995). Cold sensitive mutants of budding yeast showed further the importance of the 
residues Asp4l andAsp42 in the Centre Loop (Ayyagari et al., 1995) for RFC 
interaction, whereas residues 41-44 are needed for the binding of DNA polymerase 
ö(Okuetal., 1998). 
In PfuPCNA the C-terminus is also shortened, just as some other loops in that 
structure, and this is thought to increase heat stability. Additionally, in the complex 
structure of PfuPCNA with a peptide of RFC it seems to play an important role in the 
interaction of both proteins (Matsumiya et al., 2002). In the complex of A. fulgidus 
PCNA with a peptide derived from Fen-1 the C-terminal open flexible loop is 
engaging in the interaction with the peptide and forms with it an anti-parallel 
intermolecular J3-sheet (Chapados et al., 2004). This fact is thought to provide a 
control mechanism for mismatch repair. 
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Further residues that are important for protein interactions are 231-233 for the 
complex with p21 and 1-68 & 195-26 1 for binding to cyclin D (Tsurimoto, 1998). 
1.6 POTENTIAL DOUBLE HOMOTRIMER COMPLEX FORMATION 
Although many proteins with various functions have been found so far to interact 
with PCNA (Maga and Hubscher, 2003), none of them proved to bind to the back 
side of the trimer. 
Crosslinking and SDS-PAGE experiments showed the presence of particles twice the 
size of a trimer, suggesting the existence of double homotrimers, although this 
complex seems to be of a rather dynamic, loose nature (Naryzhny et al., 2005). We 
should also note that this complex has never shown up in any of the crystal structures 
so far (Gulbis et al., 1996; Krishna et al., 1994). Deletion studies led to the 
conclusion that Arg5 and Lysl 10 are crucial for the formation of the double 
homotrimer. Also R5AIK1 1OA double mutant CHO cells showed clearly that these 
residues are vital for survival. If PCNA does exist as double homotrimer in the cell, 
this could explain why no proteins seem to be binding to the back of the ring. 
However, it has been proposed before that the back side of PCNA is involved in 
regulation of the protein's functions, though no evidence has been found for that so 
far (Fukuda et al., 1995). Two front sides, on the other hand, would allow PCNA to 
work in both directions on DNA and help with the coordination of multiple functions 
as repair, replication and cell-cycle control. 
DNA replication is coupled with chromatin assembly, which requires the association 
of PCNA and chromatin assembly factor-1, CAF-1, (Moggs et al., 2000; Shibahara 
and Stillman, 1999; Zhang et al., 2000). Unsurprisingly, the largest subunit of CAF- 
I has been shown to bind directly to the processivity factor (Zhang et al., 2000). 
Naryzhny et al. (Naryzhny et al., 2005) carried out a number of studies on interaction 
of PCNA with DNA polymerase 6 and CAF-1, a complex of three subunits, p150, 
p60 and p48 (Smith and Stillman, 1989). 
They found that the R5AJK1 1OA PCNA mutant can only bind CAF-1 or DNA 
polymerase ö, while the wild-type protein is able to bind both simultaneously. This 
might come as a surprise since in theory there should be three binding sites, one on 
each monomer. But it appears that binding of one protein can cover up a large part of 
the trimer surface, as found in the complex of DNA ligase I (Pascal et al., 2004) and 




Figure 1-10 Model of the possible back-to-back arrangement of the double homotrimer complex 
of hPCNA. (Naryzlmy et al., 2005) 
The two rings of human PCNA (1VYM) are twisted against each other, this way the larger loop 
(f3D1E2 on the backside might fit into a grove on the other ring around aA 1 (residues 9-20), aB, 
(residues 209-211), PH, (residues 235-24 1) and 012  (residues 254-260). For clarity the structures are 
shown as a cross-section. 
PCNA crystal structures have shown that the 13D 2 13E2 loop sticks out from the back of 
the ring, so a direct interaction between R5 of one trimer and KilO of another might 
only be possible if the rings are twisted against each other to make the loops fit into 
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groves on the opposite trimer. The model proposed by Naryzbny et al.(Naryzbny et 
al., 2005) (Figure 1-10) suggests hence that a "locking-in" might occur by fitting the 
D2fE2 loop into a grove on the other ring around aA 1 (residues 9-20), aB2 (residues 
209-211), PH2 (residues 235-241) and 012 (residues 254-260). 
Another group working on PCNA in Drosophila melanogaster also found that the 
results of their genetic studies only made sense if two PCNA trimers formed a back-
to back complex (Henderson et al., 2000), so there seems to be a growing body of 
evidence to support this hypothesis. 
1.7 ALTERNATIVE PCNA ARCHITECTURES 
Dimeric PCNA structures like the E. coli sliding clamp have been also found in 
eukaryotes. In carrot two distinct PCNA genes have been found in somatic 
embryogenesis (Hata et al., 1992). One shows the typical 264 amino acids in trimeric 
PCNA monomers, the other consists of 365 residues and is 40kDa in size, which is 
very much like the E. coli monomer. Furthermore, in Xenopus laevis a 43kDa gene 
product has been found (Leibovici et al., 1990). The reason for the existence of 
alternative architectures might be the need of rapid chromosomal replication during 
embryogenesis (Kelman and Odonnell, 1995b). 
On the other hand, an alternative PCNA gene product has been found in E. coli. Its 
internal promoter is UV inducible and is located within the dnaN gene which leads to 
the formation of a 26kDa peptide. Crosslinking and size exclusion experiments have 
shown that this alternative form exists as a homotrimer and stimulates DNA 
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polymerase III. It has been suggested that it confers increased UV resistance for 
DNA repair (Skaliter et al., 1996). 
A different alternative to the common homotrimer comes from the archaeon 
Sulfolobus solfataricus. Dionne et al. (Dionne et al., 2003) detected three PCNA 
homologues in the genome sequence: PCNA 1, 2 and 3. Though PCNA1 and 2 can 
form dimers together, PCNA3 is unable to interact with either of the proteins 
individually and only a mix of all three homologues leads to the formation of a 
heterotrimer with 1:1:1 stoichiometry. Their work furthermore suggested that Fen- 1, 
DNA ligase I and DNA polymerase B 1 can associate with the trimer simultaneously 
and act possibly as a preassembled processing complex. This, of course, would 
facilitate the coupling of both DNA synthesis and Okazaki fragment processing. Also 
it could be shown that the homotetramer of the small subunit of RFC is binding only 
to the PCNA 1-2 dimer and that the single large subunit of RFC is contacting 
PCNA3, which is the last of the three to join the ring (Dionne et al., 2003). Other 
archaea seem to possess several genes for PCNA homologues as well, though it is so 
far unknown, if these form heterotrimers (Daimon et al., 2002). It is widely accepted 
that hyperthermophilic archaea are the most ancient of this domain of life, which 
makes them closer to the common ancestor of both eukarya and archaea. Hence it is 
thought, that the heterotrimer might be an evolutionary fossil of original sliding 
clamp before it specialized into homotrimeric PCNA for replication and the 
heterotrimeric 911 complex in S. pombe, which is denoted for DNA repair (Parrilla-
Castellar et al., 2004). 
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1.8 OPEN CLAMP STRUCTURE IN THE CLAMP-LOADING COMPLEX 
The RFC is essential for loading PCNA onto DNA at template-primer junctions by 
multiple stepwise ATP-binding events. This heteropentameric complex belongs to 
the AAA family and consists of Rfcl, Rfc2, Rfc3, Rfc4, and Rfc5 subunits. 
Although crystal structures so far show PCNA always in the planar ring structure, 
latest electron microscopy technology has enabled us to have a look at the archaeal 
RFC-PCNA complex ofPyrococcusfuriosus at 12A resolution (Miyata et al., 2005) 
It shows a possible intermediate state in the process of clamp-loading. In this state 
PCNA is kept open in the complex by RFC and assumes a helical shape. The 
intrinsic planarity found in crystal structures has been deformed (Figure 1-11), giving 
PCNA the opportunity for a broader contact interface to RFC binding possibly all 
five subunits of the clamp loader. This contrasts with the ScPCNA-RFC complex 
where the sliding-clamp only makes contact to three subunits of RFC (Bowman et 
al., 2004). 
This alternative mode of interaction between these two proteins may be essential for 
the opening of the PCNA ring. A possible model was proposed by Miyata et al. that 
PCNA is converted to the open form upon RFC binding. Binding of RFC to DNA 
may induce a conformational change in this protein and consequently, under ATP 
hydrolysis, PCNA will reduce its contact surface to RFC and return into the planar 
ring structure encircling DNA. 
Molecular dynamics simulations on PCNA have furthermore suggested that PCNA is 
oscillating between planar and non-planar conformations as long as it is not 
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constrained to the ring structure (Kazmirski et al., 2005). These simulations also 
show that when choosing the non-planar state the molecule distinctly seems to prefer 
a right-handed spiral distortion. The authors set up their simulations by removing one 
of the three subunits of the PCNA trimer in yeast, human and archaeal PCNA. They 
assumed stability of the open form as the T4 bacteriophage clamp has been shown to 
be predominantly an open trimer in solution (Millar et al., 2004). Also the 
bacteriophage clamp appears to be open at one interface in the presence of the 
clamp-loader complex suggesting stability of the open ring. 
Figure 1-11 The open clamp structure of PfuPCNA observed with EM. (image taken from 
(Miyata et al., 2005)) 
The image shows that in the complex with RF-C (not shown) the ring structure is opened in order to 
be able to encircle DNA. 
The results showed spontaneous lateral relaxation of the subunits and transient 
adoption of spiral conformations. The flexibility of conformations lies in the 
interface of the two PCNA subunits where the hydrogen bonds between the 13-strands 
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are maintained. The right-handed twist in the anti-parallel 13-sheets seems to lead to 
the preferred formation of a right-handed spiral. 
1.9 PCNA'S ROLE IN THE CELL CYCLE 
1.9.1 General 
As mentioned above, PCNA is involved in various aspects of DNA metabolism. In 
eukaryotes replication occurs at about 500 too 5000 bases per minute while accuracy 
is very important. DNA lesions and other obstacles can lead to replication failure or 
even broken chromosomes with fatal consequences for cells. Therefore cells have a 
need for numerous safeguard mechanisms that are directly linked to DNA synthesis. 
This setup allows not only for replication to proceed despite of problematic regions, 
but also facilitates repair of those areas or induces cell-cycle arrest through check 
point pathway in case of serious damage. The following section explains how PCNA 
is involved in the various aspects of DNA metabolism. 
1.9.2 DNA synthesis, mode of action and coordination of 
replication events 
In DNA replication PCNA is loaded onto primed DNA by Replication Factor C 
(RFC) with the C side facing the growing end. This ensures polymerases and other 
enzymes binding to this side are close to the 3' end of the elongating DNA. The next 
step is the association of polymerases Pol 8 or Pol c. Enhanced by PCNA these two 
proofreading enzymes carry out most of the DNA synthesis. On the lagging strand 
each Okazaki fragment is left with a flap structure that needs to be removed and the 
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fragments to be joined up. For these steps Fen-1 and DNA ligase I associate with 
PCNA. 
Having no enzymatic activity on its own, PCNA is able to act as a moving platform 
for various factors that need to act sequentially for highest efficiency. As mentioned 
above, most proteins that are known to bind to PCNA contain the PIP-box motif and 
are hence competing with each other for the three binding sites on the sliding clamp. 
Various studies (Chapados et al., 2004; Pascal et al., 2004), suggest that PCNA 
coordinates Okazaki fragment processing and joining in a stepwise fashion. Of all 
proteins tested for affinity to PCNA p21 is the one which binds most tightly, which 
makes sense as this interaction is most important when DNA replication has to stop 
upon DNA damage. 
In order to prevent rereplication at the origin once replication has been initiated, 
several mechanisms are in place. PCNA is contributing by its interaction with Cdtl, a 
licensing cofactor which is essential for initiating DNA replication at the origin. By 
binding to PCNA via its PIP-box motif this factor is marked for ubiquitylation and 
therefore degradation (Arias and Walter, 2006). 
1.9.3 Bypass replication and ubiquitylation of PCNA 
Although accurate replication is most desirable for the cell, it is also important that 
synthesis continues despite obstacles on the DNA. When DNA damage is detected 
bypass mechanisms are triggered that lead to ubiquitylation of PCNA. The sliding 
clamp and ubiquitin are linked via the conserved K164 in PCNA and K63 in 
ubiquitin. This modification can be a single ubiquitin moiety or a polyubiquitin 
chain. While the first kind triggers the error-prone translesion synthesis (TLS) 
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pathway, the latter one leads to an error-free bypass mode. This mechanism has been 
coined the "ubiquitin-PCNA switch" (Hoege et al., 2002) and allows both passing of 
lesions as well as a choice between bypass modes. 
1.9.4 Maintaining genomic stability by prevention of sister-
chromatid recombination 
Even in the absence of DNA damage a fraction of PCNA remains modified in S 
phase by the ubiquitin-related SUMO via K164 as observed in ubiquitylation 
(Arakawa et al., 2006; Hoege et al., 2002). SUMOylation of PCNA has been shown 
to recruit Srs2, a helicase with antirecombinogenic properties. This interaction leads 
to the disruption of Rad5 1 nucleoprotein filaments that are essential for 
recombination (Pfander et al., 2005). This mechanism is there to control sister-
chromatid recombination as a salvage pathway for stalled replication forks which can 
lead to gross chromosomal rearrangements. 
1.9.5 DNA Repair Systems 
1.9.5.1 Mismatch Repair (MMR) 
The DNA Mismatch Repair system (reviewed by (Jiricny, 2006)) recognises and 
corrects base-base mismatches, but also fixes small insertions or deletions. The 
erroneous parts of the newly synthesised DNA strand are removed which is followed 
by targeting the DNA-synthesis machinery to the single-stranded gap. The MMR 
components are sensor complexes MSH2-MSH6 or MSH2-MSH3 for recognising 
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smaller or bigger loops/deletions respectively, the transducer complex MHL1-PMS2, 
exonucleases like EXO1 that remove the flawed DNA stretch, single-stranded 
binding protein RPA, the nonhistone chromatin protein HMGB1 (only in higher 
eukaryotes) and the DNA synthesis machinery. 
PCNA is required for the early steps in the MMR process (Umar et al., 1996) and 
interacts directly with MSH6, MSH3, MLH1 and EXO1 while the first three proteins 
also contain PIP boxes. Since MMR is strand-specific, i.e. it always works on the 
newly synthesised strand, PCNA is thought to act as some sort of marker along with 
a gap or nick in the DNA originating for example from Okazaki fragments (Modrich, 
2006). Furthermore, PCNA is likely to recruit EXO1 to the site followed by its direct 
part in DNA synthesis. As binding of sensors, transducers and any of the excision or 
DNA synthesis proteins to PCNA is mutually exclusive, this arrangement seems to 
ensure the ordered course of MMR. 
1.9.5.2 Base Excision Repair (BER) 
The Base Excision Repair system (reviewed by (Sancar et al., 2004)) is responsible 
for the correction of chemical alterations of DNA bases. Degenerative influences 
leading to such alterations include alkylation, oxidation, reduction and deamination. 
BER starts with the recognition of damaged sites by specific DNA glycosylases. 
These enzymes catalyse the removal of bases from the nucleotides. The remaining 
phosphodiester bond at the 5' end of such abasic kites is cleaved by 
apurinic/apyrimidinic (AP) endonucleases. Some enzymes like NTH1 combine both 
activities in one molecule, while most other enzymes carry out either the one or the 
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other reaction. After base removal the single nucleotide gab is filled by Pol3 
followed by sealing of the nick through XRCC1-DNA ligase 3. Alternatively, for 
bigger lesions the RFC-PCNA-Pol/Pole complex is recruited to the site to perform 
DNA synthesis involving Fen-1 and DNA ligase I, which makes this process 
analogous to lagging strand synthesis. 
As in MMR PCNA seems to be involved both in early and later steps of this system. 
Uracil-DNA glycosylase IING2 contains PIP-box motif and interacts directly with 
PCNA during the initial steps of BER. Later AP endonucleases bind to the sliding 
clamp. NTH1 has also been found to bind directly to PCNA, but does not contain the 
PIP-box residues (Oyama et al., 2004). It is worth pointing out that in this repair 
pathway PCNA is not only colocalizing with the mentioned repair enzymes, but is 
also able to stimulate enzymatic activities in its binding partners (Tsuchimoto et al., 
2001; Unk et al., 2002). 
1.9.5.3 Nucleotide Excision Repair (NER) 
Nucleotide Excision Repair is a system for removal of bulky DNA lesions 
originating from exposure to radiation or chemicals (reviewed by (Sancar et al., 
2004)). The process includes detection by XPC, which is followed by unwinding and 
opening up the damaged DNA stretch by helicases XPD and XPB. Endonucleases 
XPG and XPF cut out the lesion generously and the single stranded gap is then 
closed through DNA synthesis and ligation. XPG contains a PIP-box motif and binds 
to PCNA via that region. In this interaction PCNA is thought to coordinate DNA 
excision and synthesis as has been suggested for the other repair systems. 
1.9.6 Chromatin assembly 
PCNA's function in nucleosome assembly is mediated by its interaction with 
heterotrimeric chromatin assembly factor CAF-1. CAF-1 is targeted to sites of DNA 
synthesis by PCNA via its PIP-box motif (Krawitz et al., 2002; Zhang et al., 2000). 
There it is responsible for delivering histones H3 and H4 to the replication fork for 
chromatin assembly (Smith and Stillman, 1989). PCNA-mediated CAF-1 recruitment 
is also observed at sites of NER where it is thought to aid chromatin assembly after 
the repair process is finished (Gaillard et al., 1996). 
1.9.7 Epigenetic inheritance 
The maintenance of epigenetic information encoded as modification on DNA and 
chromatin is important for cellular differentiation. This information is copied with 
high fidelity over rounds of cell division by coupling the process of DNA replication 
directly to enzymes required for preservation of epigenetic patterns. 
Cytosine methylation on C5 is found mainly in CpG islands where it induces gene 
silencing in promoter regions and is controlled by PCNA (Bird, 2002). Maintenance 
of the methylation pattern is carried out by DNA cytosine methyltransferase 1 
(DNMT1) (Hermann et al., 2004). PCNA targets this protein to replication forks by 
binding to its PIP-box motif located in the N-terminal region. It has been shown that 
PCNA not only anchors DNMT1 to these sites, but is also responsible for stimulating 
enzymatic activity (Chuang et al., 1997; lida et al., 2002). Unsurprisingly, PCNA-
mediated recruitment of DNMT1 is also found at site of DNA repair to restore 
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epigenetic information to newly synthesized DNA sequences (Mortusewicz et al., 
2005). 
Furthermore, PCNA might also be involved in gene silencing as it has been found to 
interact with histone deacetylation enzyme 1 (HDAC1) in vitro and both proteins 
colocalize at replication foci in vivo (Kovacevic et al., 2002). 
1.9.8 Cell-cycle control and survival 
As previously mentioned, binding of p21 to PCNA is effectively blocking out many 
other proteins containing the PIP-box motif. Exclusion of proteins (including Pol, 
Fen-1, Ctdl and DNMT1) (Arias and Walter, 2006; Chuang et al., 1997; Ducoux et 
al., 2001; Warbrick et al., 1997) prevents cell-cycle progression until all damage is 
repaired. 
PCNA is also involved in processes that determine cell survival or death. Binding of 
the tumour suppressor protein ING1b to PCNA via a PIP-box motif is 10-fold 
increased after UV radiation leading to apoptosis (Scott et al., 2001). In contrast to 
that PCNA performs also an antiapoptotic role through interaction with proteins of 
the Gadd45 family by inhibiting their activities (Azam et al., 2001; Vairapandi et al., 
1996). As described in further detail in Chapter 4 these proteins are implicated in 
growth control, apoptosis and DNA repair. They are very similar in sequence, but do 
not contain the specific PCNA-binding motif. 
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1.9.9 Regulation of PCNA functions 
Since PCNA is involved in so many crucial processes of cell cycle progression and 
regulation it is important to control its ability to associate with the multitude of 
partner proteins in order to prevent confusion. PCNA's partner proteins could be 
ordered according to their binding affinities with p21 right at the top, virtually 
jamming the binding pocket. On the other hand, this hierarchy can be altered through 
phosphorylation of each factor. Fen-1 for example dissociated from PCNA after 
phosphorylation by the CDK2-PCNA complex (Henneke et al., 2003). 
As PCNA provides three binding sites for PIP-box containing proteins, it is possible 
to imagine that the sliding clamp can bind three different proteins at once. An 
organization like that would be very handy in stepped processes like the repair 
systems. That this may be a possible scenario has been shown in studies with 
heterotrimeric PCNA from the archeon Sulfolobus solfataricus. Here each of the 
subunits binds specifically the polymerase, Fen-1 or DNA ligase I (Dionne et al., 
2003). 
Another form of controlling PCNA interactions is through modifying the clamp 
itself. As described above ubiquitinylated or SUMOylated PCNA attracts specific 
binding partners like Srs2 (Papouli et al., 2005) involved in prevention of sister-
chromatid recombination or translesion synthesis polymerases (Bienko et al., 2005). 
The addition of a SUMO moiety to PCNA has been shown to repress binding of PIP-
box containing proteins (Moldovan et al., 2006). 
Since only a small fraction of PCNA molecules in a cell are actually modified at any 
given time, the hypothesis is that either only certain PCNA molecules are selected 
for modification or that this alteration is generally of a transient nature. 
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Another way of PCNA regulation is the unloading of the protein from DNA and 
subsequent degradation. Unloading is mediated by RFC, which is also needed for 
loading PCNA into DNA in the first place. Human PCNA degradation seems to be 
triggered by PCNA dephosphorylation. The phosphate group is added by the nuclear 
version of epidermal growth factor receptor (EGFR) (Wang et al., 2006) and 
phosphorylated PCNA is stably associated with nucleosomes. Dephosphorylated 
PCNA and those molecules which cannot be phosphorylated are marked by 
ubiquitylation for degradation by the proteasome. 
Despite the numerous interactions PCNA engages in, the sliding clamp does not 
seem to bind directly to members of the checkpoint cascade that are responsible for 
cell-cycle arrest in case of DNA damage. This part is covered in eukaryotes by the 
PCNA-related 9-1 -1 complex and features association of certain 9-1-1 subunits with 
defined checkpoint proteins (Parrilla-Castellar et al., 2004). It is assumed that PCNA 
and 9-1-1 have evolved from the same ancestor to separate replisome and checkpoint 
components to allow ongoing replication without any hindrance due to bound 
checkpoint signalling proteins. 
1.9.10 	PCNA and diseases 
It has been shown that tumours of a similar pathologic state can result in very 
different clinical outcomes. Being such a central protein to cell-cycle control, 
dysregulation of PCNA has been an attractive parameter as a biomarker for cancer 
prognosis. 
Studies have found that in esophageal squamous-cell carcinoma the main mechanism 
of progression after invasion of carcinoma is due to cell proliferation (Kuwano et al., 
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1998), hence PCNA has been suggested as a profiling marker in cancer prognosis. 
PCNA expression as a biomarker in characterizing the degree of proliferative 
disregulation has also been suggested after a study on head and neck tumorigenesis 
(Shin et al., 1993). No significant connection could be established, however, for 
colorectal cancer and clinical outcome (Lyall et al., 2006). 
Furthermore, the link between DNA damage and repair systems in neurodegenerative 
processes has been examined. It seems that both p53 and MSH2 are involved in 
neurodegenerative processes as well as part of the recognized cancer prevention 
machinery. Many human pathological conditions that exhibit genetic defects in DNA 
damage control also show neurological deficits (Rolig and McKinnon, 2000), which 
implies an important role for DNA repair proteins neurological development. 
The deficiency in p53 is also associated with learning difficulties and has an effect 
on behaviour in mice (Amson et al., 2000). While p53 levels were elevated in non-
proliferating cultures of cortical neurons upon beta-amyloid injury associated with 
Alzheimer's disease (Copani et al., 2001), MSH2 and PCNA translocation to the 
nucleus was observed in differentiated human neuroblastoma cell lines after 
oxidative insult with H202 (Uberti et al., 2003). 
It is likely that PCNA is involved in neurological process by dint of p53 and MSH2 
association, either directly or indirectly. 
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1.10 APOPTOSIS-LIKE CELL DEATH IN YEASTS SIMILAR TO THAT 
OBSERVED IN METAZOANS 
Despite the fact that neither p53 nor p53-upregulated p21 homologues are present in 
yeasts, they have proved to be ideal model systems for studying function of 
mammalian proteins involved in apoptosis. Both budding and fission yeast display an 
apoptotic-like cell death induced by DNA damage or other stimuli suggesting 
similarities with mammalian p53-independent apoptotic pathways. This programmed 
cell death is accompanied by specific symptoms that are also presented by metazoan 
cell undergoing the process (Ink et al., 1997; Jurgensmeier et al., 1997; Madeo et al., 
1997; Tao et al., 1997; Watanabe et al., 2002). These markers include the production 
of reactive oxygen species (ROS), chromatin condensation, DNA fragmentation and 
the release of cytochrome c. 
Induction of this apoptosis in yeasts requires homologues of cell cycle checkpoint 
proteins that have been shown to be involved in metazoan cell death such as kinases 
ATM and ATR, 9-1-1 complex and Chkl and Chk (Qin and Li, 2003). In fact, initial 
genetic studies to understand the DNA damage responses were carried out in yeasts. 
Expression of human and mammalian pro-apoptotic proteins in yeasts led to cell 
death (Ink et al., 1997; Jurgensmeier et al., 1997; Ryser et al., 1999), but these 
unicellular organisms also harbour an intrinsic apoptotic pathway (Fröhlich and 
Madeo, 2000), which can be induced by exposure to low concentrations of acetic 
acid or UV radiation for example. This programmed cell death is distinctive from a 
passive cell death, also called necrosis, upon exposure to high concentrations of 
acetic acid or UV radiation (Del Carratore et al., 2002; Ludovico et al., 2001). 
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1.11 PROJECT OUTLINES 
	
1.11.1 	Crystallization and structure determination of S. 
pombe PCNA 
As described above both budding and fission yeast are model organisms which have 
been used to determine the genetic background for many complex processes in 
mammalians. As both human and budding yeast PCNA structures have been solved it 
is just a logical progress to examine the fission yeast counterpart. In many ways 
fission yeast is more closely related to humans than budding yeast and comparison 
between the eukaryotic structures was carried out to gain further insight in conserved 
protein-protein interactions. 
1.11.2 	Screening for and testing peptidomimetic anti-cancer 
drug leads to block the hydrophobic pocket of human PCNA 
for DNA polymerase 
Experiments with antisense oligonucleotides that caused a suppression of PCNA 
expression showed selective inhibition of gastric cancer cell proliferation both in 
vitro and in vivo (Sakakura et al., 1994). Based on these findings it seems reasonable 
to suggest that a similar inhibitory effect could be achieved, if PCNA was kept from 
interacting with partner proteins involved in DNA replication as has been previously 
suggested (Kontopidis et al., 2005). A number of different proteins bind to the 
hydrophobic pocket beneath the IDCL. A small molecule binding to that place by 
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mimicking these peptides should inhibit PCNA action, stop cell proliferation and 
hence pave the way to a new class of anti-cancer drugs. 
Chemical data bases were screened for suitable compounds employing the 
programme LIDAEUS and selected molecules were analyzed for binding to human 
PCNA using a thermal shift assay and a competitive assay employing labelled PL 
peptide. 
1.11.3 	Analysis of the non-PIP-box-mediated interaction 
between human PCNA and human Gadd45 
Although most proteins that have found to bind directly to PCNA exhibit the 
conserved PIP-box binding motif, some binding partners like Gadd45 do not contain 
this sequence. The third objective of this thesis was to determine exactly the section 
of Gadd45 that mediates direct contact with PCNA and to analyze the kinetics 
underlying this interaction using SPR (Surface Plasmon Resonance). 
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CHAPTER 2. Crystal structure and biophysical 
characterization of Schizosaccharomyces pombe 
PCNA unhiganded and in complex with a human 
p21 peptide 
2.1 INTRODUCTION 
Schizosaccharomyces pombe is also referred to as fission yeast and is used as a 
model organism in molecular and cell biology. Its genome with 13.8 million base 
pairs is very short for an eukaryote which makes this organism attractive to work 
with. Its genome has been fully sequenced and many genes homologous to human 
disease genes, including diabetes and cystic fibrosis, have been identified (Wood et 
al., 2002). Furthermore, many fission yeast proteins involved in cell cycle regulation 
and DNA synthesis are equivalent to the ones present in human pathways, PCNA 
being one of them. 
Knowledge of the structure of SpPCNA will complement what is known about 
eukaryotic sliding clamps. In particular the conservation of the hydrophobic pocket, 
as described in Chapter 1, is of interest. This is the site where numerous PCNA 
partner proteins that contain the PIP-box motif (e.g. p21) bind to the sliding clamp. 
Despite the fact that no homologue of p21 has been found in fission yeast, the human 
p21 20-mer that has been complex with IIPCNA by Gulbis and his colleagues (Gulbis 
et al., 1996) was found to bind SpPCNA (Reynolds et al., 2000). A search of the 
fission yeast proteome for PIP-box containing proteins found plenty of hits as 
discussed in section 2.3.6. 
In order to gain a deeper understanding of the mechanisms of protein:protein and 
protein:ligand recognition/binding, SpPCNA was crystallized on its own and in 
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complex with the human p21 peptide. The interaction between SpPCNA and p21 is 
unlikely to be biologically relevant, but shows how small differences in the target 
protein can change the binding mode of a particular ligand. 
To characterize the interaction between SpPCNA and the p21 peptide surface 
plasmon resonance (SPR) and a thermal shift assay were employed. 
SPR allows monitoring the interaction between molecules in real time. The 
technology behind it involves attaching one interacting partner, called ligand in SPR 
terminology, to the surface of a sensor chip. The analyte or second interaction partner 
is passed over the surface. Binding of the analyte to the sensor surface generates a 
response which is proportional to the bound mass, and changes in the amount of 
bound analyte can be detected down to a few picograms or less per mm 2 . 
Due to the ability to observe interactions in real time, SPR can provide information 
about the specificity, the kinetics and affinity of a particular interaction. 
The fluorescence-based thermal shift assay is a general method for identification of 
ligands for target proteins. Mostly it is used for isolating inhibitors of the protein of 
interest from compound libraries. Using an environmentally sensitive fluorescent dye 
to monitor protein thermal unfolding, the ligand-binding affinity can be assessed 
from the shift of the unfolding temperature (LTm) obtained in the presence of ligands 
relative to that obtained in the absence of ligands. The background to this method is 
further described in section 3.2.1. 
2.2 MATERIAL AND METHODS 
2.2.1 Peptides for crystallization and assays 
The human p21(141-160) peptide was provided by Dr. Emma Warbrick (University 
of Dundee) as a 10 mg/ml solution in 0.1% trichloroacetic acid. Aliquots were stored 
at -20°C. 
IGHHHH, HHHHHH and p21 (141-152) peptides were synthesised by Peptide 
Protein Research Ltd at >90% purity. DMSO stock solutions were produced at 
50mM for IGHHHH and p21(141-152) and at25mM for HHHHHH, and stored at - 
20°C. 
2.2.2 Expression and purification of SpPCNA 
The N-terminally MetArgSer(6xHis)GlyIleProMet-tagged fission yeast PCNA 
(30.4kDa) was expressed in Escherichia co/i M1 5 [pREP4] (Qiagen) from a pQE32-
Pcn1 expression vector (Qiagen), which was kindly provided by Dr. Stuart A. 
MacNeill (University of Copenhagen). The tag added by this vector to simplify the 
purification process is uncleavable, but does not interfere with trimerization or 
functionality in S. pombe (Reynolds et al., 2000). Expression and purification 
basically followed an established protocol (private communication from Dr. Stuart 
MacNeill). Essentially it was carried out as follows. 
Cell cultures (IL) were grown shaking in LB medium at 30°C to an 0D600 = 0.7 in 
the presence of 100 .tg/ml ampicillin and 25 .tg/ml kanamycin. Expression was then 
induced with 1 mM IPTG and the cells were incubated for another 6 hours. Upon 
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harvest, cell pellets were suspended in 40 ml Lysis Buffer A (50 mM NaH2PO4, 150 
mM NaCl, 20 mM imidazole pH 8.0, 1 mM PMSF and 0.1% Triton-X) and sonicated 
with 4 x 15 second bursts. Cell lysate was cleared by centrifugation for 25 minutes at 
10000 x g and the supernatant was filtered through a 0.2.tm filter. The lysate was 
applied to a 5 ml Ni-NTA agarose K9/15 column (Amersham) that had been 
equilibrated previously with Buffer X (50 mM NaH 2 PO4, 300 mM NaCl and 20 mM 
imidazole pH 8.0). PCNA was eluted with a gradient of Buffer X and Y (50 mM 
NaH2PO4, 150 mM NaC1 and 250 mM imidazole pH 8.0) at 135-145 mM imidazole 
and pooled fractions were dialysed against 20 mM Tris pH7.5, 1 mM DTT, 0.5 mM 
EDTA, 100 mM NaCl (Figure 2-1). The protein at an estimated purity of >95% was 
then concentrated to 4-5 mg/ml and stored at 4°C. 
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Figure 2-1 Purification of S. pombe PCNA using a Ni-NTA column. 
A 12% SDS-Polyacrylamide gel was run and subsequently stained with Coomassie. The total yield of 
cell pellets derived from 1 L liquid culture was 4 mg of protein at high purity. Key: lane 1 = marker, 
lane 2 = lysate, lane 3 = flow through, lanes 4 - 6 = wash steps at 40 MM, 61.5 MM and 100 MM 
respectively, lanes 7 -19 = consecutive elution fractions from a gradient between 100 mM and 150 
mM imidazole. His-tagged SpPCNA runs slightly larger than the calculated 30.4kDa, which is 
coherent with the literature (Reynolds et al., 2000). 
2.2.3 Expression and Purification of hPCNA 
The wild type human PCNA expression plasmid (pT7-hPCNA) was kindly provided 
by Emma Warbnck (Fien and Stillman, 1992). The protein was over-expressed in E. 
coli BL21 (DE3) cells grown in LB medium containing 100 g/ml ampicillin at 37 
°C to an 0D600 of 0.7. Over-expression was induced by addition of 1 mM IPTG and 
cells were grown for another 3 hours before harvesting. Cell pellets were either 
resuspended in ice-cold 10% sucrose and 25 mM Tris pH 8.0, snap-frozen in liquid 
nitrogen and then stored at -80 °C, or processed immediately by adding 40 ml of ice-
cold Lysis Buffer B (25 mM Iris pH 8.0, 1 mM EDTA, 25 mM NaCl, 2 mM 
benzamidine, 1 mM PMSF, 1 mM DTT). Lysis was performed by ultra sonication 
for 8 x 20 seconds with 40 second breaks in between bursts. All manipulations were 
carried out on ice. Following sonication, the lysate was then centrifuged for 30 
minutes at 10000 x g and the supernatant filtered through 0.2 J.tm syringe filters prior 
to application onto a 40 ml Q sepharose (Amersham) XK 16/20 column pre-
equilibrated with Buffer A (25 mM Tris-HC1 pH 8.0, 1 mM EDTA, 10% glycerol, 2 
mM benzamidine, 1 mM PMSF, 1 mlvi DTT, 100 mM NaCl). The protein was eluted 
in a two-step process using Buffer A supplemented with 700 mM NaCl. The column 
was washed with 310 mM NaC1 and protein eluted with 400 mM NaCl. Fractions 
were analysed by 12% acrylamide SDS-PAGE, pooled according to PCNA content 
and dialyzed against 5L of Buffer BI (20 mM Na-acetate pH 7.5, 2 mM DT!', 0.5 
mM EDTA and 10% glycerol) over night, with two buffer changes. The dialysate 
was filtered through 0.2 pm syringe filters prior to application onto a 30 ml Heparin 
sepharose (Amersham) XK 16/20 column pre-equilibrated with Buffer B 1. PCNA 
was eluted with a NaCl gradient from 0 - 500 mM in Buffer B 1. PCNA elutes 
between 100 mM and 120 mlvi NaCl. The peak fractions were then pooled and 
concentrated using a spin concentrator (molecular weight cut-off: 10 kDa) to 
approximately 2m1. Concentrated PCNA was then applied to a Sephacryl S-200 HR 
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gel filtration column (Amersham) (V 	120 ml; 16 cm x 60 cm) pre-equilibrated 
with Buffer B 1 supplemented with 100 mM NaCl. This step was selectively repeated 
to achieve higher purity. The protein was concentrated to 10-20 mg/ml and stored at 
4 °C in Storage Buffer (25 mM Tris-HC1, pH 7.5, 1 mM EDTA, 0.01% NP-40, 10% 
glycerol, 1 mM DTI, 2 mM NaCl). 
2.2.4 Crystallization of S. pombe PCNA 
2.2.4.1 Crystallization of monoclinic form unliganded SpPCNA crystals 
Crystallization of unliganded SpPCNA and the PCNAIp2 1(141-160) complex 
yielded crystals in various conditions. The best unliganded crystals were obtained by 
the hanging-drop, vapour diffusion method at 18°C in a condition from Structure 
Screen 1 (200 mM Lithium sulphate, 100 mM Tris pH 8.5, 30%(w/v) PEG-4000) 
(Molecular Dimensions Limited). This was optimized to 200 mM Lithium sulphate, 
100 mM Tris pH 8.5 and 25% w/v PEG-4000. Hanging drops were obtained by 
mixing 2 gl of protein 4 mg/ml and 2 j.d of well solution on siliconized cover-slips. 
Crystals appeared after 1-2 days. 
2.2.4.2 Crystallization of hexagonal form SpPCNA crystals in complex 
with human p21(141-160) 
Crystals of PCNA complexed with the p21 peptide were obtained using the same 
method, but grew from peptide/protein mixtures with the ratio 3:1 and a protein 
concentration of 2-5 mg/ml. Screening for crystal growth conditions was based 
around mixtures that had yielded unliganded SpPCNA crystals before. The best 
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condition was found to be 100 mM succinic acid pH 6.2 and 47% ammonium 
sulphate and 0.1% glycerol. Crystals appeared after 2 weeks. 
2.2.5 Data collection, Data analysis, Molecular Replacement and 
Refinement 
A crystal of unliganded SpPCNA with the dimensions of 0.5 mm x 0.4 mm x 0.2 mm 
was collected in a Cryo-loop, dipped briefly into freezing solution (30% PEG-4000 
in mother liquor) and flash frozen in liquid nitrogen. Diffraction data were recorded 
using the synchrotron source in Daresbury station 14.1 (Table 2-1). The crystal was 
found to be in the monoclinic space group P2 1 with a trimer present in the 
asymmetric unit. X-ray data were processed to 2.4 A using MOSFLM (CCP4) 
(Leslie, 1992) and scaled with SCALA (CCP4) (Evans, 1997). An mtz file was 
produced using 165 frames taken at 1 degree increments. The search model for 
molecular replacement was obtained by use of the programme 3DPSSM (Kelley et 
al., 2000). This programme takes the sequence of protein of interest and attempts to 
predict its 3-dimensional structure by calculating a score for matches between 
residues in the probe and residues in the library sequence (here hPCNA) using the 
global dynamic programming algorithm. 
Molecular replacement was carried out by using the program MOLREP (Vagin and 
Tplyakov, 1997). For refinement the programs REFMAC (CCP4) (Murshudov et 
al., 1997) and COOT (Emsley and Cowtan, 2004) were used. 
A data set of the trigonal crystals of the SpPCNAIp21 peptide (141-
KRRQTSMTDFYHSKRRLIFS-160) complex was collected at the Daresbury 
synchrotron. 
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The crystal of the SpPCNAIp2 1 peptide complex was 1 mm long. Crystals were flash 
frozen by dipping into liquid nitrogen. No freezing solution was used. The space 
group was found to be H32 with one peptide and two PCNA monomers present in the 
asymmetric unit, where each of them belongs to a different trimeric ring. X-ray data 
were processed to 2.2 A using the programs mentioned above and frames 29-178 
while omitting frames 83 and 84 due to elevated Rm erge values. 
2.2.6 Binding Assays of SpPCNA and hPCNA 
2.2.6.1 Thermal shift assay of hPCNA and the His-tags 
The assay was carried out using thin-wall PCR 96-well plates (Bio-Rad) covered 
with Optical-Quality Sealing Tape (Bio-Rad) using the iCycler iQ Real Time PCR 
Detection System (Bio-Rad). 
Each 50 j.tl sample contained 0.25 jtM recombinant human PCNA or SpPCNA, a 
1:1000 dilution of Sypro Orange (Molecular Probes) dye and increasing 
concentrations of either IGHHHH or HHHHHH peptide in thermal denaturation 
buffer 1 (25 mM Tris pH 7.5, 100 mM NaCl, 2 mM DYf). Each sample was carried 
out in triplicate and averages were calculated. The wavelengths for excitation and 
emission were 490 nm and 575 nm, respectively. Fluorescent readings were taken 
between 20 °C and 88 °C in 1 °C increments after each temperature had been 
maintained for 90 seconds. 
The fluorescent intensities were plotted against temperature in the programme 
Kaleida-Graph 4.03 (Synergy Software, Reading, PA) and the T m for each sample 
was calculated using the 
MI 
F(T) =FpOst+ [(Fpre - 	/ (I+ e (Tm - T) / C)] 	 (1) 
where F(T) is the fluorescence intensity at temperature T, Fp re and Fpost are the 
intensities for completely folded and completely unfolded protein, respectively and C 
is the slope factor. Here the slope factor acts as a scaling factor for the total increase 
of fluorescence, which may vary for different samples. 
2.2.6.2 Surface Plasmon Resonance of SpPCNA and p21 peptides 
Pure hexa His-SpPCNA was immobilized on the surface of a NTA sensor chip 
essentially as described (Wear and Walkinshaw, 2006). Experiments were performed 
with the help of Dr. Martin Wear. 
Briefly, hexa His-SpPCNA was first captured and orientated, via its N-terminal His-
tag, under neutral physiological conditions (pH 7.4, 150 mM NaCl) on an Ni 2 -NTA 
surface, followed by brief covalent stabilization using standard primary amine 
coupling chemistry. The final amount of protein immobilised on the surface was 860 
response units (RU), which gave an 85%-90% active surface. A concentration series 
of p21(141-152) from 50 nM to 25 jiM, in running buffer (10mM Hepes pH 7.4, 150 
mM NaCl, 0.005% surfactant P20, and 2% ethanol), was injected over the surface at 
a flow rate of 50 j.tl/min at 25 °C for 60 seconds. The surface was regenerated after 
each cycle by letting any complex dissociate in running buffer. 
Kinetic data were obtained by carrying out the experiment with same concentration 
range at 10 °C —45 °C in 5 °C increments. 
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2.3 RESULTS AND DISCUSSION 
2.3.1 Purification of recombinant untagged human PCNA 
The purification was carried out in three steps using ion-exchange (Q sepharose 
chromatography), affinity chromatography (Heparin sepharose resin) and finally gel 
filtration. The average purity was estimated to be >95% as shown by SDS - 
polyacrylamide gels of a typical purification (Figure 2-2). 
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Figure 2-2 Purification of untagged human PCNA. 
12% SDS-polyacrylamide gels were run with equal volumes of elution fractions and subsequently 
stained with coomassie. a) first purification step on Q sepharose; lane I = marker, lane 2= lysate, lane 
3 = flow through, lanes 4-14 = alternating elution fractions b) second purification step on Heparin 
sepharose: lane 1 = marker, lane 2 = pooled fractions from previous step. lanes 3-15 = alternating 
elution fractions c) third purification step using a S200 gel filtration column; lane I = marker, lane 2 = 
pool from previous step, lanes 3-15 = alternating elution fractions. As in fission yeast PCNA, the 
human protein runs at a higher molecular weight as calculated. 
47 
2.3.2 Sequence comparison of hexa His-SpPCNA with human and 
budding yeast PCNA 
As already discussed in Chapter 1, the overall secondary and tertiary structure 
(Figure 1-1, Figure 1-2) is well conserved among sliding clamps. Two eukaryotic 
PCNA crystal structures from humans and budding yeast have been published. The 
sequence alignment (Figure 2-3) by ClustalW (Thompson et al., 1994) shows that 
SpPCNA and hPCNA have 50% residues in common, while the two different yeast 
species share only 44% of their amino acids. hPCNA and ScPCNA are even less 
similar with a score of 35%. Nevertheless, the amino acids that make up the 
conserved hydrophobic pocket in PCNA seem to be highly conserved in all three 
species. The prediction would be that the hydrophobic pocket and the way p21(141-
160) binds to these PCNA molecules will be very similar. 
6His-SpPCNA MRSHHHHHHGIPMLEARFQQAALLKKLLDAIKELVTDANFDCNDNGISLQAMDSSHVALV 60 
hPCNA ------------MFEARLVQGSILKKVLEALKDLINEIWDISSSGVNLQSIDSSISL 48 
ScPCNA ----------- -MLEAKFEEASLFKRIIDGFKDCVQLVNFQCKEDGIIAQAVDDSRVLLV 48 
6Hi S - SpPCNA SMLIKSDGFEPYRCDRNIALGINLNALSKVLRCAQNEDLVTLKAEDTPJLVFESEKN 120 
hPCNA QLTLRSEGFDTYRCIJRNL$4VNLTSMSKILKCAGNEJJI ITLRAEDNADTLALVFEAPNQ 108 
ScPCNA SLEIGVAFQEYRCDHPVTLGWLTSLSKILRCGNTDTLTLI''PDSIILLFEDTKK 108 
6His-SpPCNA DRISDYDVKLMDIDQEHLGIPDIEYDATITMPAEFQRITRDLLTLSDS1JTINASKEG1R 180 
hPCNA EKVSDYENKLMDIEQI_GEQISCVVKMPSGEFARICRDLSH IGDAVVI SCAKDGVK 168 
ScPCNA DRIAEYSLKLMDIDADFLKIEELQYDSTLSLPSSEFSKIVRDLSQLSDSINIMITKETIK 168 
6His-SpPCNA FSCKGDIGNGSTTLKQHTDLSDQDQSIEISLTQAVTLTFSLKYLAQFTKATPLATRVTLS 240 
hPCNA FSASGELGNGNIKLSQTSNDKEEEAVTIE}EPVQLTFRYLNFFTTPLSSJTLS 228 
ScPCNA FVADGDIGSGSVIIKPFVDMEHPETSIKLEMDOPVDLTFGAKYLLDIIKGSSLSDRVGIR 228 
6His - SpPCNA MSNDVPLLVEYKNES-GFLRFYLAPKIGEEDEE 272 
hPCNA NSAD1LVVEYKIADMGHLKYILKIEDEEGS 261 
ScPCNA LSSEAPALFQFDLKS-GFLQFFLAPKFNDEE- - 258 
Figure 2-3 Sequence alignment of hexa His-SpPCNA, hPCNA and Saccharomyces cerevisice 
PCNA. 
Purple marks the residues that form hydrophobic pocket in hPCNA to which p21(141-160) binds in 
the complex structure. 	Most of them are well conserved in all three eukaryotic proteins: 56% are 
identical, while 19% are conserved in terms of charge or hydrophobicity. 
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2.3.3 Crystallization of unliganded SpPCNA and in complex with 
p21(141-160) 
After optimization of a condition from Structure Screen 1 unliganded SpPCNA 
crystals grew diffracting up to 2.2 A (a). The best SpPCNAIp2 1 co-crystals under 
optimized conditions diffracted to 2.2 A as well (Figure 2-4c). SpPCNA crystallized 
also in various other conditions (Figure 2-4b+d). 
.- 
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Figure 2-4 Protein crystals of SpPCNA. 
a) Unliganded SpPCNA, Space group: P2 1 , resolution: 2.4 A b) Unliganded SpPCNA, Space group: 
unknown, resolution: 3.6 A, conditions: 45% AS, p118.0 (100mM Tris), 10 niM CoC12, 1% PEG-
400(50%), 2.7 mg/ml protein at 4 °C for 4 weeks c) SpPCNA in complex with p21(141-160), Space 
group: H3 2 , resolution: 2.2 A d) SpPCNA in complex with p21(141-160), Space group: 113,, 
resolution: 3.5 A, conditions: 45% AS, 100 mM succinic acid pH 6.0, 4 - 6 mg/mi, peptide: protein 
ratio = 1.5:1, 18 °C for 2 days 
LJ 
2.3.4 X-ray data analysis 
2.3.4.1 Structure solution of monoclinic unliganded hexa His-SpPCNA 
crystals 
The best crystals of the 30.4 kDa His-tagged fission yeast protein (see section 2.3.3) 
diffracted to 2.2 A (Figure 2-5a), but the structure was solved using data up to 2.4 A, 
as data in higher resolution shells were of lesser quality. Statistics of the data are 





a 	 2.6 	 b 	 2.3 
Figure 2-5 Diffraction image for unhiganded and SpPCNA/p21(141-160) crystals. 
a) Diffraction image for a crystal of unliganded SpPCNA b) Diffraction for a crystal of SpPCNA in 
complex with p21(141-160) 
2.3.4.2 Structure solution of hexagonal SpPCNA/p21(141 -1 60) crystals 
The best crystals of the His-tagged fission yeast protein in complex with p21(141-
160) diffracted to 2.2 A (Figure 2-5b) and the structure was solved using data up to 
that limit. Statistics of the data are shown in Table 2-1. 
..... 	 ..... 
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a (A) 89.29 112.79 
b(A) 70.76 112.79 
c(A) 89.39 417.63 
alpha 90 90 
beta 119.69 90 
gamma 90 120 
Space group P2 1 H32 
Mean (I) I sd (I) 11.7 (2.4) 14.3(2.6) 
No of independent reflections 37113 51476 
Resolution range used in 
refinement 38.84-2.40 42.14-2.20 
Highest resolution shell 2.53-2.40 2.32-2.20 
overall completeness 97.5 (98.1) 98.2(9 1.4) 
R ym (%) 8.3 (42.5) 8.0 (38.6) 
Multiplicity 2.7 (2.7) 5.6 (2.7) 
Table 2-1 Statistics for SpPCNA crystal structures. 
2.3.4.3 Space group determination 
23.4.3.1 Unliganded SpPCNA 
Unliganded SpPCNA diffracted to 2.2 A and indexing in MOSFLM suggested P2 or 
P21 with unit-cell dimensions a = 89.29 A, b = 70.76 A, c = 89.39 A and P = 119.690  
as a possibility. The space group was confirmed as monoclinic P2 1 by the inspection 
of systematic absences of reflections in the SCALA output file (OkO reflections with 
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k # 2n were absent). Data were successfully indexed and processed to an R,YM  of 
8.3%. The unit-cell parameters and data reduction statistics are shown in Table 2-1. 
The calculated unit cell volume is 490621.8 A3 and gave a calculated Matthew's 
Coefficient (2.69 A3/Da) (Kantardjieff and Rupp, 2003) corresponding to 3 
monomers per asymmetric unit for a protein with the molecular weight of 30433 Da 
when packing in P2 1 with 54.25% solvent content. 
A self-rotation map calculated using data processed in space group P2 1 confirms the 
outcome from the Matthew's coefficient and reveals a small degree of rotational non-
crystallographic symmetry (Figure 2-6). Two threefold peaks appear at ic= 120° 
marking non-crystallographic symmetry ( 
Figure 2-6). 	 LI 
Chi= 120.0 	 Chi= 180.0 
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Figure 2-6 Stereographic projection plot of the ic= 1200  and K= 1800 sections of the self-rotation 
function of the unliganded SpPCNA data set. 
2.3.4.3.2 Space group determination (complex) 
SpPCNAIp21(141-160) complex crystals diffracted to 2.2 A and indexing in 
MOSFLM suggested H3 or H32 initially. Both variants were tried, but H3 2 was the 
only one that gave a solution. The unit-cell dimensions are a = b = 112.791 A and c = 
417.628 A. The systematic absences of reflections in the SCALA output file give 
further evidence for a 32  three-fold screw symmetry. Data were successfully indexed 
and processed with an Rsm of 8.0%. The unit-cell parameters and data reduction 
statistics are shown in Table 2-1. 
The Matthews Coefficient (2.1 A3IDa) gives the highest probability for two 
monomers of hexa His-SpPCNA present in the asymmetric unit (V= 4601190 A3) 
with 41.46% solvent content. 
A self-rotation Patterson map calculated using data processed in space group H3 2 
confirms two molecules per asymmetric unit. 
2.3.4.4 Model building and Refinement 
23.4.4.1 Unliganded SpPCNA 
3DPSSM attempts to prediôt a protein's 3-dimensional structure from its amino acid 
sequence by comparing it with structures of similar proteins. In this case the closest 
crystal structure available was hPCNA. 
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Using the trimer as a model MOLREP found three peaks for the rotation function. 
The RI/sigma scores were 14.64, 12.60 and 12.36 respectively, while the fourth 
solution was just a third of the value of the third rotation peak. For each rotation peak 
there was one solution of the translation function with correlation factors of 0.756, 
0.638 and 0.627. 
The electron density maps resulting from molecular replacement with the 3DPSSM 
output file, which included the first 254 residues of SpPCNA, as the search model 
were of sufficient quality to begin model building. One run of rigid body refinement 
in Refmac for 20 cycles yielded an R!Rfr ee factor of 45.5%/45% at a weighting factor 
of 0.3. In restrained refinement both the X-ray residual (reflecting the agreement 
between the observed and the calculated Fs), and the geometric residual (reflecting 
the fit between the expected and the observed geometry) are minimised at the same 
time. The weighting factor determines relative weighting of these two terms. A value 
of 0.3 is considered to be tight and is in the recommended range for structures with a 
low resolution limit (>1.5 A). 
The data were used up to 2.5 A and each chain was regarded as separate unit. This 
procedure was followed with a 35 cycle run of restrained refinement which yielded 
R/Rf,ee of 28.7%/36.2% at a weighting of 0.05. A first manual refinement step in 0 
(Jones et al., 1991) led to an R/Rf,, of 27.2%/34.4% after 10 cycles in restrained 
refinement. Loops (residues 101-108 and 186-189) in areas with particularly poor 
density were initially removed, neither were any residues of the hexa His-tag 
modelled. Building the loops and the hexa His-tags, which were visible for both 
chain A and B, but not for chain C, led to a drop in R/Rf ee to 25.3%133.5%. Various 
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rounds of adding water molecules using ARP/wARP as part of the CCP4 suite in 
addition to manual refinement steps led to a final R/R factor of 22.2%/29..7%. 
In an attempt to gain a higher resolution structure data from a second crystal from the 
same drop were obtained. 135 single frames in 1 degree increments were used for 
data processing. The model for use in molecular replacement was the final result of 
the previous refinement with all water molecules removed. A single rigid body 
refinement run with 20 cycles and a weighting factor of 0.3 yielded an R/Rf re, of 
32.8%/33.1%. Data were initially used up to 2.2A. A round of restrained refinement 
for 35 cycles and a weighting factor of 0.05 lowered the RIRfr ee to 25.2%130.5%. The 
addition of water molecules and manual refinement using COOT led to an R/Rf re, of 
22.8%/30.1%. Since it seemed to be impossible to improve the statistics any further 
the frames used for the structure solution were reviewed and batches number 18-20 
were excluded as their Rm erge was elevated in comparison with the remaining frames. 
Refinement was continued with a new SCALA output file (while retaining the Rf r 
data from the first SCALA output) to 22.7%/30.7% R/R. As the R/Rft ee statistics 
were essentially unaffected by omitting those frames, TLS (thermal —libration-screw) 
refinement was employed for further improvement. Initially one group consisted of 
the entire PCNA monomer. 
When refinement stagnated at 21.7%/29.3% R/R the TLS grouping was reviewed. 
The number of TLS groups to include in the refinement was assessed with the 
TLSMD server (Painter and Merritt, 2006) and different subdivisions were tested. 
The best result was obtained with five groups per monomer (1-19 plus His-tag if 
visible, 20-80, 81-124, 125-213, 214-254 or the last residue that was modelled). 
Throughout the refinement water was added in COOT and questionable loops were 
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attempted to be remodelled by superimposition with hPCNA. This led to an R/R1 
of 21.3%/28.7%. Final statistics for refinement and structural details can be found in 
Table 2-2. 
The quality of the model was assessed with PROCHECK (Laskowski et al., 1993) 
and analysis of the Ramachandran plot (Figure 2-7) showed 91.1% of non-glycine 
and non-proline residues in the most favoured regions, 7.9 % of all residues were in 
additionally allowed regions, 0.7% of the residues lie in generously allowed areas 
and 0.3% of residues are located in disallowed regions of the plot. This latter fraction 
consists of G1u106 and Asn108 in chain B and both of them are located in the same 
loop element of the protein structure. Many of PCNA's loops are very flexible with 
high B factors, which indicates disorder of those regions. 
we 
Structure Parameters unhiganded PCNAJp21(141-160) complex 
Rfactor(%) 21.3 19.2 
R free (%) 28.7 24.4 
B values (A) 
Main chain 40.41 37.13 
Side chain and waters 41.13 41.783 
Ligand (peptide) - 43.91 
Succrnic acid - 58.25 
Observed r.m.s. from ideal geometry in A 
Bond lengths 0.010 0.026 
Bond angles 1.469 2.272 
Dihedrals Chiral 0.11 Chiral 0.17 
Ramachandran plot, residues in % 
Most favoured regions 91.1 93.6 
Additionally allowed regions 7.9 6.5 
Generously allowed regions 0.7 - 
Disallowed regions 0.3 - 
• 	No. of water molecules 302 398 
Table 2-2 Structure Refinement Statistics for SpPCNA crystal structures. 
A fully consistent model of these regions could not be built, however, for 
completeness they were included in the PDB file in modelled positions. While the 
residues in the generously allowed and disallowed regions coincide with loop 
elements, the residues in allowed regions are located in well ordered sheets and 
helices. 
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Figure 2-7 Ramachandran plot for the structure of unliganded SpPCNA. 
Most residues have allowed conformations, but 7 residues (red) in difficult to model loops are outside 
the ideal areas. For details see Table 2-2. 
2.3.4.4.2 5pPCNA1p21 (141-160) complex 
The data that were obtained from a first crystal diffracted to 3.45A. Various SCALA 
runs were attempted for both space groups H3 and H3 2 as the determination of the 
correct space group was not straight forward. 
MOLREP runs with different number of molecules in the asymmetric unit were 
carried out. The only correct solution, however, was with 2 monomers in the 
?asymmetric unit using data processed in H3 2 . Using chain A from unliganded 
SpPCNA as a model MOLREP found one peak for the rotation function. The 
Rf7sigma score was 9.43, while the second solution was just half of the value of the 
first rotation peak. For the single rotation peak there was one solution of the 
translation function for the first monomer with a correlation factor of 0.3 50. The 
solution of the translation function for the second monomer yielded a correlation 
factor of 0.518. 
A number of restrained refinement steps with a weighting of 0.5 for 20 cycles 
yielded an R/Rf'ree of 19.3%/28.0%. 	 / 
A second crystal yielded useable data of up to 2.2A. A SCALA output file was 
obtained using frames 29-178 while omitting frames 83 and 84 due to elevated Rmerge 
values. The best model from the initial low quality crystal was used for molecular 
replacement. A single step of rigid body refinement for 20 cycles and a weighting 
factor of 0.05 gave an R/Rfree of 38%137.9%. Further restrained refinement steps led 
to an improvement of statistics to 23.60/6128.4%. For further decrease of the R/Rf ree  
values TLS refinement was employed using one group for each monomer. This 
procedure yielded an R/R&ee of 19.7%/24.3%. The use of 5 groups per monomer as 
described for the unliganded SpPCNA refinement procedure led to an R/Rf ree of 
19.2%/24.4% which was a slight deterioration, but helped to bring the remaining 
residues of disordered regions into allowed conformations. Final refinement statistics 
are displayed in Table 2-2. 
The quality of the model was assessed with PROCHECK (Laskowski et al., 1993) 
and analysis of the Ramachandran plot (Figure 2-8) showed 93.5 % of non-glycine 
and non-proline residues were in the most favoured regions while the remaining 
6.5% were found in the additionally allowed areas. As in the unliganded SpPCNA 
structure most loop regions are very flexible with high B factors, which resulted in 
regions that were difficult to model. 
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Figure 2-8 Ramachandran plot for the SpPCNAJp21(141-160) complex structure. 
All residues have allowed conformations as the modelling was facilitated by a better data 
quality/slightly higher resolution compared to the unliganded SpPCNA structure. For details see Table 
2-2. 
2.3.5 Description of the unhiganded SpPCNA crystal structure 
2.3.5.1 Conservation of the general structure 
The model of the PCNA trimer comprises the first 254 residues of 260 in chain A 
and C and 253 in chain B, 302 water molecules and 5 or 8 residues of the His-tag in 
M. 
chain A or B, respectively. No density for a His-tag in chain C was detected. The 
amino acid sequence is shown in Figure 2-3, where it is aligned with human and 
budding yeast PCNA. 
As in other eukaryotic loading clamps, functional SpPCNA consists of a set of three 
PCNA monomers that assemble to form a ring with a hole wide enough for a DNA 
double helix to pass through (about 35A) (Figure 2-9). A superimposition of the Ca 
backbone of all three chains of the SpPCNA model shows that each chain is folded 
very similarly, with a maximum rmsd fit of 0.338 A based on all 253 Ca atoms 
(Figure 2-1 Oa). 
Figure 2-9 Surface charge of unliganded SpPCNA. 
Left = front = C-side, right = back side. The overall surface charge is negative with a positively 
charged cavity to accommodate DNA. The same pattern is observed in all sliding clamps. 
Unsurprisingly, when superimposing SpPCNA, hPCNA and ScPCNA, the 3D 
structure of these proteins is very similar (Figure 2-1Ob). 
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SpPCNA seems to have a single helical turn in monomer A and C formed by 
residues 54-56 in a loop connecting I3D i and f3E 1 (Figure 2-11). Assembly into the 
ring- structure via 3D2 and 01, of adjacent monomers leads to the formation of a 
contiguous surface across each intermolecular boundary as the anti-parallel nine-
stranded f-sheets of each monomer connect. The central hole is lined by all together 
12 a helices, 4 from each monomer, which is a conserved structural feature in 
PCNA. These are held in place by a scaffold formed by the already mentioned 3 13-
sheets plus another three sheets located underneath the connector loop that are 
formed by 13D 1 and 1312  of each monomer. 
a 	 - 	 b 
Figure 2-10 Comparison of the backbone structure of SpPCNA, hPCNA and ScPCNA. 
a) Superimpositions of the Ca backbone of the three monomers of SpPCNA trimer. RMSD: chain B 
to chain A: 0.338A, chain C to chain A: 0.327 A; Key: ere(2n = A, blue = B, ieieenru = C; b) 
Superimposition of Ca backbone of the three eukaryotic PCNA structures. RMSD is 0.834A for 
hPCNA and SpPCNA and 1.132A for ScPCNA and SpPCNA_A. Key: purple = hPCNA, green = 




single helical loop (13 D1 - E 1 ) 
Figure 2-11 Regions of varying B factors and disorder in unliganded SpPCNA. 
a) Backbone structure of unliganded SpPCNA with colouring according to B factors. Red shows high 
and blue signifies low values. b) The red sections show areas that were difficult to model and that fit 
the density less well than the remaining areas. 
2.3.5.2 Connector loop and conservation of hydrophobic pocket 
As in the structure of unliganded human PCNA, the final residues 255-260 of 
SpPCNA are not visible as the C-terminus seems to be coordinated upon binding to 
p21 WAF  or a peptide derived from this checkpoint protein, which is an association 
control factor for PCNA in the cell (Waga et al., 1994). Residues 121-132 form the 
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interdomain connector loop (IDCL), which joins the N-terminal domain with the C-
terminal domain. The IDCL is flexible in unliganded PCNA structures and difficult 
to model. In addition to the IDCL the unliganded structure of a SpPCNA monomer 
contains, as in the hPCNA, zones with high temperature factors that correspond to 
loop regions between adjacent 3-strands Loops that are particularly affected include 
residues 6-8 (A i -aA i ), 93-97 (3G- 3H 1 ), 105-111 (G 1 - 3I),  164-165 (J3132- t3C2) 
and 182-193 (3D2- 3E2) (Figure 2-11) (Figure 1-2). 
As to be expected, the His-tag residues that appear in density also have high B-
factors. 
Some of these loop regions are also disordered and difficult to model, which leads to 
a small number of residues to be in disallowed regions of the Ramachandran plot 
(Figure 2-7). 
Furthermore, the sequence alignment of SpPCNA and hPCNA shows that the 
residues involved in the formation of the hydrophobic pocket are nearly identical in 
S. pombe and human PCNA (Figure 2-3). The only exceptions of those 16 residues 
are Cys27 vs. Asn27, Leul2l vs. Ile 121 and Va1123vs. G1n123. Ile and Leu are 
very similar in their chemical properties, but not in size. 
In the crystal structure one can see that indeed most residues forming the pocket are 
located at the same positions except for hydrophobic residues from the connector 
loop, which is slightly distorted anyway (Figure 2-12). The residues deep in the 
pocket (Met40, Va145, LeuJIle47, Tyr133, Pro234, Tyr249/50, Ala251/2 and 
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Figure 2-12 PCNA's hydrophobic pocket. 
a) Overlay of unliganded hPCNA (magenta) and unliganded SpPCNA (green). The residues in grey 
show the hydrophobic pocket which accommodates the p21 peptide in the complex crystal structure 
with hPCNA. In cases where name or position of an amino acid is not conserved between human and 
fission yeast proteins the first name or number stands for the human variant, the second one for yeast. 
As one can see the ammo acids deep in the pocket are orientated in the same position in both 
structures. The residues in the IDCL that contribute to the hydrophobic pocket are in different 
positions, which is to be expected as that linker is very flexible and disordered in the absence of a 
peptide ligand. b) Depictured is the semitransparent surface of SpPCNA. The grey areas show 
residues of the hydrophobic pocket. c) Overlay of the surface of hPCNA and SpPCNA. The larges 
variations are contributed by the flexible IDCL. On the whole the core pocket of fission yeast PCNA 
seems to be slightly larger than in hPCNA. 
2.3.5.3 Crystal packing showing His-tags act as a p21 mimic 
When looking at the crystal packing of the SpPCNA trimers (Figure 2-13), it 
becomes clear that both His-tags of chain A and B in one ring make interactions with 
the hydrophobic pocket/IDCL of an adjacent trimer. This contact makes the tag 
become more rigid and can hence be detected in the electron density maps (Figure 
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2-14). Crystal structures containing clear density for His-tags are fairly rare, since 







Figure 2-13 Crystal packing of unliganded SpPCNA. 
a) This picture shows clearly the 2-fold screw symmetry. The His-tags of chain A and B (red) make 
neat interactions with adjacent rings. There is no density for the third tag. Tnmers of different layers 
are staggered b) This picture shows the unit cell outline and the positioning of the trimenc ring and 
second ring related by the two-fold screw symmetry. c) The trimers are not neatly stacked, but are 
tilted against each other. While chains A - C and B - A in adjacent rings are close together, the tilt 
in the layering means that the N-terminus from one ring is too far away from the hydrophobic pocket 
of the neighbouring chain B. Therefore the His-tag of chain C and cannot make the stabilizing contact 
with a hydrophobic pocket. 
The interactions between the tags and the hydrophobic pocket are both hydrophobic 
and hydrophilic. The hydrophobic contributions come from lie-i and His residues 
that have no hydrogen-bonding potential left (Figure 2-15). Hydrophilic interactions 
are formed by direct and indirect hydrogen bonds: Chain A - His-4/NE2 Leu 126 
(Chain C)! 0, His-3/NE2 Water 14; Chain B 4 His-4/NE2 Leui26 (Chain 
Me 
A)/O). Furthermore, the interaction between two rings is stabilized by hydrogen 
bonds between non-His tag residues and the hydrophobic pocket. For Chain A: 
Asp63/0D2 Asp 130/N, Arg64/NH1 and Arg64/NE G1y127/0. For chain B: 
Asp63/0132 Water 84 and Water 136, Arg64/NH1 Leu126/O and G1yl27/O. A 
list of all distances of up to 4A between atoms of two adjacent rings can be found in 
Table 2-3. 
a 
Figure 2-14 Electron-density for both His-tags in the unliganded SpPCNA crystal structure. 
Density maps show clearly the location for up to 8 residues of the His-tags. a) SpPCNA Chain A b) 
SpPCNA Chain B 
His -4 and His -3 bind directly to the hydrophobic pocket (Figure 2-16). While His -3 
is located in the same place as Tyrl5l in the hPCNA/p21(141-160) complex, His-4 
is situated near where Met 147 in the human complex structure can be found. 
Both His-residues have an overall neutral charge as they use up their hydrogen 
bonding potential by forming a hydrogen bond with each other and with nearby 
water molecules (Figure 2-15). Hence they seem to be able to assume the position of 
the hydrophobic/aromatic residues of the p21 peptide, especially at neutral pH. 
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Figure 2-15 Hydrogen bonds that facilitate binding of the His-tag in the hydrophobic pocket. 
Both His -4 and His 4 are forming two hydrogen bonds with their side chains. Partners are either the 
other histidine residue or other residues/water molecules. 
Despite the seeming specificity of the hydrophobic pocket, which accommodates 
normally residues of the PIP-box binding motif, it surprisingly seems to be able to 
accept any residues which mimic aromatic amino acids (as found in the His-tags), if 
their freedom of movement is restricted. This notion is further reinforced by findings 
in the SpPCNA/p2 I co-crystal structure described below. 
Figure 2-16 Orientation of the His-tags in the hydrophobic pocket. 
For both chain A and B residues His-4 and His-3 are able to bind in the hydrophobic pocket due to 
overall neutral charge. Key: blue = residues -5 - 0 of chain A, green = residues -8 - 0 chain of B, 
= p21 of complex with hPCNA. 
His -tag Chain A Chain C Distance 
o HIS -8 SD MET 40  3.37 
CE MET 40  3.51 
CB HIS -7 CG GLU 124  3.85 
O HIS 125  3.67 
CG HIS -7 CG GLU 124  3.4 
O HIS 125  3.61 
NDI HIS -7 CG GLU 124  3.58 
C HIS 125  3.9 
O HIS 125  2.74 
CE  HIS -7 CG GLU 124  3.86 
o HIS 125  3.76 
NE2 HIS -7 CG GLU 124  3.86 
CD2 HIS -7 CG GLU 124  3.58 
O HIS -7 0 LEU 126  3.35 
CA LEU 126  3.54 
C LEU 126  3.9 
CDI LEU 126  3.49 
NDI HIS -6 0 HIS 125  
C LEU 126  
Ze 
o LEU 126  3.1 
CE1 HIS -6 0 HIS 125  3.73 
o LEU 126  3.57 
C HIS -5 CE MET 40  3.68 
0 HIS -5 CE MET 40  3.19 
o HIS 44  3.88 
CB HIS -4  SD MET 40 3.79 
CE MET 40 3.8 
CD2 LEU 47  3.95 
CG HIS 4 CD2 LEU 47  3.67 
NDI HIS -4 CDI LEU 47  3.8 
CE  HIS -4  CD2 LEU 47 3.86 
C LEU 126  3.98 
o LEU 126  3.25 
o GLY 127  3.8 
NE2 HIS -4  CD2 LEU 47 3.82 
C LEU 126 C LEU 126 3.76/3.91 
o LEU 126 0 LEU 126 3.03/3.4 
CB LEU 126 CB LEU 126 3.87/3.2 
CG LEU 126 3.3 
CD2 HIS -4  SD MET 40 3.99 
CE MET 40  3.86 
CB LEU 126 3.59 
CG LEU 126 3.45 
CD2 LEU 126 3.73 
CD2 LEU 47  3.65 
CB HIS -3 CG PRO 129  3.98 
CG HIS -3 CG PRO 129 CG PRO 129 3.56/3.95 
CD PRO 129  3.81 
N1D1 HIS -3 CG PRO 129  3.36 
CD PRO 129 CD PRO 129 3.94/4.0 
CG PRO 234  3.81 
CD PRO 234  3.8 
CE  HIS -3 CG PRO 129  3.78 
CB PRO 234  4 
CG PRO 234  3.73 
0 HOHW 5  3.23 
NE2 HIS -3 CG PRO 234 CG PRO 234 3.87/3.74 
CD PRO 234 3.87 
CD2 HIS -3  CG PRO 129 3.81 
CG PRO 234 3.62 
CD PRO 234 3.5 
CD PRO 129  3.83 
CG1 ILE -1  CG PRO 129 3.99 
CD] ILE -1  CB PRO 129 3.73 
CG PRO 129 3.83 
CGI ILE 131 3.6 
CDI ILE 131 CDI ILE 131 3.78/3.53 
CG2 ILE 131  3.62 
CG2 ILE -I  CB VAL 233 3.99 
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CGIVAL233 3.69 
CE MET I CG PRO 129 CG PRO 129 3.83 
CD PRO 129 CD PRO 129 3.8 
CD ARG 61 0 ASP 130 0 ASP 130 3.36/3.44 
0 HOHW 84 3.82 
NE ARG 61 0 ASP 130 0 ASP 130 3.52/3.53 
CZ ARG 61  0 ASP 130 3.95 
NH2 ARG 61 CB PRO 129  3.86 
CB ASP 63  CA PRO 129 3.99 
CG ASP 63 CA PRO 129 CA PRO 129 3.86/3.83 
N ASP 130 3.88 
ODI ASP 63 CA PRO 129  3.29 
CB PRO 129  3.68 
CD PRO 129  3.7 
0D2 ASP 63  CA PRO 129 3.26 
N ASP 130 3.01 
C PRO 129 3.62 
0 ASP 63  CA GLY 127 3.78 
CB PRO 129 3.95 
CG ARG 64  0 GLY 127 3.96 
NE ARG 64 0 LEU 126 0 LEU 126 3.92/2.94 
O GLY 127 0 GLY 127 3.66/3.9 
CZ ARG 64 0 LEU 126  3.84 
O GLY 127 0 GLY 127 3.92/3.51 
NF11 ARG 64 0 LEU 126 0 GLY 127 3.11/3.19 
O GLY 127  3.27 
Table 2-3 Distances between two adjacent rings via the affinity tags and other atoms at the 
interface. 
The yellow highlighted selection shows hydrogen bonds (or possible ones) between two chains. There 
are three monomers in the asymmetric unit, defined as chains A, B and C. Only chain A and C have 
contacts to affinity tag residues. In a few instances the same atoms in chain A and C are able to form 
hydrogen bond contacts with affinity tag residues. 
Many proteins are purified via an affinity tag of which the hexa His-tag is the most 
popular one. Often it is cleaved prior crystallization, but sometimes it is left on as it 
has been shown previously that the effect of the His-tag on the protein structure is 
generally not significant (Chant et al., 2005). A recent review of the impact of His-
tags on protein structures (Carson et al., 2007) found that less than 10% of the solved 
structures actually contain a His-tag and of those less than 6% (65 structures) have 
main-chain coordinates for four or more consecutive histidine residues. Only 29 
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structures have five or more consecutive histidine residues with complete side-chain 
coordinates and an average B factor for those residues of 40 A2 or less. A closer 
examination of the latter group showed that almost all of those tags take part in 
making crystal contacts, where a third of them are bound to the unliganded protein 
and the remainder extends into the solvent to bind into pockets on adjacent protein 
molecules. As one expects those pockets are mainly of an acidic nature to provide 
hydrogen-bond acceptors. Sometimes metal ions like nickel, cadmium or zinc are 
associated with the tags. In a few cases the electrostatic surface of the adjacent 
molecule shows an overall basic charge. 
Histidine has a special status among amino acids as its protonation state is pH 
dependent. Its pKa  lies between pH 6 and 7 for the side chain and is highly dependent 
of the environment. At a neutral pH histidine is "singly protonated" and is uncharged 
(Figure 2-17). In this state it is able to interact with positively charged residues acting 
as a hydrogen-bond acceptor. Therefore histidine will be harder to protonate in a 
positively charged environment which leads to a lower effective pK a. In the neutral 
form histidine has also aromatic properties and can be found stacked between or 
head-on with tyrosine and phenylalanine. 
At pH 6 the amino acid is "doubly protonated" and hence positively charged. In this 
form it is likely to seek interactions with acidic residues. 
What is the importance of this special amino acid in the formation of protein-protein 
interactions? Upon comparison of homodimers (e.g. cytochrome c') and 
heterocomplexes (e.g. antibody-antigen, enzyme-inhibitor) histidine residues have 
been found to have a relatively high interface propensity in heterocomplexes. 
Propensity describes the likelihood of a residue to be involved in the formation of a 
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protein-protein interaction interface over the rest of the protein surface (Jones and 
Thornton, 1996). Hence it is in accordance with naturally occurring protein-protein 
complexes that His-tags make contact with adjacent protein molecules in crystals. Of 
course the space restrictions in crystal packing can promote the non-specific binding 
of histidine residues to protein pockets or surfaces due to reduced degrees of 
freedom. 
-N• ,-Ni1 
negatively charged /\ 	/ "doubly protonated" 
N 	4HN 	
Positively charged 
"singly proton afed" = uncharged 
Figure 2-17 Protonation states of histidine. 
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2.3.6 Thermal denaturation assay of SpPCNA and hPCNA to test 
for His-tag binding 
The fact that the His-tag is located in the hydrophobic pocket of PCNA is 
explainable, but nevertheless intriguing since the drugability of this pocket in 
hPCNA has been discussed recently (Kontopidis et al., 2005). If anything with a 
remotely aromatic character can be found to bind there, then the specificity of this 
pocket may be questioned. 
To test if the binding of the His-tag to the pocket is a mere artefact of crystal packing 
induced by spatial restriction and to confirm the specificity of the pocket, a thermal 
denaturation assay was carried out with both SpPCNA and hPCNA. In this assay the 
unfolding of both proteins is monitored in the absence and under increasing 
concentrations of two hexameric peptides (100 .tM, 200 .tM, 500 IiM and 1 MM for 
SpPCNA and 500 jtM and 1 mM for hPCNA): IGHHHH and HHHHHH. The crystal 
structure of unliganded SpPCNA shows that residues Ile-1 and Gly-2 which are part 
of the linker region between protein and the six histidine residues make an 
interaction with certain residues at the pocket. As Figure 2-12 shows the comparison 
of the human and fission yeast binding pocket shows minor differences, which might 
be just significant. It has been shown that ligand binding has a stabilizing effect on 
proteins which can be visualized with the thermal denaturation assay as a Tm shift 
towards a higher temperature (Ericsson et al., 2006; Lo et al., 2004). Figure 2-18 
shows the melting curves of SpPCNA in the presence of the two peptides. It is 
difficult to distinguish any significant differences between the melting curves by eye, 
so it is important to apply a suitable equation which calculates the melting or 
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Figure 2-18 Thermal denaturation curves of SpPCNA in the absence and presence of IGHHHH 
and HHHHHH. 
a) Fission yeast PCNA under the influence of IGHHHH b) Fission yeast PCNA under the influence of 
HHHHHFI. Key: red = no peptide, dark blue = 100 tM peptide, green = 200 pM, black = 500 AM 
peptide, pink = 1 mM. When analysing the curves just by eye the difference between them, i.e. the T m , 
seems small if at all present. Only by fitting the data to a function, significant changes in T m may 
become apparent. 
Table 2-4 summarizes the Tm values for both SpPCNA and hPCNA. While the 
transition midpoint shifts at 0.1 mM and 0.2 mM lie within the error compared to 
protein in the absence of any potential ligand at 0.5 mM of both peptides seem to 
have a stabilizing effect on fission yeast PCNA. With increasing peptide 
concentrations the amount of DMSO in the sample increases as well as this is the 
solvent of the stock solutions (25 mM for HHHHHH and 50 mM of IGHHHH). 
DMSO has been shown to have a destabilizing effect on PCNA as is to be expected 
(the extent will be quantified in section 3.4.3). At same concentration of each peptide 
HHHHHH will contain hence twice the amount of solvent. In order to correct for the 
effect of DMSO controls have been carried out that include just protein and DMSO 
at the equivalent peptide concentration. At 1 mM concentrations of both peptides it 
seems that HHHHHH has a slightly stronger stabilizing effect on SpPCNA than 
75 
IGHHHH when judging by the ATm shift between control and experiment, which 
implies a higher affinity for the protein. Human PCNA was only exposed to peptides 
at 0.5mM and 1mM. 
Concentrations T. (°C) for SpPCNA Tm (°C) for hPCNA 
of peptides 
(MM) IGHHHH 	HHHHHH IGHHHH 	HHHHHH 
o 45.22 ± 0.21 52.92 ± 0.20 
0.1 45.32 ± 0.22 45.56 ± 0.22 - - 
0.2 45.68 ± 0.22 45.90 ± 0.20 - - 
0.5 46.27 ± 0.21 45.98 ± 0.17 52.86 ± 0.15 52.18 ± 0.15 
(control = (control = 
45.35 ± 0.36) 51.67 ± 
0.15) 
1 48.08±0.59 47.42±0.52 50.04±0.15 49.16±0.17 
(control = (control = (control = (control = 
45.35 ± 0.36) 43.78 ± 0.39) 51.67 ± 0.15) 50.69 ± 
 0.15) 
Table 2-4 Comparison of T m values for SpPCNA and hPCNA for various peptide 
concentrations. 
Control: To correct for the destabilizing effect of DMSO at higher peptide concentrations equivalent 
volume ofjust DMSO is added to the protein to observe the effect on T m of solvent alone. 
To sum up, both peptides have a stabilizing effect on SpPCNA, while HHHHHH is 
slightly more stabilizing than IGHHHH, suggesting a higher affinity for the sliding 
clamp. The calculated K js of IGHHHH and HHHHHH for SpPCNA at the melting 
temperature are 893 tM and 9171.tM, respectively. 
In contrast to SpPCNA the human sliding clamp experiences no significant 
stabilization upon complexing with either of the hexapeptides; in fact at a 
concentration of 1mM for both peptides, the T m value of the DMSO control is higher 
than for the Tm value for either of the peptides. This suggests a destabilizing effect of 
the peptides which is observed when a ligand has a higher affinity for the unfolded 
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protein than for the folded form. Of course this experiment is carried out under non-
natural conditions. Neither DMSO nor this kind of elevated temperature would be 
experienced in a cell. 
Possible explanations for the difference of the thermal shift results 
On the whole hPCNA seems to be more stable than - the yeast version of the sliding 
clamp as the transition midpoint difference between hPCNA (T m= 52.92°C ± 0.20) 
and SpPCNA (Tm  45.22°C ± 0.21) in the absence of peptides and DMSO suggests. 
As already mentioned in Chapter 1 sliding clamps differ in the number of hydrogen 
bonds that are located at the interface of monomers. The higher developed an 
organism is the more bonds are located at this interface which is increasing the 
stability of the trimer/dimer. When calculating hydrogen bonds of up to 3.5A in 
SpPCNA there are 13 (7 for main chain only) between chain A and chain B and 11 
between both A and C (6 for main chain only) and B and C (8 for main chain only) 
(Figure 2-19). In comparison hPCNA contains for the same parameters the same 
number of hydrogen bonds, but two more main chain to main chain bonds. These 
two contacts offer an explanation for the increased Tm of 1iPCNA in comparison to 
SpPCNA. 
Despite the high degree of conservation of the hydrophobic pocket, the data from the 
thermal shift assay suggest that there are certain differences between both sliding 
clamps that are not obvious, but may be able to influence the way proteins recognize 
each other in both species. Proteins containing the PIP-box binding motif have been 
found also in the fission yeast genome. Despite the lack of an obvious homologue to 
p21, other proteins like DNA ligase IIcdcl7 (Martin et al., 2004), DNA polymerase 
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/Cdc27 (Reynolds et al., 2000), Fen-1 (Tanaka et al., 2004), AP-endonuclease Apn2 
(Dianova et al., 2001), uracil DNA N-glycosylase Ungi (Ko and Bennett, 2005) and 
MSH6/MutS (Clark et al., 2000) protein have been found to either bind directly to 









Figure 2-19 Hydrogen bonds between monomers in SpPCNA trimer. 
in 
The PIP-motif is mainly located near the termini of the proteins which makes it more 
likely to be solvent accessible and available for protein-protein interaction. 
Numerous other proteins have been found to contain the motif (140 with Q-x-x-
IIMIL-x-x-Y/F-Y/F as search template); some have the sequence near a terminus, 
others have it in the middle of the sequence, which does not necessarily occlude the 
site. However, other proteins have shown to contain only a fraction of the binding 
motif. 
An example is the adenine DNA glycosylase MutY (Table 2-5). This protein 
contains the full motif in human and mouse, but only L and F are present in fission 
yeast. Nevertheless, the remainder of the motif is essential for binding to PCNA 
(Chang and Lu, 2002). A search with parts of the motif will therefore undoubtedly 
uncover many more proteins that may bind to that pocket. 
S. pombe proteins with Total length of PIP- 
homologues in humans 	 Motif motif containing 
proven to bind to hPCNA  proteins in S. pombe 
AP-endonuclease Apn2 396-QSKLLSFF-403 523 
uracil DNA N-glycosylase 
25-QPRLDNFF-32 332 
Ung 1  
MutS protein homolog 
(mismatch 
22-QKTLFGFF-29 
_repair, _mshó)  
1254 
Feni 338-QGRLDSFF-345 380 
Cdc27/DNA Pol 6 362-QKSINSFF-369 372 
cdcl7/DNA ligase I 24-QSDIsN1;- F-31 768 
MutY 438-vTSLSNFK-445 461 
Table 2-5 PIP-box motifs in fission yeast proteins. 





2.3.7 Description of the hexagonal SpPCNAIp2I(141-160) crystal 
structure 
2.3.7.1 General structure and crystal packing 
The asymmetric unit contains two monomers, which belong to two different trimeric 
rings of PCNA and one peptide molecule, which is shared between the two PCNA 
monomers (Figure 2-20, Figure 2-2 1). 
Figure 2-20 Crystal packing in hexagonal SpPCNAJp21(141-160) complex crystals. 
a) View along axis c b) Side view of the unit cell. The two PCNA monomers of one asymmetric unit 
are shown in blue and green, while the shared peptide is highlighted as magenta. The green monomer 











Figure 2-21 The complex of SpPCNA with p21 (140-160). 
a) Electron-density for p21(141-160) in the SpPCNAJp2I complex structure. The map clearly shows 
the location of residues 141-159. While amino acids 142-153 are bound to Chain B (blue), Chain A 
(green) accommodates the remainder of the peptide. b) + c) Direct hydrogen bonds between the two 
monomers of SpPCNA. 
In order for the unit to repeat, the two joined rings have to be fitted back to front with 
other pairs. The two molecules touch each other head to head. Apart from having the 
p21 peptide bound across, the two PCNA monomers are linked directly by a few 
interactions via their IDCLs (Figure 2-20, Figure 2-21). 
Table 2-6 gives a list of distances <4.0 A and possible contacts between the peptide 
and both PCNA monomers. 







CE MET 40 CA MET C 147  3.66 
CA MET C 147  3.23 
C MET 	147  3.98 
N THRC 148  3.82 
CG2 THR C 148  3.97 
o SER 43 CZ ARG C 156 3.48  
NH1ARGC156 3.3  
NH2ARGC156 3.4  
CB HIS 44 CG ARG C 155 3.73  
O HIS 44 CA SERC 146  3.61 
CB SERC 146  3.71 
OG SERC 146  3.89 
C SERC 146  3.7 
N MET 	147  2.84 
CA MET C147  3.71 
CB MET C 147  3.54 
N ARG C 156 3.72  
N}I1ARGCI56 3.46  
N LEUC 157 3.34  
CB LEU C 157 3.58  
CG1 VAL 45 CD GLNC 144  3.62 
OE1GLNC 144  3.95 
NE2GLNC 144  3.5 
CD ARGC 156 3.68  
NEARGC156 3.81  
CZARGC156 3.98  
NIHIARGC 156 3.4  
CG2 VAL 45 CG GLN C 144  3.72 
0 THRC 145  3.98 
C VAL 45 CG MET C 147  3.78 
0 VAL 45 CG MET C 147  3.51 
SD MET 	147  3.69 
CB LEUC 157 3.92  
MN 
CG LEUC 157 3.88  
CD2LEUC 157 3.8  
C ALA 46 CG MET C 147  3.93 
CB LEU 47 CG MET C 147  3.94 
CD  LEUC 1 57 3.82  
o HIS 125 CA SER C 153  3.36 
CB SERC 153  3.26 
CA LEU 126 C AHIS C 152  3.92 
C BHIS C 152  3.86 
o AHISC 152  3.53 
o BHIS C 152  3.47 
CD1 LEU 126 CB MET 	147  3.96 
o TYRC 151  3.82 
CDI LEUC 157 3.54  
o LEUC 157 3.79  
C LEU 126 0 AllIS C 152  3.65 
o BHIS C 152  3.59 
N GLY 127 C AHIS C 152  3.9 
C BHIS C 152  3.85 
o AlliS C 152  2.85  • BHIS C 152  2.79 
CAGLY127 0AHISCI52  3.81  • BHIS C 152  3.77 
0 GLY 127 CB TYRC 151  3.38 
CGTYRC15I  3.82 
CD2TYRC 151  3.84 
CB PHEC 159 3.81  
CD1 P1-IF C 159 4.0  
CG  ILE 128 CD  TYR C 151  3.92 
CD  ILE 128 CE  PHE C 159 3.54  
CG2 ILE 128 CZ PHE C 159 3.91  
CD PRO 129 CE2TYRC 151  3.89 
CD2TYRC 151  3.83 
CB PHEC 159 3.65  
CG PHEC 159 3.74  
CD2PHEC 159 3.73  
CDI ILE 131 OH TYRC 151  3.3 
CB THR 206 CD ARG C 142  3.84 
NEARGC142  3.93 
OGITHR2O6 NEARGC142  3.81 
CZ ARG C 142  3.45 
NIB ARG C 142  3.24 
CG2 THR 206 CD ARG C 142  3.75 
O ASP 232 CE2 PHE C 150  3.13 
CD2 PHE C 150  3.69 
CG  VAL 233 OH TYRC 151  3.74 
CB PRO 234 SD MET C 147  3.9 
CE MET 	147  3.92 
CD2LEUC 157 3.78  
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CG PRO 234 SD MET 	147  3.85 
CE MET 	147  3.76 
CG PHEC 150  3.75 
CD1PHEC15O  3.6 
CE1TYRC151  3.92 
CD2LEUC 157 3.78  
O ILEC 158 3.71  
CE2 PHE C 159 3.99  
CD PRO 234 CB PHEC 150  3.87 
CG P1-IEC 150  3.51 
CD1PHECISO  3.84 
CD2 PHE C 150  3.74 
OHTYRCI5I  3.7 
O ILEC 158 3.67  
CB TYR 249 SD MET C 147  3.94 
CE MET 	147  3.63 
CD2 LEUC 157 3.89  
CG TYR 249 CZ PHEC 159 3.95  
CE2 TYR 249 CZ PHE C 159 3.94  
CD2TYR249 CZ PHEC 159 3.52  
N ALA 251 SD MET 	147 3.77 
N ALA 251 CD2LEUC 157 3.82  
CB ALA 251 NE2 GLN C 144  3.84 
CG2 THR C 145  3.32 
C THRC 145  3.72 
O THRC 145  3.31 
C SERC 146  3.58 
O SERC 146  3.79 
N MET 	147  3.7 
CBARGC1S6 3.93  
C ARGCI56 3.79  
O ARGC 156 3.68  
N LEUC 157 3.92  
C ALA 251 NE2GLNC 144  3.54 
O ALA 251 CD GLNC 144  3.92 
NE2GLNC 144  2.91 
N PRO 252 CG2THRC 145  3.74 
CD PRO 252 CG2THRC 145  3.54 
CE1PHEC 150  3.99 
CZ PHE C 150  3.98 
C PRO 252 NE2 GLN C 144  3.92 
O PRO 252 0 ARGC 143  3.77 
NE2GLNC 144  3.51 
N THRC 145  3.14 
CA THRC 145 3.74 
CB THRC 145  2.97 
OGITHRC 145  3.74 
CG2 THR C 145  3.22 
CA LYS253 0 ARGC 143  3.15 
M. 
CB LYS 253 0 ARG C 143  3.88 
CG LYS 253 OEI GLN C 144  3.4 
CD LYS 253 OEI GLN C 144  3.87 
C LYS253 0 ARGC 143  3.44 
o LYS253 CD ARGC 142  .81 
NE ARG C 142  3.55 
N 1LE254 C ARGC 143  3.88 
o ARGC 143  2.82 
CA 1LE254 0 ARGC 143  3.98 
CG  ILE B 254 0 ARG C 143  3.88 
OG1THRC145  3.83 
CD1 ILE 254 OG1 THR C 145  3.99 
C 1LE254 N ARGC 143  3.96 
o 1LE254 CA ARGC 142  3.14 
CB ARG C 142  3.75 
C ARGC 142  3.33 
N ARG C 143  2.75 
CA ARG C 143  3.74 
CG ARG C 143  3.74 
o ARG C 143  3.58 
Table 2-6 Distances between p21(141-160) and both monomers in the SpPCNA complex 
structure. 
The yellow highlighted selection shows hydrogen bonds (or possible ones) between the peptide 
(KRRQTSMTDFYHSKRRLIFS) and either of the two monomers in the asymmetric unit. 
2.3.7.2 Comparison of unhiganded and complexed SpPCNA 
The N and C terminal residues of the peptide p21 (141-160) were not visible and 
only electron density for residues 142-159 was detectable. No His-tags are visible in 
this structure. When superimposing a monomer of unliganded SpPCNA and one 
from the complex with p2! peptide (ligand removed) (Figure 2-22), it is obvious that 
the secondary features remain the same. Loops, including the IDCL, are the only 
regions with significant backbone changes, but as they are generally flexible and 
assume different conformations in each single monomer, this is to be expected. 
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Particularly in the area of the hydrophobic pocket the superimposition shows 
identical conformation. Interestingly the three [3-strands (PI, [3C 2 and [3D2) are more 
extended in the unliganded structure than in the complex: residues 109-117 vs. 
residues 111-117, residues 167-172 vs. residues 166-170, residues 176-182 vs. 
residues 178-182. 
As mentioned above no density was observed for His-tags (Figure 2-20). A reason 
might be the unavailability of connector loop and hydrophobic pocket for 
coordination of the histidine residues in this structure (see section 2.3.5.3 for crystal 
packing of unliganded SpPCNA) as connection between the two monomers is 
established via these structural features (Figure 2-20, Figure 2-21). 
Figure 2-22 Superimposition of the backbone structure of unliganded and complexed SpPCNA 
(peptide omitted). 
Key: blue = unliganded, green = complexed, RMSD: 0.67A 
Apart from the shared peptide which may act a bit as a connector holding the two 
separate PCNA rings together, five hydrogen bonds are formed between the 
monomers directly (His44/NE2 (chain A) 	Aspl22/ODI and 0D2 (chain B), 
Me 
Asp l22fN (chain A) Asp 120/0 (chain B)) or by bridging water molecules (Figure 
2-2 lb+c). 
Some electron density is displayed for the C-terminus of Chain A (1-254), though it 
was not possible to model the positions of the side chains correctly. Chain B is 
modelled up to residue 255. However, this additional density for the C-terminus 
agrees with previous finding that the C-terminus is coordinated upon complex 
formation with p21 peptide derived as the N-terminus of the peptide pairs up with the 
C-terminus of the sliding clamp. 
Furthermore, the IDCL is more rigidified in the complex with p21, shown by a 
reduction in B factors, which was also observed as previously in the human PCNA 
complex structure, although the difference is more obvious in the human case (Table 
2-7). 
However, while the peptide binds along the IDCL in the human structure (Figure 
2-23), in the fission yeast example the C-terminal half (Sen 53-Phel 59) bends away 
from the monomer in which it occupies the hydrophobic pocket with the PIP-box 
motif. So while the N-terminus with PIP-box motif is bound to monomer B, the C-
terminus is coordinated into the hydrophobic pocket of an adjacent monomer, which 
belongs to a second trimer, in this structure called monomer A (Figure 2-20, Figure 
2-21, Figure 2-23). 


















B Average Chain A Chain A 
121 45.63 43.08 39.53 42.75 27.61 30.23 28.92 119.06 16.45 
122 48.79 46.14 41.08 45.34 25.99 33.83 29.91 126.10 31.29 
123 51.50 48.75 42.74 47.66 30.94 37.54 34.24 129.83 29.38 
124 52.57 50.35 44.28 49.07 34.07 36.62 35.35 132.17 27.67 
125 53.22 51.11 44.35 49.56 37.5 39.44 38.47 129.24 21.09 
126 51.81 50.67 44.40 48.96 38.97 35.31 37.14 128.65 16.47 
127 49.02 50.47 42.16 47.22 40.6 33.32 36.96 125.14 18.10 
128 45.84 50.08 39.58 45.17 42.85 35.63 39.24 127.98 15.66 
129 45.08 49.15 38.19 44.14 47.87 38.96 43.42 124.98 34.41 
130 A4.43 47.56 37.45 43.15 52.34 42.71 47.53 111.91 36.66 
131 44.21 45.54 36.44 42.06 47.89 40.17 44.3 91.93 41.35 
132 43.53 42.98 35.67 40.73 40.03 39.43 39.73 126.97 45.42 
Table 2-7 B factors for the IDCL residues in both unliganded and complex crystal structures of 
SpPCNA and hPCNA. The overall B factor for main chains atoms is 40.41A 2 for the unliganded 
structure and 37.13A 2 for SpPCNA in complex with p21(141-160). 
In the hPCNA structure the peptide forms hydrogen bonds with the IDCL (Table 
2-8). Seven out of eleven of those bonds involve main-chain to main-chain contacts 
and should be available for complex formation in the yeast case as well. Residues 
Asp 120 and Glu 124 are conserved between both fission yeast and human PCNA, so 
the side chain contacts provided by these amino acids should be possible for both 
proteins. 
Table 2-6 shows distances of 4 A or less between the peptide and either of the two 
chains in the asymmetric unit. 
As the superimposition of unliganded hPCNA and SpPCNA shows (Figure 2-12a, 
Figure 2-23) there are only minor differences in the backbone and surface. 
IDCL residues in hPCNA 
involved in hydrogen bonds 
with p21  (141-160) 
Equivalent IDCL residues 
in S. pombe PCNA 
Met ll9(0) Met 119 
Asp120 (OD1) Asp120 
Leul2l(N and O) 11e121 
Asp122(0) Asp122 
Va1123(N and O) Gln123 
G1u124 (0D2) G1u124 
G1n125(N and O) His125 
G1y127(N) G1y127 
Table 2-8 Residues involved in bonding between the IDCL in hPCNA and p21(141-160). 
The highlighted amino acids contribute entirely towards main-main chain contacts. Most of those are 
also identical or similar in both proteins. The two remaining residues Asp120 and Glu124 form 
contacts via side chain atoms, which are conserved in hPCNA and SpPCNA. 
Even the residues of the small second pocket (humanISpPCNA: Cys/Asn27, Met4O, 
A1a67, G1y69, LeuJIie 121 and Val/G1n123) (Figure 2-12b) that accommodates the 
C-terminus of the peptide in the human complex structure are largely conserved. 
Most of the residues are conserved with very similar orientation of side chains. 
However, a few small changes on the surface, mainly in the linker region, do exist 
(Figure 2-12c) and residues Cys27 and Va1123 are replaced by Asn and Gin 
respectively in fission yeast (Figure 2-12a). So there is the possibility that these 
variations between hPCNA and SpPCNA lead to the observed difference in p21 
binding. 
When superimposing the complex of human PCNA and p21 with SpPCNA and the 
same peptide, then one can see that the PIP-Box residues (Gin 144, Met 147, Phel 50 
and Tyr 151) are in both structures at the same position (Figure 2-23, Figure 2-24a), 
which supports the idea of the conserved pocket/binding motif that has been 







Figure 2-23 Comparison of the complexes of human and fission yeast p21 complex structures. 
a) Superimposition of SpPCNA (dark green) with p21 peptide (light green) bound and hPCNA 
(purple) with p21 peptide (magenta); b) Surface charge of SpPCNA with stick models of p21 peptides 
as it binds to hPCNA (magenta) and to SpPCNA (light green). 
As Gulbis and colleagues (Gulbis et al., 1996) found out, the second part of the 
peptide binds along the connector loop in the human complex structure, where it 






Figure 2-24 Binding of p21(141-160) to SpPCNA in comparison to hPCNA. 
a) The PIP-box part of the peptide seems to bind in a very similar way to the hydrophobic pocket in 
both complex structures. G1n144, Met147, PhelSO and TyrlSl are exactly in the same place with 
same side chain orientations in the human (magenta) and the fission yeast (light green) structure. b) 
The very C-terminal portion of the peptide is coordinated into the hydrophobic pocket of the second 
monomer in the asymmetric unit. In magenta is shown the p21 peptide as it binds to the pocket in 
hPCNA. Only the residues 156-159 of the peptide in the SpPCNA are shown for clarity. Here Phe 159 
acts as TyrlSl and Leu157 assumes roughly the position of Met147. 
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In contrast with the SpPCNA complex structure, the second half of the peptide does 
not form a n-sheet with the IDCL strand as it does in the hPCNA structure. Instead it 
dissociates from the one subunit at Sen 53 (Figure 2-20, Figure 2-21, Figure 2-23) 
and is coordinated by the hydrophobic pocket of a neighbouring ring. While Phel 59 
assumes the position of TyrlSl in the PIP-box motif (Figure 2-24b), which agrees 
with the hydrophobic interaction of the PIP-box motif on that site, Leu157 is found at 
the same site where Met 147 is positioned in the PIP-box motif. 
2.3.8 SPR binding experiments of SpPCNA and human p21 
peptides 
The crystal structure of SpPCNA in complex with human p21  (141-160) suggests that 
the portion of the peptide which binds along the linker strand in the human crystal 
complex has a low affinity for the yeast linker as it appears to prefer to bind to the 
hydrophobic pocket of an adjacent ring via aromatic/hydrophobic. The possible 
reasons for that have been discussed above. In order to find out if a peptide version 
missing this portion [p21  (141-152)] has a similar affinity for SpPCNA as the full-
length one, SPR studies have been carried out. If the second portion is freely mobile 
in solution then the affinity of the full length peptide and the shorter version should 
be similar, otherwise the longer peptide should bind more tightly to the sliding 
clamp. 
Globally fitting a kinetic model where a 1:1 complex is formed between His- 
SpPCNA and p2l(141-152) to data similar to those illustrated in Figure 2-25 gave 
very good fits. Kinetic data suggest a reaction with a fast on rate at 1 •9*  1 06/Ms and a 
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fast off rate of 0.47/s at 25 °C for the shorter version of the p21 peptide (Figure 2-25, 
bottom). A steady-state affinity of about 500 tiM (Figure 2-25, top) for p21(141-152) 
was calculated, which is close to the ITC derived 307nM (see section 3.3.3) for the 
interaction of p21(141-152) with hPCNA. These values increase with temperature. 
The Kd of p21(141-160) for the interaction with hPCNA has been determined as 114 
nM by ITC (Zheleva et al., 2000), which agrees with the fact that the second portion 
of the full-length peptide is contributing to the binding by making interactions with 
the linker strand as seen in the crystal structure. In the fission yeast crystal complex 
this second part of the interaction is not observed, so the K d for p21(141-160) is 
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Figure 2-25 Results of the SPR binding assay. 
The top curve shows the binding curve for p2l(14I-152) to SpPCNA at 25 °C. A steady-state analysis 
yielded an affinity of about 500 nM for this reaction. The bottom graph shows the quick on and off 
rates for this binding reaction at 25 °C. 
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2.4 SUMMARY, CONCLUSION AND FUTURE WORK 
The crystal structures of SpPCNA in the unliganded form or in complex with 
p21(141-160) show four different ligands in the hydrophobic pocket. In the 
unliganded structure two His-tags of adjacent rings bind to the supposedly specific 
binding site that usually accommodates the PIP-box motif. 
In the crystal complex of SpPCNA and p21  (141-160) one peptide molecule fills two 
hydrophobic pockets that are located on two adjacent rings. One pocket contains the 
PIP-box motif as expected from the hPCNAIp2 1 co-crystal structure. The second site 
accommodates the C-terminus of the peptide containing hydrophobic/aromatic 
residues. 
Histidine-rich hexapeptides mimicking the His-tag showed different binding 
affinities for SpPCNA and hPCNA, respectively. Furthermore, the binding mode for 
the p21 peptide to SpPCNA differs significantly from how it binds to hPCNA. All 
these results suggests that the observed changes in amino acid sequence and side 
chain orientation between both eukaryotic PCNA molecules have a considerable 
effect on specificity of the binding pocket. 
The fact that both histidine-rich peptides or aromatic/hydrophobic residues can bind 
to the hydrophobic pocket, which is supposed to be specific to the PIP-box motif, 
seems to suggest that there may be a lack of specificity concerning the ligand. An 
exact match to the motif does not seem to be required for a low binding affinity at 
least. 
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Concerning the His-tag mimic hexapeptides, further studies are required to see if 
those two hexamers bind specifically to the hydrophobic pocket or if they cover the 
surface of SpPCNA non-specifically and help to protect it from thermal denaturation. 
Competition experiments (e.g. FP) using p21 peptides and the hexamers at the same 
time would show if binding of both at the same time is possible. Furthermore, mutant 
PCNA which is unable to form a trimer due to single amino acid substitution 
(Jonsson et al., 1995) would be small enough to fly in MALDI-TOF experiments. 
Analysis of the spectra of the PCNA-peptide mixture could then be used to determine 
the stoichiometry of the complex. 
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CHAPTER 3. A structure-based approach to find 
inhibitors for PCNA as an anti-cancer drug target 
3.1 INTRODUCTION 
As discussed in Chapter 1, p21  is an association control factor for PCNA in the cell. 
When p21 binds to the loading clamp it prevents DNA polymerase ö from attaching 
itself to PCNA and as result brings DNA synthesis to a stop (Waga et al., 1994). 
PCNA is also involved in DNA repair, and this process can continue while the cell-
cycle is paused until a decision is made for either completion of DNA repair or, in 
case of too severe damage, apoptosis. 
PCNA has been shown to be deregulated/overexpressed in several cancer forms like 
esophageal cancer (invasive squamous-cell carcinoma) (Kuwano et al., 1998), head 
and neck squamous cell carcinoma (Shin et al., 1993) and non-small cell lung cancer 
(Fontanini et al., 1992), while p21 has been found to be frequently downregulated in 
laryngeal squamous cell carcinoma (Hirvikoski et al., 1999) and primary colon 
carcinomas (Bukholm and Nesland, 2000). 
PCNA's hydrophobic binding pocket to which p21 binds has been discussed already 
in this thesis. As shown in Chapter 1 it is highly conserved among the loading 
clamps and accommodates the conserved residues of proteins carrying the PIP-box 
binding motif (Q-x-x-h-x-x-a-a), where 'x' stands for any amino acid, while 'h' 
denotes a moderately hydrophobic and 'a' an aromatic residue. In previous work this 
pocket was examined and evaluated as a druggable site suited for the design of 
peptidomimetics (Kontopidis et al., 2005). 
The idea of trying to mimic protein-protein interactions is a fairly new one. In 2004 
nutlin, a small-molecule antagonist of MDM2 was found (Vassilev et al., 2004). 
Nutlin prevents the interaction of MDM2 with p53, a tumour suppressor protein, and 
keep levels of p53 high. Both compounds were developed by structure-based drug 
design using X-ray structures of the target proteins complexed with peptides of the 
binding partners. 
The lack of numerous examples of drugs developed by this approach hints at possible 
problems inherent in the approach of structure-based drug design for protein-protein 
interactions. There are a number of parameters which are unique to protein-protein 
interactions and which need to be considered when deciding on the suitability of a 
site. First of all the drug molecule must achieve high affinity and selectivity for that 
site. Most protein-protein interaction interfaces are rather large and devoid of deep 
indentations making it hard to mimic by a small molecule (Fry and Vassilev, 2005). 
While a protein will be able to make numerous contacts with its partner a small 
molecule will only ever be able to cover a subset of these and hence struggle for 
adequate affinity. A lack of specificity will lead to toxic effect in the body due to 
non-specific protein binding. So it is important to maximise the energetic 
contribution of each of the interactions for maximum affinity. A good drug site will 
sequester a large portion of the surface area of the ligand away from solvent. 
However, if the drug target is intracellular a ligand with too much polar character 
will have difficulties getting across the cell membrane. The Lipinski rules that should 
be met by the drug candidate are 1) a molecular weight under 500g/mol, 2) less than 
5 hydrogen bond donors, 3) less than 10 hydrogen bond acceptors and 4) a partition 
coefficient (logP) under 5 which is the log i o of the ratio of the concentration of the 
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molecule in n-octanol over the concentration in water (Lipinski, 2000; Lipinski et al., 
2001). 
It is difficult to design good fitting molecules from scratch, so library screens tend to 
be carried out. There are an estimated 10 40 drug-like molecules (Lipinski, 2000), so it 
seems it should be possible to find a suitable molecule for each pocket. 
Unfortunately, predicting the affinity of a molecule is difficult as it requires a 
detailed understanding of the interactions between the compound and the protein as 
well as the interactions between the compound and the solvent when it is free in 
solution. 
For this study the p21 binding pocket in PCNA was closely examined using the 
database-mining programme LIDAEUS (Wu et al., 2003), which searches 3D 
databases for potential ligands that meet the criteria linked to a specific binding 
pocket. This in silico screening (carried out by Simon Harding) provided potential 
ligands which were examined with two binding assays discussed in this chapter. The 
first assay determines the thermal denaturation/unfolding of proteins in the presence 
of ligands and the second assay uses labelled PCNA-binding peptides and monitors a 
change in Fluorescence Polarization by competitive ligand binding. 
3.2 THEORY OF THE THERMAL STABILITY OF PROTEINS AND 
FLUORESCENCE POLARIZATION 
3.2.1 Thermal Stability 
A protein is functional if it exists in its native, correctly folded state. In this form the 
secondary and tertiary structure elements are maintained by hydrogen bonding, 
keeping the bulk of hydrophobic residues inside and hence hidden from the solvent. 
Generally charged amino acids are found on the surface of the protein where they 
make interactions with solvent molecules. Upon exposing the protein to increasing 
amounts of heat the hydrogen bonds are broken leading to partial or total unravelling 
of the protein. The covalent bonds between amino acids that form the backbone of a 
protein on the other hand remain intact. The process of heat denaturation is generally 
considered to be irreversible. While denaturation is also possible by exposure to 
extreme cold, this type of unfolding is often reversible (Privalov, 1990). From a 
thermodynamic point of view denaturation is achieved when sufficient energy is 
transferred to the native protein form to induce a change in its molecular 
conformation. This energy is made up of two parts: 1) the activation energy to 
overcome the energetic barrier and 2) the total heat of the system absorbed/released 
during the unfolding process (enthalpic) (Figure 3-1). 
Proteins differ in their sensitivity to thermal denaturation, which can be observed by 
monitoring the transition or melting temperatures (T m). This is defined as the 
temperature at which 50% of the protein denatures. However, the general definition 
for Tm is the temperature at which the rate of unfolding is at its maximum. For 
mammalian proteins the onset of thermal denaturation usually lies between 40 °C and 
45 °C. When reaching the onset temperature first changes in the structure can be 
detected. The Tm  is also dependent on the rate of heating. The transition from native 














Figure 3-1 Diagram of the relationship between energy and the state of the protein. 
The protein exists at the beginning in its native state. When enough energy in the form of heat is 
added to the system in order to overcome the energy barrier (activation energy) the protein is 
activated. Hydrogen bonds are broken up and the protein is denatured. At this point, due to increased 
entropy, the protein contains more energy than it did in its native state. Alternatively, denatured 
protein molecules may aggregate in a random fashion which leads to a decrease in entropy and to 
more favourable conformations, therefore leaving the molecule at a lower energetic state in 
comparison with the starting point. 
Since the term denaturation is often inappropriately used for other protein states, it is 
worthwhile to define them here. Aggregation describes in general terms the 
formation of higher molecular weight complexes of proteins via protein-protein 
interactions. These complexes are usually not functional, in contrast to naturally 
occurring multimers. In more detail, we speak of coagulation when already 
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denatured protein randomly aggregates, which is usually an irreversible process. 
Gelation, however, is an orderly aggregation of native or denatured proteins and can 
be reversible. It is important to note that proteins tend to aggregate as part of the 
denaturation process and that those complexes may contain both native and 
denatured proteins. 
A protein can be stabilised and to some degree protected from heat denaturation 
when a ligand in form of a peptide or a small molecule binds to the surface of the 
native form. This stabilization is perceived as an increase in T m. By contrast a small 
molecule that binds to the even slightly unfolded form of a protein will cause a T. 
shift to a lower temperature as it further destabilizes the protein (Brandts and Lin, 
1990). This effect has been used in drug screening (Waldron and Murphy, 2003) and 
is especially useful in the absence of activity assays, as is the case for PCNA. 
3.2.2 Fluorescence Polarization 
Fluorescence is the process of photon emission as a result of the return of an electron 
in a higher energy orbital back to a lower energy orbital. 
Fluorescence emitting molecules, also called fluorophores, remain excited for 
between 10-5  to  10-8  s, while the process of excitation, during which energy in form 
of a photon is absorbed, takes only about 1015  s. The delay between absorption and 
fluorescence leaves enough time for fluorescent molecules to tumble and diffuse. 
Polarization describes a preferential orientation in space. With light waves the 
transverse oscillation can be polarized. When light in the form of electromagnetic 
waves is emitted from many atoms or molecules with random orientations, those 
emitted waves will also have a mixture of orientations. The light in this case can be 
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described as unpolarized. When the emissions are selected for a particular 
orientation, the light is partially polarized. When the oscillating fields become 
aligned and oscillate in one plane only, the light is linearly polarized light. 
Transition moments for excitation and emission are fixed within fluorescent 
molecules and are termed absorption and emission dipoles respectively. 
Fluorophores only absorb photons with electric oscillations parallel to the electronic 
transition moments of the fluorophores themselves. In solution, fluorescent 
molecules will assume random orientations. Hence a beam of polarized light will 
selectively excite only those molecules with absorption dipoles parallel to the electric 
oscillation of the excited photon. The result is partially polarized fluorescence 
emission, also known as Fluorescence Polarization (FP) (Maim and Krull, 2003). 
In experiments either the change in fluorescent polarization or anisotropy (directional 
dependence) is measured, while the angle between the absorption and emission 
dipole defines the maximum measurable anisotropy. 
The equation defining fluorescence anisotropy (r) is 
r= (Ivv-GIVH)/(l 	.J(. ) = (Ivv-GIVH)/ 'TOT. 	(1) 
= total fluorescence intensity 
And for polarization (P) it is 
P = (Ivy— GIVH) / (I vv  GIVH). 	 (2) 
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Ivy = intensity for parallel or vertical component of polarized emitted light 
'VH = intensity for perpendicular or horizontal component of polarized emitted light 
G = correction factor to account for instrumental differences in detecting emitted 
components as the glass of the photo tube can introduce parallel diffraction 
anomalies. G = IVV/'VH 
In the experiment, the sample containing the fluorescent probe is excited with linear 
polarized light and the vertical and horizontal components of the intensity of the 
emitted light are measured. These intensities are then used to calculate P or r using 
equations (1) and (2) (Figure 3-2). 
P has possible values between -0.33 and 0.5 and r ranges from -0.25 to 0.4. The 
maximum anisotropy is found in solutions in which the absorption and emission 
dipoles are co-linear and where there are no depolarizing processes (Devlin, 1997). 
In a non viscous solution molecules are free to rotate and move, so there is a larger 
loss of fluorescence polarization than in more viscous environments, in which the 
rotation of molecules is slowed down significantly. A reduction of rotational speed 
also occurs when the fluorophore binds to a larger molecule. By attaching a 
fluorophore to a small molecule or ligand the binding of that molecule to another of 




Figure 3-2 Schematic layout of a general Fluorescence Polarization experiment. [adapted from 
(Mann and Krull, 2003)]. 
A light source emits photons/waves with different polarization planes. They get filtered through a 
polarizer and then passed through the sample as linear polarized light. Any light that passes straight 
through the sample is ignored. The light that gets emitted in an angle (up to 900)  is passed through 
another polarizer and the intensities for vertical and horizontal emissions in relation to the original 
plane are monitored. 
According to the original model described by Perrin (Perrin, 1926), which was 
derived from the Brownian motion theory, FP is dependent on a number of different 
factors which can be explained by equation 3: 
(1/P-1/3)=(1 To- 1/3)(1+t/p) 	 (3) 
P = polarization 

















T = excited state life time of the dye 
= rotational correlation time of the dye or dye conjugate, which can be estimated 
by 
= 1V/RT. 	 (4) 
V is the molecular volume of the fluorophore or dye conjugate and which can be 
estimated from the MW of the dye. ii is the solvent viscosity, while T and R 
represent temperature and gas constant respectively (Haugland, 2005). 
- * W - 0, "0 H- 0 
A 	0 0 time (nsç 	4I:cì 
= unexcited fluorescent tracer 	= excited fluorescent tracer 
Figure 3-3 Physical basis of a fluorescence polarization assay. 
(adapted from (Haugland, 2005))Onl y dye molecules/tracers with absorption transition vectors 
aligned parallel to the electric vector of linearly polarized light get excited. The labelled small 
molecules or peptides that remain free in solution continue to rapidly rotate and lose their 
photoselected orientation, which results in low FP. The labelled molecules bound to the large, slowly 
rotating protein molecule (here PCNA with three binding sites per trimer) change only marginally 
their orientation which results in high FP. The extent of signal relates directly to the extent of tracer 
binding to the protein. 
Hence FP decreases with increasing t, and increases with molecular weight and 







attached to a spherical carrier. One of the most commonly used fluorophores is 
fluorescein which has an excited state life time (t) of 4ns. 
FP is also instrument dependent as implied in equations (1) and (2); hence the data 
quality is linked directly to the quality of the used instrument. Three points are 
important to note: 
The angle at which polarized/depolarized light is detected differs between 
instruments. 
Detectors measure intensities in different ways as photons can be sensed directly 
or with use of an enhancer. Fluorescence is measured in arbitrary units, so when 
applying equations (1)-(4) to the data collected with different detectors the value for 
r. should be identical providing the sample and the angle at which 
polarizedldepplarized light is detected remain the same. 
The volume of the sample influences the error in the measurements: a larger 
volume gives smaller errors. 
A number of publications report the use of FP to quantify the binding of various 
molecules, including peptides, to protein targets (Parker et al., 2000; Rozema and 
Poulter, 1999; Tota et al., 1994; Veis et al., 2000). More recently FP has also been 
employed for competitive assays (Figure 3-3) (Turek et al., 2001), where a known 
ligand is labelled and unlabeled potential ligands are added. If the unlabeled 
compound is able to compete with the known ligand, a decrease in FP is observed, if 
the concentration of the fluorophore is kept constant. 
For the work described in this chapter, 5(6)-carboxyfluorescein was coupled to the 
PL/consensus motif peptide (Kontopidis et al., 2005; Zheleva et al., 2000) which 
binds via its PIP-box motif to PCNA with a Kj of 100 nM. The binding of this small, 
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labelled peptide (-1 .5kDa) to the much larger PCNA molecule is observed by 
monitoring an increase of polarization/anisotropy. If a second molecule is able to 
compete with the labelled peptide for binding to PCNA a decrease of polarization is 
predicted. 
3.2.3 LIDAEUS 
LIDAEUS (Wu et al., 2003) is a molecular docking programme for screening large 
chemical libraries for small molecules matching a certain set of parameters based on a 
the physiochemical properties and structure of a target binding pocket. 
Here LIDAEUS was used to construct a cubic grid of site-points representing the 
hydrophobic pocket into which the PIP-box residues of p21 bind. Figure 3-4 shows 
the p21-based template for screening runs and the interactions that need to be 
mimicked by a successful PCNA inhibitor. 
Each site-point has associated calculated properties including van der Waals-
interaction energy, hydrogen bonding capacity and buriedness. They can be separated 
into: hydrophobic (C), extremely hydrophobic (Csp), hydrogen bond acceptor (HBA) 
and hydrogen bond donor (HBD). The user can set a threshold, below which a point's 
potential energy must be, for it to be considered a site-point. 
Initially atom types are assigned to the target molecule e.g. hydrogen donor or 
acceptor. The second step is docking, in which compound atoms are fitted onto site-
points. This can lead to several different poses of the same compounds to the pocket. 
A ligand is regarded as a potential hit when a defined number of its atoms (e.g. 4 as 
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in this case) matches the geometry and property prerequisites of the calculated site 
points. 
In each run a score is given to each potential ligand's pose. This is an approximation 
of the binding free energy of the ligand-protein complex calculated by summing the 
van der Waals and electrostatic interactions. An energy map, which combines 
information on hydrophobic and potential hydrogen bonding interactions, is allocated 
to each set of atoms verified in a ligand during the docking. The values for each 
potential atom interaction are added up after weighting factors have been applied. 
Optionally, as in this case, a Pose Interaction Profile (PIP) score can be added to 
these sums. The aspect represents the condensed description of the interactions of the 
posed ligand to the target protein. The score is then compared with the PIP of the 
model ligand (p21 in this case). The result will be a value between 0 and 1, where 1 
is considered to be a perfect match of the model interaction. 
Finally, LIDAEUS ranks the poses based on the above calculated values. All ligand-
protein contacts are tested to ensure there are no severe steric clashes between the 
ligand and the protein. High ranking compounds with negative scores should have no 
steric clashes as any such clashes would translate into a highly positive contribution 
to the score. Asinex and Specs 3D libraries of drug-like small molecules were chosen 
on the grounds of available online pricing information, prompt delivery and cost-
effectiveness. 
Chemical similarity was assessed by Dr. Mike Greaney (University of Edinburgh), so 
that a diverse set of compounds could be ordered. For this study all work with 
LIDAEUS was carried out by Simon Harding. 
tDI: 
Figure 3-4 The binding of residues p21 Q144, M147, F150 and Y151 to the hydrophobic pocket 
of PCNA (Figure by Simon Harding). 
a) Interactions between PCNA (white) and the four PIP-box residues of p21 (yellow) are displayed as 
hydrogen bonds (red dotted lines) and likely van der Waals contacts (yellow dotted lines). While 
Ml 47 and Y 151 residues of p21 are positioned directly into the pocket, F 150 is lying outside, between 
two proline residues of PCNA, P234 and P253. The conserved PIP-box residue Q144 is not part of the 
hydrophobic pocket, but is vital for p21 binding to PCNA and was hence part of the LIDAEUS search 
template b) A typical set of site points calculated for the MFY template. The distribution of site-points 
depends on the template used and if Pose Interaction Profile (PIP)-scores were used to influence the 
site-point generation. PIP-scores will increase the likelihood of docking molecules to the pocket that 
are able to create specific/chosen interactions like hydrogen bonds. 
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3.3 MATERIALS AND METHODS 
3.3.1 Analysis of PCNA Oligomerization 
A 7 .tM sample of purified human PCNA in 25 mM Tris pH 7.5,2 mM DTT and 150 
mM NaCl was analysed with an OmniSIZE 2.0 Dynamic Light Scattering detector 
(Viscotek) at 25 °C. 
200 tl of a 50 p.M sample of purified native (untagged) human PCNA was run on a 
Superdex 200 gel filtration (Amersham) column at 4 °C in 25 mM Tris pH 7.5, 2 
mM DTT and 150 mM NaC1. 
3.3.2 Peptides 
N-terminally 5(6)-carboxyfluorescein labelled peptides p21  (141-160 = 
KRRQTSMTDFYSKRRLIFS-OH), PL/consensus motif 1 
(SAVLQKKITDYFHPKK-OH) and p21(141-54 = KRRQTSMTDFYHSK) were 
synthesized by Mimotopes. 10mM stock solutions in 100% DMSO were prepared 
and stored at -20 °C. 
An unlabelled shortened version of the p21 peptide (residues 141-152; 
KRRQTSMTDFYH) was synthesised by Peptide Protein Research Ltd. A 50 mM in 
100% DMSO stock was prepared and stored at -20 °C. 
All peptides were at least 90% pure as determined by mass spec. 
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3.3.3 Isothermal Titration Calorimetry (ITC). 
ITC experiments were performed by Peter Brown using an AutoITC machine 
(Microcal Inc. Northampton, MA). A solution of purified human PCNA at 4.57 j.tM 
was titrated with lOOjtM of p21(141-152) at 25 °C in 10mM HEPES pH 7.4 and 
100mM NaCl. The injection volume was 5pJ and the final reaction volume was 2m1 
with a starting volume of 1 .42m1. The enthalpy of binding (AH, kcal.moi') was 
determined by integration of the injection peaks and the corrections for heat released 
due to dilution were determined in a control experiment without peptide. The 
resulting corrected binding isotherm was fitted by non-linear least-squares analysis to 
a variety of binding models using MicroCal Origin software, supplied with the 
instrument. 
3.3.4 Compounds/Potential PCNA inhibitors candidates 
The 3D libraries Specs and AS1NEX which comprise about 100.000 compounds 
each were screened by Simon Harding for potential PCNA inhibitors using the 
programme LIDAEUS (Wu et al., 2003) under consideration of Lipinski rules as 
selection criteria. The top hits were chosen for better solubility according to logP 
values. 
AG-205/33676017, AG-690/11632020, AG-690/08637022, AG-690/ 12242265, AG-
205/07677038, AK-968/15252997, AP-828/41100751, AH-487/15582102, AG-
205/11867190, AE-562/12222430 and AR-013/42256276 were supplied by Specs. 
ASN-04 196551, ASN-039043 73, ASN-04369399, ASN-048867 13, ASN-04254797, 
ASN-041 90395 and ASN-01 516558 were ordered from Asinex. 
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Stock solutions of 100 mM or less were prepared in 100% DMSO and stored in the 
dark at room temperature. 
3.3.5 Fluorescence Polarization Assay and Data analysis 
Assays were carried out either using an Edinburgh Instruments FS900 T-geometry 
fluorescence spectrometer with a temperature-controlled sample cuvette with Glan-
Thomson quartz polarisers, or a SpectraMax M5e plate reader (Molecular Devices). 
The experimental setup is significantly different for each instrument. 
For the Edinburgh Instruments FS900 T-geometry fluorescence spectrometer a single 
quartz cuvette, with a 1 cm path length and 600 jtl maximum volume was used. The 
assay was carried out in PBS (3.8 MM NaH2PO 4, 16.2 mM Na2HPO4, 150 mM NaCl, 
pH 7.4), 5% (v/v) DMSO, 5 mM DTT using 50 nM of a labeled PL peptide only or 
additionally 10 p.M of the short p21 peptide as model competitor. Recombinant 
human PCNA was titrated at volumes between 0.1 p.1 and 1 p.1 into the sample from a 
17.4 p.M stock solution and intensities measures were recorded as an average of 5 
reads. The total sample volume was 300 p.1 plus any protein added. For simplicity the 
change of volume was considered to be insignificant (<10%). 
To test the small molecules for binding, small amounts of the stocks dissolved in 
DMSO were diluted into the reaction buffer instead of the model competitor until 
maximum concentration was reached and the solutions were still clear (see Table 3-1 
for solubility). 
Experiments performed with the plate reader were carried out in black (both wall and 
bottom) 96-well plates (Greiner) with readings taken from above. The reaction buffer 
remained the same, but the total sample volume was reduced to 250 p.1. The 
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concentration of labeled peptide and model competitor /small molecule remained as 
in the previous setup, but each well contained a fixed concentration of PCNA. Each 
concentration point was carried out in triplicate and intensities were recorded as an 
average of 100 reads. The fluorescent dye was excited at 485 nm and read at 530 run. 
The anisotropy was calculated using equation (1) and the apparent affinity (I(j) for 
the labelled peptide was calculated using the following equation (5): 
r = rf+ (rb - rf) {(K.j + [A] + [B]) -i(( Kj + [A] + [B])2 —(4 [A] [B])) / (2 [A])}. (5) 
Where [A] is the fixed concentration of labelled ligand and [B] is the concentration 
of titrated PCNA. 
The following equation was employed to calculate the Kj of p21(141-152) (i.e. K 1) 
from the competition experiment: 
K1 = Kapp / (1+ [Lig] L / K) 
	
(6) 
Here K1 is the affinity of the inhibitor, Kapp is the apparent Kj of the labeled peptide in 
the presence of inhibitor, [Lig]L is the concentration of labeled peptide and Kj the 
affinity of labeled peptide in the absence of inhibitor as calculated using equation (5). 
3.3.6 Thermal shift assay and Data analysis 
The assay was carried out using thin-wall PCR 96-well plates (Bio-Rad) covered 
with Optical-Quality Sealing Tape (Bio-Rad) using the iCycler iQ Real Time PCR 
Detection System (Bio-Rad). 
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Each 50 p.1 sample contained 0.25 p.M recombinant human PCNA, a 1:1000 dilution 
of Sypro Orange 5000X (Molecular Probes) dye and either of potential inhibitors (at 
maximum concentrations) or increasing concentrations of the short p21 peptide, in 
thermal denaturation buffer 1 (25 mM Tris pH 7.5, 100 mM NaCl, 2 mM DTF) or 
thermal denaturation buffer 2 (PBS, 5 mM DTT, 5% (vlv) DM50). Each sample was 
carried out in triplicate and averages were calculated. The wavelengths for excitation 
and emission were 490 nm and 575 nm, respectively. Fluorescent readings were 
taken between 20 °C and 88 °C in 1 °C increments after each temperature had been 
maintained for 90 seconds. 
The fluorescent intensities were plotted against temperature in the programme 
Kaleida-Graph and the T m for each sample was calculated using the following 
equations: 
F(T) =Fp0st+  [(F - F 0 ) / ( 1 + exp 
(TM -1)/ C)] 	 (7) 
Where F(T) is the fluorescence intensity at temperature T, Fpre  and Fpost are the 
fluorescence intensities for completely folded and completely unfolded protein, 
respectively and C is the slope factor. Here the slope factor acts as a scaling factor 
for the total increase of fluorescence, which may vary for different samples. 
For the model ligand p21  (141-152) the Kj at different concentrations was calculated. 
For this purpose the simplified equation above had to be supplemented with terms for 
L\H (the enthalpy of protein unfolding) and AC (the heat capacity change of protein 
unfolding) (equation 8): 
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F(T) = Fpost+ (Fpre 	/ [ 1+ exp {(-AH / R) (1/ T - 1/T m) + ACI R (in [TI Tm] 
+Tm /T1)}] 
 
When no stabilizing ligand is present Tm = T0, AH = AHuT° and ACpu  = ACPUTO 
To calculate the ligand association constant (KL = Ka = l/K) for the ligand at Tm 
following equation was used: 
KT.) = exp{(.AH uT0  I R) (1/ Tm - 1/ T0) + AC T° / R (In [Tm ! T0] + T0 / Tm 1)}/ 
[Lim] 
 
where [LTA  is the free ligand concentration at Tm, which is approximately the same 
as the total ligand concentration when the ligand is added in great excess to protein. 
To calculate affinities at room temperature for comparison of data obtained 
previously from ITC experiments at 25 °C an extrapolation has to be carried out 
using the following equation (10): 
KT) KUTm)exp {(AHUT ) / R)(1!T1!Tm)+ '( 	 I 	1-II} 
 
where AHL(T) is the van't Hoff enthalpy of binding at temperature T. ACPL is the heat 
capacity change on binding. An average value for ACPL has been determined 
experimentally derived and will be considered to be -0.5 kcal.mol'.K' (Wear and 
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Walkinshaw, 2006). AHL(T) was equally calculated from previous ITC experiments 
carried out by Peter Brown. 
The second exponential term in red is usually quite small compared to the first 
exponential part when dealing with small drug-like compounds as ligands. However, 
it has been shown that the heat capacity change over temperature for peptide binding 
can have a significant influence on affinity. 
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3.4 RESULTS AND DISCUSSION 
3.4.1 Oligomerization state of human PCNA 
It has been claimed that PCNA may occur as a double homotrimer in solution 
(Naryzhny et al., 2005). A single trimeric ring of PCNA has a molecular weight of 
about 90 kDa. Dynamic Light Scattering (DLS) showed 99% of particles were 
contributed by a species with a diameter of about 4.4 nm (data not shown). 
According to software analysis this would represent a globular, compact protein of 
about 200 kDa. However, the sliding clamp has a 35 A cavity in the middle which is 
not picked up by DLS. 
Furthermore, any rotation of IiPCNA in solution would make it appear as a much 
larger particle, due to the overall large difference between width and thickness 
(flatness). It could hence be argued that the species with a diameter of 4.4 nm is 
probably representative of a single trimeric PCNA ring. 
Analytical gel filtration analysis using a Superdex 200 column produced a single 
peak with a retention volume of 12.69 ml. 
This is indicative of a globular protein of about 120.6 kDa (Figure 3-5). Altogether 
these results suggest that untagged hPCNA used in this study is probably a single 
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Figure 3-5 Size estimation of human PCNA by gel filtration. 
The elution volume of 12.68m1 on this column corresponds to an estimated size of 120 kDa by 
comparison with standards of known molecular weight. This agrees with the fact that PCNA appears 
slightly bigger than its actual molecular weight due to its ring shape. 
3.4.2 Solubility of compounds from LIDAEUS runs and logP 
prediction 
In order to find small drug-like molecules that could mimic the interactions that are 
made by the p21 peptide in the hydrophobic pocket two different LIDAEUS runs 
were set up by Simon Harding. The main interaction between p21 and PCNA is 
based on the four conserved residues that form the PIP-box motif and are that found 
in many PCNA binding proteins. 
The first run investigated the interactions made by three hydrophobic residues 
(Met147, Phe150 and Tyrl5l) of p21 with PCNA. Compounds ASN-04196551, 
ASN-039043 73, ASN-04369399, ASN-048867 13, ASN-04254797, ASN-04 190395, 
ASN-01516558, AP-828/41100751 AH-487/15582102, AG-205/11867190 and AG- 
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690/12242265 (Table 3-1) were selected from the best fitting hits for lower logP, 
chemical stability, lack of obvious toxic groups and difference in chemistry from 
each other. These criteria were also applied to the selection of compounds from other 
runs. 
The second run was carried out using site points calculated for p21 homing in on 
G1n144 in addition to the three hydrophobic residues. From the result hits list 
following compounds were analysed: AG-205/33676017, AG-690/11632020, AG-
690/08637022, AG-205/07677038, AK-968/15252997, AE-562/12222430 and AR-
013/42256276 (Table 3-1). 
As the site-point selection for the hydrophobic pocket alone gave rise to rather 
hydrophobic molecules, the extension of the search pocket to include the glutamine 
was expected to improve the water solubility of hit compounds. 
According to the Lipinski rules only compounds with a logP value below 5 were 
listed as a hit. In theory compounds with higher solubility in water have lower logP 
values. The logP values of the selected compounds were regarded to be acceptable 
since well-known drugs like Glivec (logP = 4.5) and Prilosec (logP = 2.6) have fairly 
high values, but are sufficiently soluble in the body. 
Despite the attempt to choose water soluble compounds to maximise the screening 
success with assays that were going to be carried out in aqueous solutions, some of 
the compounds turned out to be less soluble than others (Table 3-1). 
There is, however, a general correlation between the solubility of the compound in an 
aqueous buffer plus 5% (v/v) DMSO and the logP. Nevertheless, there are a few 
outliers to this rule which are less soluble than predicted, especially in comparison 
with compounds that were allocated a similar logP. 
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The use of a buffer containing 5% (v/v) DMSO increased the active concentration of 
free ligand in solution (data not shown) and proved to be compatible with PCNA 




Compound ID (Company) (v/v) DMSO, 100% DMSO calculated LogP 5mM DTT 
(MM) (mM)  
AG-205/336760 17 (Specs) 
N 
5 100 -0.46 
AG-690/11632020 (Specs) 




0.2 100 3.96 
AG-690/12242265 (Specs) 
0.2 100 3.79 
AG-205/07677038 (Specs) 
2.5 50 0.4 
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AK-968/15252997 (Specs) 
1 100 2.49 
AE-562/12222430 (Specs) 
5 100 0.91 
AR-013/42256276 (Specs) 
5 100 -0.9 
AP-828/41100751 (Specs) 
0.2 100 3.27 
A}4-487/15582 102 (Specs) 
cc NK,,a-, 0.1 100 4.38 
AG-205/11867190 (Specs) 
NWH 








0.6 100 1.645 
ASN-04369399 (Asinex) 
0.6 100 0.941 
9c 0  
ASN-048867 13 (Asinex) 
0 





W—';)— 0.133 33.3 1.806 
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ASN-04 190395 (Asinex) 
N 
0.1 16.5 0.759 
ASN-015 16558 (Asinex) 
NH2 0.1 33.3 4.39 
Table 3-1 List of selected potential PCNA inhibitors and their solubility. 
Stocks in DMSO were prepared at a maximum concentration of 100mM. In order not to exceed 5% 
DMSO in the assay buffers even very soluble compounds in 100mM stocks were not added beyond 5 
mM. Higher logP values predict a lower solubility in water, but without a linear correlation. 
3.4.3 Thermal shift assay of human PCNA under the effect of 
peptide binding and changing buffer conditions 
To measure the affinity of small molecule compounds to PCNA a previously 
described thermal shift assay for establishing conditions for protein stabilization 
(Ericsson et al., 2006) or for testing the structural basis of inhibitor binding (Bullock 
et al., 2005) was adapted for human PCNA. 0.25 .tM of PCNA in combination with 
1 in 1000 dilution of the commercially available Sypro Orange dye (5000X) 
(Molecular Probes) (originally designed as a protein gel stain) gave a sufficiently 
strong fluorescent signal upon protein unfolding. Similar to I -anilinonaphthalene-8-
sulphonate (Eling and DiAugustine, 1971) this probe is quenched in aqueous solution 
and only emits fluorescence when bound to a hydrophobic environment. This can 
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occur when a protein unfolds and exposes the interior hydrophobic side chains to the 
solvent. The increase of fluorescent intensities over a temperature range is hence 
directly related to the extent of protein unfolding. Thermally induced protein 
unfolding follows a typical two-state model with a sharp transition between native 
and denatured states. After reaching the completely unfolded state, the fluorescent 
intensity decreases again (Ericsson et al., 2006). This effect cannot be accounted for, 
but is assumed to be connected with protein aggregation. Therefore the data after the 
maximum are omitted from the calculations. 
The result of the thermal shift assay of hPCNA in absence and presence of p21  (141-
152) are shown in Table 3-2 and Figure 3-6. The model ligand p21 (141-152) has a 
Kj of 307 nM at 25°C as determined by ITC. The data show that p21 is able to 
stabilize PCNA under heat-denaturing conditions leading to a shift in T. towards a 
higher temperature. This shift is detectable under both thermal denaturation buffers. 
T. in 'C 
Concentration of 
peptide (NM) 
Thermal denaturation buffer 
1 
Thermal denaturation buffer 
2 (incl. 5% DMSO) 
0 53.14 ± 0.24 52.71 ± 0.13 
12.5 53.44±0.19 52.27±0.13 
25 54.88 ± 0.17 53.1 ± 0.12 
50 55.21±0.16 53.2±0.13 
100 57.44±0.16 54.02±0.1 
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Figure 3-6 Thermal shift assay of human PCNA in the absence and presence of p21 (141-152). 
hPCNA at a concentration of 0.25 iM was subjected to increasing temperatures. The red trace denotes 
the sample without peptide, blue = 12.5 jiM peptide, green = 25 j.tM peptide, black = 50 jiM peptide 
and pink = 100 jiM peptide. All experiments in a) were carried out in thermal denaturation buffer 1 
whereas b) used thermal denaturation buffer 2. Data were fitted in Kaleida-Graph, and error-bars have 
been omitted for clarity. 
However, the presence of 5%(v/v) DMSO has two effects: first it leads to lowered 
protein stability, which is marked by a small T m shift from 53.1 °C (buffer 1) to 52.7 
°C (buffer 2) in the absence of ligand; and secondly, an smaller Tm shift over the 
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ligand concentration range is observed when DMSO is present. The AT. for 0 p.M 
ligand and 100 p.M peptide is 4.3 °C in buffer 1. For the second buffer condition this 
is 1.3 °C. Although a significant shift outside error boundaries occurs for both buffers 
at 25 p.M peptide, it is more obvious without DMSO. 
Using equations (7)-(10) the binding data were extrapolated to calculate the apparent 
KEj of the peptide at 25 °C. In thermal denaturation buffer 1 peptide concentrations of 
12.5 p.M, 25 p.M, 50 p.M and 100 p.M yielded affinities of 0.212 p.M, 0.337 p.M, 
0.667 p.M and 0.946 p.M respectively, with the last one being the most accurate as 
the peptide concentration approaches saturation level (Table 3-3). 
In thermal denaturation buffer 2 the same concentrations gave affinities of 0.265 p.M, 
0.455 p.M, 0.897 p.M and 1.54 p.M respectively. In comparison with the ITC derived 
Kj of 307nM, the affinities calculated for 100 mM peptide are 3 - 5fold weaker. 
Nevertheless, the extrapolated affinities lie within an order of magnitude of the 
directly ITC derived value. A reason for observed deviations of the actual values 
could be differences in buffers used for the different techniques for determining Kds 
(Table 3-3). 
Apparent K. of the p21(141-152) at 25 °C in FtM 






12.5 0.212 0.265 
25 0.337 0.455 
50 0.667 0.897 
100 0.946 1.54 
Table 3-3 Apparent K 1 of p2l(141-152): dependence on peptide concentration. 
Having established the ability of this assay to detect ligand binding, it was carried out 
under the same conditions with maximum compound concentrations that could be 
126 
reached in thermal denaturation buffer 2. The addition of 5% (v/v) DMSO to the 
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Figure 3-7 Thermal shift assay in the presence of two compounds. 
Neither Asinex 04196551 (blue) nor the Specs compound AG-205107677038 (green) showed a 
significant T m  shift in comparison with PCNA on its own (red). These curves are representative for the 
remaining compounds that were tested using this assay. 
Unfortunately, none of the tested compounds showed a stabilizing effect of PCNA 
under stated conditions at the maximum concentration that could be reached. Figure 
3-7 shows two examples curves of the set of tested compounds. Neither Asinex 
04196551 nor the Specs compound AG-205/07677038 showed a significant Tm shift 
with 50.9 °C and 50.5 °C respectively in comparison with 50.9 C° of PCNA on its 
own. These are typical results for the remaining compounds. If any change was 
observed at all, it was rather a destabilizing effect leading to a lowered Tm (Table 3-
4). This is explained by a tendency of the compound to bind to the 
unfolded/unfolding protein. It cannot be concluded that none of the compounds 
127 
actually bind to the surface of PCNA, however, none of them seem to have a 
stabilising effect. 
Compound T. in C° T. control in C° 
AG-205/33676017 (Specs) 50.58 ± 0.15 50.96 ± 0.22 
AG-690/11632020 (Specs) 47.83 ± 0.22 48.79 ± 0.31 
AG-690/08637022 (Specs) 46.58 ± 0.19 46.49 ± 0.1 
AG-690/12242265 (Specs) 44.33 ± 0.23 45.85 ± 0.12 
AG-205107677038 (Specs) 50.49 ± 0.18 50.96 ± 0.22 
AK-968/15252997 (Specs) 44.85 ± 0.61 48.79 ± 0.31 
AE-562/12222430 (Specs) 50.068 ± 0.25 50.96 ± 0.22 
AR-013/42256276 (Specs) 44.07 ±0.11 44.56± 007 
AP-828/41100751 (Specs) turbid n/a 
AH-487/15582102 (Specs) turbid n/a 
AG-205/11867190 (Specs) turbid n/a 
ASN-04196551 (Asinex) 50.93 ± 0.24 50.96 ± 0.22 
ASN-03904373 (Asinex) 49.92 ± 0.13 50.35 ± 0.11 
ASN-04369399 (Asinex) 50.43 ± 0.21 50.35 ± 0.11 
ASN-04886713 (Asinex) 50.12± 0.2 50.35 ± 0.11 
ASN-04254797 (Asinex) 49.57± 0.17 50.35 ± 0.11 
ASN-04190395 (Asinex) 50.31 ± 0.19 50.35 ± 0.11 
ASN-015 16558 (Asinex) 50.22 ± 0.09 50.35 ± 0.11 
Table 34 TmS of assayed compounds. 
3.4.4 Fluorescence Polarization (FP) Competitive Assay 
The theory of this assay is based on the fact that small molecules (e.g. peptides) 
rotate fast in solution, but upon binding to large, slowly tumbling molecules like 
proteins (e.g. PCNA) their rotational speed decreases. The change in rotational speed 
of the small molecule can be traced as a change in fluorescent anisotropy, if a 
fluorescent probe is used for labelling. In this case the fluorescent signal comes from 
5-(6)-carboxyfluorescein labelled peptides: p21(141-160 and PL. As determined by 
ITC experiments, unlabelled p21 was shown to have an affinity for PCNA of 114 nM 
while the PL exhibits a Kj of 100 nM (Zheleva et al., 2000). 
IKI 
PCNA is titrated into a fixed concentration of fluorescently labelled peptide to 
determine the maximum fluorescent anisotropy. For the competition assay a fixed 
concentration of the model ligand, p21 (141-152), or of a potential PCNA inhibitor is 
added prior to titration of PCNA, and anisotropies are compared. 
Two different instruments were used to measure FP data for PCNA and ligands: the 
FS900 T-geometry fluorescence spectrometer and the M5e plate reader. While the 
first one is far more sensitive than the plate reader, each single point had to be 
titrated by hand for the FS900 T-geometry fluorescence spectrometer rendering this 
method very time-inefficient. The differenceof sensitivity lies in the angle at which 
emitted light is detected (900  for the FS900 T-geometry fluorescence spectrometer 
and 150  for the plate reader). Figure 3-8a shows a comparison of measurements with 
and without p21  (141-152) for both instruments. The change of anisotropy is clearly 
detectable for both, but the detected absolute change in anisotropy (Ar) is 
considerably smaller with the plate reader. 
Using equations (5) and (6) all data were analyzed in Kaleida-Graph. In order to 
make it easier for fairly weak binding compounds to compete against the labelled 
peptide a third peptide based on p21 was employed [p21(141-154]. It was shown to 
be the weakest binding p21-derived sequence still being able to compete against 
p21(141-160) (Zheleva et al., 2000). The weaker binding p21(141-154 = 
KRRQTSMTDFYHSK), however, gave noisy data and yielded only a small Ar. This 
made detection of competitive binding difficult (Figure 3-8b) and was hence rejected 
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Figure 3-8 Comparison of the FP competitive assay data quality in terms of labelled probes and 
instruments. 
Curves for binding of labelled PL peptide in the absence (red) and presence (blue) of 1 OiM 
p21(141-152). These data were recorded using the M5e plate reader. The affinity for PL was 
calculated to be 140nM ± 35nM, while it was I l9OnIvI ± 47nM in the presence of competitor. In 
comparison the more sensitive FS900 T-geometry fluorescence spectrometer yielded a Kd of I O6nM ± 
15nM (black) for the PL binding and 847nM ± 135nM (green) in the presence of lOjiM p21(141-152). 
Despite the difference in sensitivity both instruments measure data that lie within the same order of 
magnitude. 
Binding of labelled PL (black) and weaker p21(141-154)(red) to PCNA in the absence of a 
competitor. The green and blue lines show the apparent affinity of PL and p21 (141-154) when 1 O.tM 
of p21(141-152) are present. While the addition of unlabelled peptide has a competitive effect on PL 










is not influenced. 
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The measured Kd for the model inhibitor p21(141-152) was 877 nM using the M5e 
plate reader and 576 nM for the FS900 T-geometry fluorescence spectrometer 
(Figure 3-8a). These results are close to the ITC-derived Kd for p21(141-152) and 
provide confidence in the ability of this assay to pick up compounds that bind 
specifically to PCNA via the hydrophobic pocket. 
For testing the potential inhibitors, the M5e plate reader was chosen over the more 
sensitive instrument as the specific experimental setup for the latter was highly time-
consuming and hence not suitable for a screening procedure. For economic reasons 
only four PCNA concentrations were chosen: 0 jiM, 0.029 jiM, 0.116 jiM, 0.463 jiM. 
The addition of model inhibitor showed a clear competitive effect despite the limited 
number of data points. This provides confidence in the ability of the assay to pick up 
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Figure 3-9 FP competitive assay of ASN 04254797 and ASN 04190395 measured using the MSe 
plate reader. 
The black and green points show PL binding in the absence and presence of p21(141-152), 
respectively. Compound ASN 04254797 (blue) and ASN 04190395 (red) were added at lOOj.tM and 









Having established the suitability of this assay all hits were tested at their maximum 
concentrations in reaction buffer (PBS, 5% (v/v) DMSO, 5 mM DTT) (Table 3-1). 
Figure 3-9 shows the results of the FP assay for two compounds in comparison with 
p21(141-152). Unfortunately none of the selected compounds showed competition 
under the stated conditions and at maximum concentrations. 
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3.5 SUMMARY AND FUTURE WORK 
The overall outcome of this study was that none of the potential inhibitors showed 
detectable binding in either of the two employed assays. There are a number of 
possible reasons for this result. 
Despite the fact that the thermal shift assay and the FP competitive assay are able to 
detect peptide binding there are caveats. The binding affinity of a given ligand can 
decrease by 2-5 times per any 10 °C rise in temperature. A weakly binding 
compound at room temperature may have a significantly lower affinity at 40 °C, the 
onset temperature for the unfolding of PCNA. Due to a decreased number of possible 
contacts that a small molecule can make with the target protein this thermodynamic 
effect is expected to affect small molecules far more than peptide binding. 
Being aware of this fact we employed the FP competitive assay as well, which is 
carried out at 25 °C. The drawback with this method is the use of a tight binding 
peptide which needs to be replaced by a molecule with an affinity in a similar order. 
With p21(141-152) a model competitor with a 3-fold lower affinity to PCNA than 
the PL peptide was used. However, a 200fold excess of this ligand had to be present 
in order to see a distinct competitive effect. As with the thermal shift assay, a small 
molecule will be at a disadvantage compared to a peptide ligand, which is able to 
make more contacts, and much higher concentrations in solution would be necessary 
to see an equivalent effect of stabilization/competition. 
Furthermore, the inherent insolubility of ligands in aqueous solution was posing a 
problem as only low concentrations were reached in some cases. 
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Another explanation is that the conserved hydrophobic binding pocket on PCNA 
might not be a suitable drug target. Dr David Fry (Roche) carried out an evaluation 
of the pocket for "druggability" (private communication). A programme called 
cavSearch (Stahl et al., 1999) analyzes pockets on the surface of proteins by surface 
area and depth (Figure 3-10). According to the analysis the PCNA hydrophobic 
pocket lies just below the thresh-hold for a suitable drug target. Although this is the 
evaluation of a single programme, this might suggest that PCNA is not an easy target 
to be tackled by structure-based drug design. 
Binding site assessment 
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Figure 3-10 Selection of amenable and non amenable drug targets. 
Pockets were evaluated according to surface area and depth. Fairly shallow pockets are classed as not 
druggable. The hydrophobic pocket that was targeted in this study is called pcna_03 and lies just 
below the threshold. 
Even so, the fact that, according to cavSearch analysis, MDM2 lies only just above 
the threshold for an amenable site is suggesting that the PCNA pocket might still be a 
druggable target. This is backed up further by the fact that the MDM2/p53 
134 
interaction is in some way similar to PCNAIp2 1, with three hydrophobic residues 
binding in a hydrophobic patch. 
Other researchers have adopted a different approach: they are searching for a ligand 
able to bridge from the hydrophobic pocket to the glutamine binding-site. Instead of 
searching for a whole molecule, their aim is to screen mixtures for small fragments 
that bind to either of those sites. When two fragments have bound to both pockets a 
covalent bond is formed between the two and the resulting larger compound can be 
identified (personal communication). 
Another possibility would be to engineer a hexa His-tagged PCNA molecule to 
produce a stable surface for surface plasmon resonance (SPR) experiments in which 
potential inhibitors would be passed over the protein surface. A change in the 
refractive index would give information of binding affinities. However, this 
technique would be fairly expensive. The advantage of this method would be the 
possibility to carry it out at room temperature. Furthermore, there would be no 
requirement for the use of a tight binding peptide that any potential ligand would 
have to compete against. 
Another approach would be to increase the molecular weight cut-off for the 
LIDAEUS screening to enlarge the number of possible interactions between 
compound and protein. The draw-back would be that the compounds would turn 
more into peptide-like drugs, which can be difficult to administer in an effective way. 
Also a lowered specificity might be the result. 
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CHAPTER 4. Interaction of PCNA with Gadd45 
4.1 INTRODUCTION 
The development of treatment resistance in malignant cancer cells originates from 
genetic lesions that alter the function of genes that play a role in normal cell 
homeostasis, especially in determining cell cycle progression and apoptosis. Hence it 
is of importance to understand the molecular genetic pathways that mediate growth 
control. The Gadd45 gene family - first described by Fornace et al (Fornace et al., 
1988; Fornace et al., 1989) - contains three highly related growth-arrest and DNA 
damage inducible proteins; Gadd45, MyD1 18 and CR6 (Zhan et al., 1994; Zhang et 
al., 1999). Only Gadd45, a 165 amino acid, 1 8kDa protein, has been shown to be a 
direct down-stream target of p53. Upon DNA damage p53 is activated and induces 
expression of Gadd45 by binding to a 20 bp specific recognition site in the third 
intron of its target (Kastan et al., 1992). Gadd45 in turn causes arrest in G2/M phase 
and inhibits Cdc2. Gadd45 knockout mice show a similar phenotype to p53-deficient 
knockout mice, namely genomic instability as well as increased radiation 
carcinogenesis (Wang et al., 1999b). 
Although the role of Gadd45 proteins in growth arrest and DNA repair is not well 
elucidated, they have been shown to interact directly with various cell cycle related 
proteins, such as Cdc2/cyclin B (Zhan et al., 1999), p2  1 (Kearsey et al., 1995) and 
PCNA (Smith et al., 1994). The techniques employed involved yeast-two-hybrid, 
immunoprecipitation, ELISA and activity assays. 
The Gadd45 family shares similar, but not identical functions along different 
apoptotic and growth suppression pathways. Gadd45, but not MyD1 1 8/CR6 is a 
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target for p53 function. MyD11 8, but not Gadd45 is activated upon transforming 
growth factor f31-induced apoptosis. All three proteins appear to be induced with 
different expression kinetics during terminal hematopoietic differentiation, which is 
associated with growth arrest and apoptosis (Guillouf et al., 1995; Kastan et al., 
1992; Selvakumaran et al., 1994a), and each gene is probably optimally induced by a 
certain subset of environmental stresses (Takekawa and Saito, 1998; Wang et al., 
1999a). In addition, all three proteins also seem to be able to interact with each other 
in a synergetic fashion (e.g. by suppression of colony formation in several human 
tumour cells lines) (Vairapandi et al., 1996; Zhang et al., 1999). 
The interaction between PCNA and Gadd45 was further characterized by Hall et al. 
(Hall et al., 1995a) using yeast two hybrid and co-immunoprecipitation experiments. 
In addition they analyzed the binding of recombinant human Gadd45 to a peptide 
array representing the whole of human PCNA and localised the domain responsible 
for the interaction with PCNA to the N-terminus of the protein. 
Chen et al. (Chen et al., 1995) looked at the interactions between Gadd45 and PCNA 
and found evidence for a competitive interaction between p21 and Gadd45 for the 
binding of PCNA. Far-Western blots also showed that Gadd45 disrupts the ability of 
p21 to bind to PCNA, and conversely, p21 blocks the ability of Gadd45 to bind to the 
sliding clamp. 
Other yeast two-hybrid experiments with Gadd45, MyD1 18 and CR6 (Azam et al., 
2001; Vairapandi et al., 2000), in contrast to Hall et al (Hall et al., 1995a) located the 
PCNA-binding domain to the C-termini of all three proteins (Gadd45: residues 95-
165, MyD1 18: residues 114-156, CR6: residues 76-159). 
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When recombinant Gadd45 and MyD1 18 were used in ELISA assays to determine 
the affinity of the full-length proteins to PCNA, low nanomolar Kjs were calculated 
for both proteins. 
The interaction of MyD 118 and Gadd45 with PCNA via their C-termini was further 
confirmed in mammalian cell lines by in vivo interaction studies using over-
expression of full-length and truncated HA-Gadd45/MyD 118 constructs. 
Gadd45 seems to be a key protein in cell cycle regulation and possibly involved in 
regulation of DNA synthesis/repair via its interaction with PCNA and p21. 
Furthermore, the Gadd45 gene is down regulated in most breast cancers by 
methylation of its promoter region, a common mode of regulation for a cancer 
suppressor. Gadd45 has also been found to be frequently mutated in resectable 
invasive pancreatic ductal carcinomas (Yamasawa et al., 2002) and down regulation 
of this gene is found in ovarian cancer, although the mechanism for this is not clear. 
The aim was to investigate the nature of the interaction between Gadd45 and PCNA 
to gain further understanding on how these two proteins might be involved in cell-
cycle check point control. Localising the PCNA binding site of Gadd45, with 
subsequent crystal structure of a complex between the Gadd45 and PCNA would 
have been interesting as so far only structures exist of proteins binding to PCNA via 
the PIP-box motif and few proteins have been found to bind to PCNA that do not 
contain this motif. Furthermore, I was interested in the true affinity of the 
Gadd45/PCNA complex as an ELISA assay gives usually fairly crude results. 
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4.2 MATERIALS AND METHODS 
4.2.1 Cloning 
The full-length human Gadd45 ORF was subcloned into a pET-14b vector 
(Novagen) using NdeI and BamHI sites to give a hexa His-tagged protein (Carrier et 
al., 1994) and was a kind gift provided by Dr. Albert J. Fomace (Lombardi 
Comprehensive Cancer Center, Georgetown University). 
4.2.1.1 Full-length untagged Gadd45 
The cDNA corresponding to full-length Gadd45 was generated by polymerase chain 
reaction (PCR) using pET14b-Gadd45 as a template. The sequence was amplified 
with Elongase Enzyme Mix (Invitrogen Inc.) using forward primer 1 and reverse 
primer 2 (Table 4-1).The product (Figure 4-1a), digested with NdeI and XhoI (New 
England Biolabs) and ligated into a similarly digested pET-23a vector (Table 4-1, 
lane 3) (Novagen). The C-terminal hexa His-tag intrinsic to this vector was not 
expressed due to an inserted 5' STOP codon in the reverse product (Table 4-2). 
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Figure 4-1 DNA agarose (1.5%) gels of PCR products and control digests for Gadd45 
constructs. 
a) PCR product of full length Gadd45 generated with NdeI and XhoI sites b) Restriction enzyme 
digest of Gadd45 constructs; gel stained with ethidium bromide. Lanes: 1= Marker, 2 = pET 14b-
Gadd4S, 3 = pET23a-Gadd45, 4 = pGEX-KG- 95-165, 5 = Marker 
4.2.1.2 GST- Gadd45 (95-165), GST- Gadd45 (93-137) and GST-Gadd45 
(137-165) 
Truncated GST-fusion constructs of Gadd45 were generated by PCR with forward 
primer 3 and reverse primer 2 (Gadd45 95-165), forward primer 3 and reverse primer 
4 (Gadd45 93-137), forward primer 5 and reverse primer 2 (Gadd45 137-165) 
(Figure 4-2). Gadd45 (95-165) is the shortest truncation of the C-terminus that was 
shown to bind to PCNA in a yeast two hybrid assay (Vairapandi et al., 2000). The 
other two constructs divide this sequence approximately in half avoiding disruption 
of predicted secondary structure elements. 
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Figure 4-2 PCR product s of Gadd45 for GST-fusion constructs. 
lane I = marker, lanes 2-8 = Gadd45(93-137) at different annealing temperatures (54 °C - 60 °C), 
lane 9 = marker, lanes 10-16 = Gadd45 (137-165) at different annealing temperatures (53 °C - 59 °C) 
Lane 1 = marker, lanes 24 = Gadd45 (93-165) at different annealing temperatures (54 °C, 56 °C, 
58 °C), lane 5 = marker 
All three products were subcloned into pJETI .2 using a C1oneJET PCR cloning kit 
(Fermentas) and subsequently cut out by digestion with BamHI and XhoI (Gadd45 
93-137 and 137-165) or Smal and XhoI (Gadd45 95-165) (Figure 4-Ib) respectively. 
The resulting fragments were ligated into similarly digested pGEX-KG (Table 4-2). 
The sequence also contained a thrombin cleavage site for tag removal. 
Primer Restriction Sequence 
name Site 
Primer L G((- \ \I I- C'tq?rfilll§ACTTTGGAGGAATTCTCGGC NdeI 
Primer 2 C (CTCGAG IC ACCGTTCAGGGAGATTAATCAC XhoI 
Primer 3 0 jGGATCCA(YC.AA 	CCGGCTG BamHI, Smal 
(3 ICTCGAGI I AGTC1TTCCATTGAGATGAATGTGGAT XhoI Primer 4 
CG GACCCAGCTCTGTCTCAGTTGA1TTGTFYIT Primer F • BamEll GCCGGGAAAGTCGC 
Table 4-1 List of Primers. 
The restriction sites to be incorporated into the PCR product are highlighted in green. 
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Plasmid Tag Primers used Cloning Sites 
Sequence 
verified 
pET14b-Gadd45 611is n/a NdeI, BaniHT ok 
pET23a-Gadd45 None 1+2 NdeI, XhoI ok 
pGEX-KG-Gadd45 (95-165) GST 2+3 Smal, XhoI ok 
pGEX-KG-Gadd45 (93-137) GST 3+4 BamHI, XhoI ok 
pGEX-KG-Gadd45 (137-165) GST 2+5 BaniHi, XhoI ok 
Table 4-2 List of plasmids. 
The table shows the different Gadd45 constructs obtained for this study including the presence of 
affinity tags and which restriction sites were engineered for cloning. 
4.2.2 Expression and purification 
4.2.2.1 Full-length hexa His-tagged Gadd45 
Recombinant hexa His-tagged Gadd45 (20.5 kDa) was expressed in BL21 (DE3) E. 
coli (Novagen) in LB liquid media containing 50 p.g/ml carbenicillin. Cultures were 
grown with shaking (250 rpm) at 37 °C until the A600 was 0.6, then continued at 
37 °C or moved to 20 °C upon which over-expression was induced by adding 0.4 
mM isopropyl-J3-D-thiogalactopyranoside (IPTG). Induction was continued for 2 or 5 
hours, 37 °C and 20 °C, respectively and cells were harvested by centrifugation (5000 
x g for 25 minutes at 4 °C. Cell pellets were flash frozen in liquid nitrogen and stored 
at -80 °C. 
Pellets were thawed on ice and resuspended at 30 ml per 0.5 1 of original cell culture 
in lysis buffer (Buffer A; 200 mM NaCl, 25 mM Tris pH 7.5, 2 mM 3-
mercaptoethanol, 10 mM imidazole, 1 mM PMSF) supplemented with 0.05% NP-40 
and 400 p.g/ml lysozyme. The suspension was incubated on ice for 30 minutes before 
sonication on ice for 6 x 15 second bursts with cooling in between. The cell lysate 
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was subjected to centrifugation at 15,000 x g for 30 minutes at 4 °C. The supernatant 
was filtered through 0.2 gm filter and applied onto a 14 ml Talon-NTA (Clontech) 
HR 16/10 (Pharmacia) column pre-equilibrated with Buffer A. Non-specific 
interactions with the resin were avoided by having 10 mM imidazole present in the 
equilibration buffer and bound proteins eluted with an imidazole gradient of 0% (10 
mM imidazole) to 40% (206 mM imidazole) of buffer B (Buffer B; 200 mM NaCl, 
25 mM Tris pH 7.5, 2 mM f-mercaptoethanol, 500 mM imidazole, 1mM PMSF) at 1 
ml/minute Over 10 column volumes. 
Hexa His-tagged Gadd45 eluted in 4 peaks at 70 mM, 85 mM, 110 mM and 130 mM 
Buffer B respectively. Fractions containing Gadd45 were pooled, concentrated to 0.4 
mg/ml and loaded onto a Superdex 200 HR 10/30 (Pharmacia) gel filtration column 
(Vt = 23.8 ml) equilibrated with Buffer C (25 mM Tris pH7.5 and 200 mM NaC1). 
The elution profile of recombinant hexa His-Gadd45 shows the presence of 3 distinct 
peaks, calculated from molecular weigh standards, corresponding to species with 
apparent molecular weights of 107 kDa, 66.5 kDa and 28.5 kDa. 
Hexa His-Gadd45 was also purified using conventional methods. For that pellets 
were thawed on ice and resuspended at 30m1 per 0.5 1 of original cell culture in lysis 
buffer (Buffer D; 20 mM Tris pH 7.5, 1 mM DTT, 5 mM EDTA, 1 mM PMSF) 
supplemented with 400 tg/ml lysozyme. The suspension was incubated on ice for 30 
minutes before sonication on ice for 6 x 10 second bursts with cooling in between. 
Ammonium sulphate was added slowly under stirring to give a final concentration of 
1 M and the resulting solution was incubated for 1 hour on ice. The cell lysate was 
subjected to centrifugation at 15,000 x g for 0.5 hours at 4 °C. The supernatant was 
filtered through 0.2 gm filter and applied onto Phenyl Sepharose HiTrap (Phannacia) 
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column (Vt = 5ml) pre-equilibrated with Buffer E (25 mM KMOPS pH 7.0, 1 mM 
EDTA, 10% glycerol, 2 mM DTT) supplemented with 1 M ammonium sulphate. 
After washing the column with Buffer E supplemented with 0.4 M ammonium 
sulphate, recombinant hexa His-Gadd45 was eluted with a gradient of ammonium 
sulphate from 0.4 M to 0 M ammonium sulphate over 20 column volumes at 2 
ml/minute in Buffer E. Peak fractions were analyzed by SDS-PAGE, pooled and 
concentrated. The pooled protein was run on a Superdex 200 HR 10/30 gel filtration 
column equilibrated with Buffer E supplemented with 0.2 M ammonium sulphate. 
4.2.2.2 Full-length untagged Gadd45 
Recombinant untagged Gadd45 was expressed in B834 (DE3) E. co/i (Novagen) in 
LB liquid media containing 50 jig/ml carbenicillin. Cultures were grown with 
shaking (250 rpm) at 37 °C until the A600 was 0.6, then moved to 28 °C upon 
which expression was induced by adding 0.4 mM IPTG. Induction was continued for 
3 hours and cells were harvested by centrifugation at 4 °C (5000 x g for 25 minutes). 
Pellets were flash frozen in liquid nitrogen and stored at -80 °C. 
Untagged Gadd45 was purified according to the same protocol used for conventional 
purification of hexa His-Gadd45 with minor modifications. 
Samples of different concentration were applied to either a Superdex 200 HR1O/30 
or Superdex 75 HR1O/30 (Pharmacia) gel filtration columns (V t =23.8 ml) pre-
equilibrated with Buffer E supplemented with 0.2 M ammonium sulphate. 
Alterations to the purification protocol involved addition of 10% glycerol, DTT or 
NaCl to various concentrations and any effects are discussed within the results. 
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4.2.2.3 GST and truncated GST-Gadd45 constructs 
Recombinant GST and truncated GST-Gadd45 constructs were expressed in BL2 1 
(DE3) E. co/i (Novagen). Cultures were grown with shaking (250 rpm) at 37 °C until 
an 0D600 of 0.6 was reached, and expression was induced by adding 1 mM IPTG. 
Induction was continued for 3 hours and cells were harvested by centrifugation at 4 
°C (5000 x g for 25 minutes). Pellets were flash frozen in liquid nitrogen and stored 
at -80 °C. 
Pellets were thawed on ice and resuspended at 30 ml per 0.5 1 of original cell culture 
in lysis buffer (Buffer F; 50 mM Tris pH 8.0, 1 mM DTT, 1 mM EDTA, 1 mM 
PMSF, 2 mM benzamidine) supplemented with 0.02% Triton X-100 and 400 jtg/ml 
lysozyme. The suspension was incubated on ice for 30 minutes before sonication on 
ice for 6 x 10 second bursts with cooling in between. The cell lysate was subjected to 
centrifugation at 15,000 x g for 30 minutes at 4 °C. The supernatant of GST, GST-
Gadd45 (93-137 and 137-165) was filtered through 0.2 gm filter and applied onto a 
Mono Q (30DM) 10/10(Pharmacia) column (V 5m1) pre-equilibrated with Buffer 
F. Recombinant proteins were eluted with a NaC1 gradient from 0 M to 1 M Over 20 
CV at 1.5 ml/minute (Buffer F plus 1 M NaCl) with the bulk of fusion protein eluting 
at 150 mM NaCl. Peak fractions were analyzed by SDS-PAGE and pooled. The 
enriched fractions were applied to a GSTPrep FF 16/10 (V 20m1) column 
(Pharmacia) pre-equilibrated with Buffer F. The proteins were eluted with Buffer F 
supplemented with 10 mM reduced glutathione in a single step at 10 mM. Relevant 
fractions were pooled and buffer exchanged into storage buffer (Buffer G; 20 mM 
HEPES pH 7.5, 80 mM NaCl, 1 mM EDTA, 1 mlvi DTT, 1 mlvi PMSF, 2 mM 
benzamidine) at a ratio of 1:100 of sample to buffer and concentrated using Vivaspin 
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20 centrifugal concentrators (Sartorius). If necessary peak fraction were pooled, 
concentrated to < 200 p.1 and applied to a Superdex 200 HR1O/30 column 
equilibrated with buffer G. Peak fractions were analyzed by SDS-PAGE and the 
purest fractions were pooled and concentrated. 
The supernatant of GST-Gadd45 (95-165) was applied directly to the glutathione FF 
column equilibrated with Buffer F and the protein was eluted with Buffer F 
supplemented with 10mM reduced glutathione. Peak elution fractions were pooled, 
applied to Mono Q 10/10(30 p.m) (bed volume = 5 ml) column and eluted with a 1 M 
NaCl gradient from 0 M to 1 M over 20 CV at 1.5 ml/minute. 
For GST-tag removal thrombin (Sigma) digest reactions were setup according to 
manufacturer's protocol (3 hours at 37 °C in 20 mM Tris pH 8.4, 2.5 mM CaC12, 150 
mM NaC1) and quenched by addition of PMSF to give a final concentration of 2 
mM. The samples were then subjected to SDS-PAGE (18 % acrylamide). 
4.2.2.4 Purification of untagged human PCNA 
Purified recombinant human PCNA was produced as described in section 2.3.1. 
4.2.3 MALDI-TOF of GST-Gadd45 constructs 
The mass spectrometry analyses were carried out on a Voyager DE-STR MALDI-
TOF (Applied Biosystems) instrument using an a-cyano-4-hydroxycinnamic acid 
(CHCA) matrix for proteins that were digested with trypsin (Promega) prior to 
peptide mass fingerprinting. 
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4.3 PCNAIGADD45 BINDING ASSAYS 
4.3.1 Gel filtration studies 
10 gM of untagged Gadd45 and 10 iM or 50 j.tM of untagged human PCNA were 
mixed in Buffer H (25 mM Tris pH 7.5, 2 mM DTT and 150 mM NaCl) and 
incubated at 4 °C for 30 minutes before applying them to a Superdex 200 column 
pre-equilibrated with Buffer H. Elution volumes were compared. 
4.3.2 Pull-down binding experiments 
Hexa His-tagged Gadd45 was incubated at concentrations between 0.25 jiM and 20 
jiM of with 1 jiM of human PCNA in a total volume of 250 jil in Buffer I (25 mM 
Tris pH 7.5, 10% glycerol, 200 mM NaCl, 1 mM J3-mercaptoethanol) at 4 °C for lhr 
in the presence of 20 jil of Talon resin. After centrifugation for 5 minutes at 12,000 x 
g aliquots of the supernatants were analysed by SDS-PAGE. 
4.3.3 Surface Plasmon Resonance 
Pure hexa His-Gadd45 was immobilized on the surface of a NTA sensor chip 
essentially as described (Wear and Walkinshaw, 2006) Experiments were performed 
by Dr. Martin Wear. 
Briefly, hexa His-Gadd45 was first captured and orientated, via its N-terminal His-
tag, under neutral physiological conditions (pH 7.4; 150 mM NaCl) on a Ni 2tNTA 
surface, followed by brief covalent stabilization using standard primary amine 
coupling chemistry. The final amount of protein immobilised on the on the surface 
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was 313 response units (RU). A concentration series of human PCNA from 196 nM 
to 50 .tM, in running buffer (10 mM Hepes pH 7.4, 150 mM NaCl, 0.005% 
surfactant P20, and 2% ethanol), was injected over the surface at a flow rate of 50 
tl/minute at 25 °C for 60 seconds. The surface was regenerated after each cycle by 
letting any complex dissociate in Running Buffer. 
GST-tagged Gadd45 fusions were covalently immobilised on CM5 chip utilising 
standard amine coupling chemistries. A concentration series of human PCNA from 
196 nM to 50 jiM, in Running Buffer (10 mM Hepes pH 7.4, 150 mM NaCl, 0.005% 
surfactant P20, and 2% ethanol), was injected over the surface at a flow rate of 50 
j.tl/minute at 25 °C for 60 seconds. 
4.4 RESULTS AND DISCUSSION 
4.4.1 Secondary and tertiary structure prediction of Gadd45 
A sequence alignment below (Figure 4-3) of the three members of the human 
Gadd45 family (Gadd45, MyD1 18 and CR6) shows the overall high conservation of 
residues, with some stretches being identical. 
Figure 4-4 shows the secondary structure prediction obtained May 2007 for human 
Gadd45 [PredictProtein (Rost et al., 2004)]. It is worth mentioning that the crystal 
structure of mouse Gadd45y/CR6, which shares 53% of all residues with hGadd45, 
was published after the experimental work on hGadd45 for this thesis had been 
completed (Schrag et al., 2008). 
hGadd4 5b MTLEELVACD - - -NAAQKMQTVTAAVEELLVAAQRQDRTJIVGVYESAKLVDPDSWLC 57 
57 
hGadd4 5g MTLEEVRGQDTVPESTARMQGAGKALHELLLSAQRQGCLTAGVYESAKVLNVDPDNVTFC 60 
hGadd45b LLAIDEEEEDDIALQIHFTLIQSFCCDNDINIVRVSGMQRLAQLL-----GEPAETQGTT 112 
117 
hGadd45g VLAAGEEDEGDIALQIHFTLIQAFCCENDIDIVRVGDVQRLAAIV ------ GAGEEAGAP 114 
hGadd4 Sb EARDLHCLLVTNPHTDAWKSHGLVEVASYCEESRGNNQWVPYI SLQER 160 
165 
hGadd45g G--DLHCILISNPNEDAWKDPALEKLSLFCEESRSVNDWVPSITLPE- 159 
Figure 4-3 Sequence alignment of the human Gadd45 protein family using ClustaiW. 
(Chenna et al., 2003) 
149 
10 	 20 30 	40 50 
hGadd45 MTLEEFSAGE --- QKTER' SQRTITVL T.NVDPDNIj 	57 
mGadd45y/CR6 MTLEEVRGQDTVPESTARNQGAGIc CUAG 	 60 
10 	20 30 	40 50 
hGadd45 :DEDDDDVALQ:}{FTLIQAFCC I ILR 	PGRLAEL LETDAGPAASEGAE 117 
rnGadd45y/CR6 ?II:EDEG IALQHFTLIQAFCCE DIVRV 	VQRLAI 
... 
:SDEEGG -------- 112 
* 
hGadd45 	 QPP1CVLVJPHSSQWr .L8QLICFCREIYMDc PVIN?ER 165 
mGadd45y/CR6 	APC HCILIS.IPNEDTh PALEKLSFCEE91Fr' 	SI :- 159 
Figure 4-4 Sequence alignment of human Gadd45 and mouse Gadd45y/CR6 with secondary 
structure prediction or as observed in the crystal structure (Schrag et al., 2008). 
Magenta highlighting shows the sequence that has been shown to be important for Cdc2 interaction 
and is not present in either MyDI 18 or CR6. Smal and BamHl mark the restriction sites used for 
cloning as described later. The green and blue highlighted sections mark a-helices and n-strands, 
respectively. 
However, the regions of predicted and actual secondary structure elements are very 
similar in both proteins. 
The C-terminal half of the Gadd45 (residues Pro95 - Argi 65) that previously has 
been shown to interact with PCNA contains two predicted helices and two stretches 
of 3-strand, which are also confirmed by the mouse Gadd45y/CR6 crystal structure. 
A PROSITE motif search (de Castro et al., 2006) found five potential post-
translation modification sites (Table 4-3). 
Post-translational Modification Site (residue number) 
Protein kinase C phosphorylation (13) TER, (32) SQR 
Casein kinase II phosphorylation (2) TLEE. (7) SAGE 
N-myristoylation (39) GVYEAA 
Table 4-3 Post-translation modification sites in Gadd45. 
The latter half of the protein is rich in prolines and also contains six cysteines. The 
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yielded two predicted disulfide bonds; the cysteines predicted to be involved in those 
bonds however differ between the two results. While Dipro suggests bonds for 
C57/C83 and C82/C124, the most likely result for DISULFIND is C57/C82 and 
C 124/C 147. 
While this information does not help with the determination of Gadd45's function in 
the cell, it helps to explain certain inherent problems/peculiarities of the protein 
which will be discussed later in this chapter. 
4.4.2 Expression and Purification of Gadd45 proteins 
4.4.2.1 Hexa His-Gadd45 
A series of expression trials were carried out to establish the best growth and 
expression conditions for recombinant human hexa His-Gadd45 (20.5 kDa) (Figure 
4-5). Growth to mid log phase (A600 0.6 - 0.8) at 37 °C, in LB followed by 
induction of over expression by addition of IPTG to 0.4 mM and further growth at 
either 37 °C for 3 hours or 20 °C for 5 hours gave the best results. 
I 	2 	3 	4 	5 6 	7 	8 	9 	10 11 12 	13 14 
Figure 4-5 Expression trial for full-length hexa His-Gadd45. 
A 12% SDS-polyacrylamide gel was run with equal amounts of culture volume and subsequently 
stained with coomassie. Lane I = marker, lanes 2-6: pre-induction, after 30mm, 1 hour, 2 hours and 3 
hours of induction at 37 °C, lane 8-12: after 30mins, I hours, 2 hours, 3 hours, 4 hours, lane 7: after 5 
hours, lane 13 after 10 hours, lane 14 after 22 hours of induction at 20 °C 
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Hexa His-Gadd45 was expressed as described in the methods section. The first 
purification step used the affinity tag and a Talon-NTA column. The protein only 
bound well to the column when expressed at the lower temperature and could be 
eluted with an imidazole gradient (Figure 4-6). The pooled protein was >95% pure. 
A second method of purifying Gadd45 using conventional, non-affinity 
chromatographic methods was adapted for hexa His-Gadd45, based on that described 
(Kovaisky et al., 2001). 
I 	2 	3 	4 	5 	6 	7 	8 	9 	10 	II 	12 	13 
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Figure 4-6 Purification of hexa His-Gadd45 on a Talon Column. 
A 12% SDS-polyacrylamide gel was run with equal amounts of fraction volume ands subsequently 
stained with coomassie. Lane 1 = marker, lane 2 = lysate, lane 3 = flow through, lanes 4 to 13 = 
alternate elution fractions. An imidazole gradient from 10mM to 250mM was run over the column and 
Gadd45 eluted mostly between 190mM and 210mM. 
A typical purification run using this protocol is shown in Figure 4-7 and Figure 4-8 
using an ammonium sulfate cut to 1 M final concentration followed by hydrophobic 
interaction (HIC) and gel filtration chromatography. This three step protocol gave a 
final yield of 10 mg per liter of original cell culture and protein of 95% purity, as 
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Figure 4-7 Purification of hexa His-Gadd45 using conventional methods. 
a) Purification on Phenyl Sepharose column: Lane 1 = marker, lane 2 = lysate/after AS cut, lane 3 = 
flow through, lanes 4 - 26 = alternate elution fractions. Protein was eluted with an ammonium 
sulphate gradient from 0.4 M to 0 M. b) Elution fraction from Superdex 200 column: lane 1 = marker, 
lanes 2 - 11 = subsequent elution fractions of relevant peaks. Gels are made of 12% SDS-
polyacrylamide and were stained with coomassie. Equal volumes of elution fractions were analyzed. 
Elution Volume (ml) 
Figure 4-8 Elution profile of hexa His-Gadd45 on a Superdex 200 HR 10/30 column. 
Most of the protein is found in factions Cl0-D4. 
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4.4.2.2 Untagged Gadd45 
To check for expression levels of untagged Gadd45 an expression trial was carried 
out (Figure 4-9a). Induction of expression for 3 hours at 28 °C gave the optimal 
expression conditions. 
Untagged Gadd45 was purified using the conventional methods protocol described 
above for hexa His-Gadd45. A typical purification run is illustrated (Figure 4-9b and 
c). Untagged Gadd45 was? 95% pure after the final step, as judged by SDS-PAGE. 
a ill'. 
2SkDa 
16.5kDe 4iMWA4-- Gadd45 
Figure 4-9 Expression and purification of untagged Gadd45. 
Coomassie-stained gels in this figure are 12% SDS-polyacrylamide and equal volumes of elution 
fractions were analyzed. a) Expression trial. Lane 1 = marker, lanes 2 - 6: pre-induction, after 30 
minutes, I hours, 2 hours and 3 hours of induction. b) Purification on Phenyl Sepharose. Lane 1 = 
marker, lane 2 = after lysate/AS cut, lane 3 = flow through. lane 4 = wash at 0.2 M AS, lanes 5 - 12 = 
alternate fractions of elution. Elution of Phenyl Sepharose started at 0.2 M AS instead of 0.4 M AS, so 
Gadd45 eluted in 0.2 M AS wash. c) Purification on Superdex 200 column. Lane 1 = marker, lane 2 
pool of fractions of lane 4 and 5 from b) (2.5 mg/ml), lanes 3 - 14 = subsequent elution fractions. 
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4.4.2.3 GST and GST-Gadd45 constructs 
Expression trials were carried out for all three GST-Gadd45 fusion proteins. Good 
levels of over-expression were achieved, for all three fusion constructs, by induction 
for 3 hours at 37 °C with 1 mM IPTG (Figure 4-10). 
The calculated molecular weights of the constructs were 31 kDa for GST-Gadd45 
(93-137), 29.7 kDa for GST-Gadd45 (137-165) and 34.2 kDa for GST-Gadd45 (95-
165). GST-Gadd45 (93-137) ran at about 32.5 kDa which is close to its calculated 
weight, GST-Gadd45 (137-165) was visible as a band running slightly lower than its 
calculated molecular weight. 
 





Figure 4-10 Expression trial of GST- Gadd45 constructs. 
12% SDS-polyacrylamide gels were stained with coomassie. Equal amounts of culture volume were 
analyzed. a) Fragments 93-137 and 137-165, lane 1 = marker, lanes 2 + 4 = pre-induction 93-137, lane 
3 + 5 = 3 hours after induction, lanes 6 + 8 = pre-induction, lanes 7+ 9 = 3 hours after induction b) 
fragment 95-165. Lane 1 = marker, lane 2 = pre-induction, lane 3 = 3 hours after induction 
Interestingly, the largest construct GST-Gadd45 (95-165) ran between those first two 
constructs, with an apparent molecular weight of approximately 30 kDa. It is worth 
noting that residues 95-165 contain 8 proline residues in total. The constrained 
conformation of the peptidyl-prolyl bond, and the resultant 'kinks" it creates in the 
polypeptide chain, can result in proteins that contain a higher than normal prevalence 
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of proline residues running with higher or lower apparent molecular weights on SDS 
polyacrylamide gels depending on the shape of the kink. This might explain a higher 
than expected apparent molecular weight of this construct. 
After expression of the three constructs they were purified utilizing a protocol with 
ion-exchange and affinity chromatography steps (Figure 4-11, Figure 4-12), as 
described above. The proteins were either judged to be sufficiently pure after the 
glutathione column or required a further 'polishing' gel filtration step, as in the case 
of GST-Gadd45 (137-165) (Figure 4-13). 
1 	2 3 	4 	5 	6 	7 8 	9 	10 
a 	 - 
1 	234 S6 7 
	





Figure 4-11 Purification of GST constructs on a MonoQ column. 
a) GST-Gadd45 (93-137): lane I = marker, lane 2 = flow through, lanes 3-10 = selected elution peaks 
fractions b) GST-Gadd45 (137-165) and GST only: lane 1 = marker, lane 2 = GST-Gadd45 (137-165) 
lysate, lane 3 = flow through, lanes 4 to 7 = selected elution peak fractions, lane 8 = GST only lysate, 
lane 9 = flow through, lanes 10-13 = selected elution peak fractions. 12% SDS-polyacrylamide gels 
were stained with coomassie. Equal amounts of fraction volume were analyzed. 
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Figure 4-12 Purification of GST constructs on a GST FF column. 
a) GST-Gadd45(93-137): lane 1 = marker, lane 2 = pool from MonoQ step, lane 3-10 = subsequent 
elution fractions b) GST-Gadd45(137-165) and GST: lanel = marker, lane 2 = GST-Gadd45(137-165) 
pool from MonoQ step, lane 3-9 = subsequent elution fractions, lane 10 = GST pool from MonoQ 
step, lanes 11-14 = subsequent elution fractions. 12% SDS-polyacrylamide gels were stained with 
coornassie. Equal amounts of fraction volume were analyzed. 
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The supernatant from cells expressing GST-Gadd45 (95-165) only contained small 
amounts of the tagged fusion-protein. Most of the protein was found insoluble in the 
cell debris pellet (Figure 4-14a). For enrichment the lysate was applied directly to the 
GST FF column and following elution of the fusion protein with reduced glutathione, 
subjected to ion exchange chromatography on a MonoQ column. The apparent lack 
of solubility of most of the expressed protein was not observed for the other two 
constructs. It is suggestive of an inherent instability/solubility problem for the largest 
Gadd45 fusion protein. 
1 2 3 4 5 6 7 8 9 10 11 12 
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Figure 4-13 Purification of GST-Gadd45 (137-165) on Superdex 200. 
Lane 1 = marker, lane 2 = pool from GST FF step, lanes 3-12 = subsequent elution fractions. A 12% 
SDS-polyacrylamide gel was run with equal amounts of fraction volume and stained with coomassie. 
All three GST fusion constructs showed signs of instability in terms of the fusion 
partner losing their GST tag (Figure 4-12, Figure 4-14). A lower molecular weight 
band runs below the GST fusion band and could correspond to GST alone, which has 
a molecular weight of-- 26 kDa, or an intermediate break-down product(s). 
This breakdown instability was most prevalent for the GST-Gadd45 (95-165) fusion 
protein (Figure 4-14) and manifested itself most obviously following the glutathione 
(Fast Flow) step. 
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Figure 4-14 Purification of GST-Gadd45(95-165) on GST FF and MonoQ. 
a) GST-FF step: lane 1 = marker, lane 2 = lysate before centrifugation, lane 3 = supernatant after 
centrifugation, lane 4 = pellet, lane 5 = flow through after GST FF, lanes 6-11 = subsequent elution 
fractions b) MonoQ step: lane 1 = marker, lanes 2-10 = subsequent elution fractions. 12°/o SDS-
polyacrylamide gels were run with equal amounts of fraction volume and stained with coomassie 
As the Gadd45 constructs were going to be used in in vitro solution binding assays, 
they were tested to see whether the shorter Gadd45 fragments were accessible to the 
solvent and available for interaction with other proteins or if they had become 
occluded/included by being proximal to GST. 
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Figure 4-15 Thrombin digest of GST-Gadd45(93-137) and GST-Gadd45(137-165) on 18% SDS 
PAGE with various protein amounts. 
a) Lane 1 = marker, lane 2 + 3 = undigested and digested GST-Gadd45(93-137) respectively, lane 4 + 
5 = undigested and digested GST-Gadd45(137-165), lane 6 =purified GST only. 0.35 til of each 
sample were loaded b) lane 1 = marker, lane 2 + 3 = undigested and digested GST-Gadd45(93-137) 
respectively, amount loaded = 11.il of each sample. Lane 4+5, same as 2+3, but with 3i.tl of each 
sample loaded, lanes 6-9 like 2-5, but with GST-Gadd45(137-165) 
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Therefore the peptides were cleaved from the GST tag by thrombin (only for Gadd45 
93-137 = 4909 Da and Gadd45 137-165 = 3624 Da). 
The cleavage of peptides from the GST tag was successful (Figure 4-15) as cleaved 
peptides and tag-free protein could clearly be distinguished from the uncleaved 
construct. Unfortunately, the incubation time for the digestion might have been too 
long as only little peptide was present in the samples in comparison to cleaved 
protein which suggests that some of the peptide might have been destroyed by 
unspecific thrombin activity. The resolving power of the 18% SDS polyacrylamide 
gel was not high enough to give realistic values of the molecular weight of the two 
peptides. The large differences of apparent molecular, weight might be due to the 
same reason that leads to the variations of apparent molecular weight in the GST-
Gadd45 constructs prior digestion. 
4.4.3 Oligomeric state of full-length Gadd45 
As part of the purification protocol both hexa His-tagged and untagged Gadd45 were 
subjected to analytical gel filtration using a Superdex 200 HR 10/30 column. 
Hexa His-Gadd45 eluted from a Talon-NTA column between - 50 mM and —160 
mM imidazole. When samples of selected fractions across the elution gradient were 
applied to a Superdex 200 column, it was apparent that the protein eluting at higher 
imidazole concentrations contained higher order multimers compared to fractions 
from earlier in the imidazole gradient (Figure 4-16). 
At all concentrations tested, Gadd45 elufed as a mixed oligomeric population, 
including large aggregates that eluted in the void volume (>1.3 MDa). However, the 
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occurrence of higher order oligomers was directly related to higher protein 
concentrations. A sample of the protein eluted in the earlier part of the imidazole 
gradient was concentrated from 0.3 mg/ml (-14 riM) (Figure 4-16) to 2.5 mg/ml 
(-115 .tM) and run on the Superdex 200 gel filtration which yielded just protein in 
the void volume. This suggests that aggregation is concentration dependent. Addition 
of 10% glycerol as well as 2 mM DTT resulted in a minimal stabilizing effect on the 
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Figure 4-16 Elution profile of various hexa His-Gadd45 fractions from Talon-NTA on a 
Superdex 200 column. 
The boxes show the imidazole concentration at which the protein was eluted from a Talon-NTA 
column. Protein which eluted at a low imidazole concentration contains more of a species of about 
29.7 kDa, as well as 64.6 kDa and about 97 kDa. With increasing imidazole concentration protein was 
eluted that contained more of higher molecular weight species. Only small amounts appeared in the 
void volume, which is due to the very low total protein concentration. The calculated molecular 
weight of hexa His-Gadd45 is 20.5 kDa, so it seems that the smallest species present runs half way 
between a monomer and a dimer. (15.63 ml = 29716 Da, 14 ml = 64662 Da, 13.15 ml = 96896 Da) 
Furthermore, untagged Gadd45 was purified using an AS cut to 1 M final 
concentration and a phenyl sepharose HIC step. Even at 10 times higher 
concentration hexa His-Gadd45 did not aggregate as badly compared to when it was 
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Figure 4-17 Elution profile of hexa His-Gadd45 on Superdex 200. 
The same protein sample was applied to the column in 25 mM Tris pH 7.5, 200 mM NaC1 plus just 
10% glycerol (magenta) or both 10% glycerol and 2 mM DTT(blue). There seems to be a slight 
difference in the latter run, which contains proportionally more of the 29.7 kDa species than the other 
run, which suggest a small stabilizing effect of glycerol and DTT together. 
Figure 4-18 Hexa His-Gadd45 purified using conventional methods. 
The protein coming off the Phenyl Sepharose was pooled, concentrated and applied to a Superdex 200 
column. Despite a large amount of the protein ending up in the void volume, a lot of the protein is still 
present as the 29.7kDa and 64.6kDa species. A similar concentration of NTA purified protein 
aggregated completely (data not shown). 
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The previously published gel filtration studies on untagged full-length Gadd45 
carried out on a S200 column and cross-linking experiments suggested Gadd45 had a 
natural tendency to oligomerize, however it appeared to be predominantly dimers 
(Kovaisky et al., 2001). The apparent affinity for self-association was calculated to 
be 2.5 .tM. 
Untagged Gadd45 purified using the non-metal affinity/conventional 
chromatographic methods approach ran as a single species (Figure 4-19), with an 
apparent molecular weight of 29.7 kDa. There was, however, protein in the void 
volume. 
Furthermore, Kovalsky et al. (Kovalsky et al., 2001) realized that Ni-purified protein 
was not able to protect DNA in a nucleosome assay and had an increased level of 
oligomerization which is consistent with our findings. As no protection in general 
was observed with Gadd45 on naked DNA, it is assumed that the interaction between 
Gadd45 and nucleosomes is probably due to protein/protein complex formation with 
histones. 
The authors predicted hence that the mode of interaction is dependent on the 
oligomeric status of Gadd45, which could also be a regulating step for Gadd45, 
assuming that a certain level of oligomerization in the cell is natural and not an 
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Figure 4-19 Untagged Gadd45 appears to run as a dimer. 
Despite the high amount of protein in the void volume untagged Gadd45 purified using conventional 
methods seems to be less prone to aggregation into various multimeric states than hexa His-Gadd45 
4.4.4 Interaction of human PCNA and full-length Gadd45 
4.4.4.1 Pull-down (depletion) assay 
Pull-down experiments were carried out to analyze the ability of hexa His-tagged 
Gadd45 to bind human PCNA. Human PCNA does not bind to the NTA-Talon resin 
on its own (Figure 4-20, Lane 3). The band of 0.25 .tM Gadd45 without resin (lane 
4) and the one with 1 .tM Gadd45 plus resin and PCNA (lane 8) show about the 
same amount of free protein in the supernatant. As the resin has a maximum binding 
capacity of about 5-10 mg/ml even most of the His-tagged protein of the highest 
concentration (20 .tM, lane 11) should be bound to the resin and hence not appear on 
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the gel. This further points towards misfolding/aggregation of Gadd45 leading to 
occlusion of the stretch of histidine residues necessary for resin binding. 
Unsurprisingly, the amount of human PCNA in the supernatant does not change 
which shows a lack of affinity of hPCNA for His-tagged Gadd45 purified in the 
stated way. 
As mentioned above the way of purification, the concentration and the presence of a 
tag influences the degree of aggregation. 
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Figure 4-20 Pull-down binding assay of hexa His-Gadd45 and PCNA. 
A 12% SDS-polyacrylamide gel was run with equal amounts of supernatant and stained with 
coomassie. 
It appears that hexa His-Gadd45 is not able to bind to PCNA as the latter protein remains in the 
supernatant despite addition of Gadd45 in molar excess. Also most of Gadd45 does not get bound to 
the resin, which suggests a folding problem with this protein. However, a positive binding result in 
this assay would require a fairly tight and stable association between both proteins. A transient 
interaction would probably be missed. Key: lane I = marker, lane 2 = 1 PM PCNA, lane 3 = 1 jiM 
PCNA + resin, lane 4 = 0.25 j.tM Gadd45, lane  = 20 jiM Gadd45 + resin, lanes 6-11 = 0.25, 0.5, 1, 
5, 10, 20 jiM Gadd45 + resin + lp.M PCNA. 
4.4.4.2 Gel filtration studies 
200 tl samples were run on a Superdex 200 column with 50 .tM untagged Gadd45 
and 50 j.iM or 250 jiM hPCNA. hPCNA eluted at about 12.69 ml and Gadd45 at 
15.63 ml (Figure 4-21). There is a tiny shift towards a higher retention volume for 
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hPCNA (12.81 ml) at the higher concentration. According to a calibration curve (Dr. 
Martin Wear) Gadd45 eluted as 29.7 kDa and hPCNA as 120.6 kDa at 12.69 ml and 
113.9 kDa at 12.81 ml. Although the over all mass of trimeric hPCNA is about 90 
kDa, it has been shown previously that it elutes as a protein with a higher mass due 
to the ring-shape with cavity. Gadd45 has been shown to occur in a mainly dimeric 
form (Kovalsky et al., 2001), but 29.7 kDa lies in between a monomer and a dimer of 
Gadd45 (18.3 kDa). The structure of the closely related mouse CR6 is now known 
(Schrag et al., 2008) and its shape is of a globular nature. The authors of the paper 
suggest fairly globular dimer possibilities, which could explain a retention volume 
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Figure 4-21 Testing untagged Gadd45/PCNA complex formation using a Superdex 200 gel 
filtration column. 
Incubation of proteins together did not yield any significant differences in elution volume in 
comparison with running the proteins separately, which suggests a lack of interaction between these 
two proteins under given conditions. It is worth mentioning that this assay is also more suitable to 
pick up tight and stable interactions as in the case of the pull-down assay in 3.4.1. Key: Blue trace = 
50.tM hPCNA, red trace = 250iM IIPCNA and 50iM Gadd45, grey trace = 501.LM Gadd45, brown 
trace = 501.LM Gadd45 and 50iM PCNA. 
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The total amount of free Gadd45 does not seem to differ at all which would suggest 
that no interaction between hPCNA and Gadd45 takes places. Neither is there any 
sign of the formation of new peak or increased trailing of existing ones which would 
be expected for complex formation. The only other peak that is present in the 
chromatogram is signifying the void volume (Mre = 1.3 MDa), presumably from 
Gadd45 aggregates. 
Overall the verdict is that Gadd45 and hPCNA show no sign for direct interaction, 
that Gadd45 is inherently unstable and shows a tendency for aggregation. On the 
other hand, Gadd45 might not be able to interact in this form due to misfolding. Also 
this method is best suited to pick up tight interactions (-. < 10 j.tM) and ones with 
rapid kinetics, so a possible weak interaction might have been missed. 
4.4.4.3 SPR 
Further analysis of the putative hexa His-Gadd45: human PCNA interaction was 
performed using a surface plasmon resonance (SPR). Representative sensorgrams 
from a PCNA concentration series generated on a surface of covalently stabilized 
hexa His-Gadd45, are shown in Figure 4-22. PCNA solutions of increasing 
concentrations (195 nM, 390 nIM, 781 nM, 3125 nM, 6.25 j.tM, 12.5 .tM 25 pM and 
50 jiM) were passed over a Gadd45 surface. Figure 4-22 shows the response of the 
surface to human PCNA. The only model that was able to fit the data at all well was 
a two-state reaction which includes a reaction that allows for an internal 
conformational change upon binding. The sensorgrams have clear bi-phasic 
character, both for the association and dissociation phases. A rapid binding 
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interaction followed by a slower internal conformational rearrangement that 
stabilizes the complex could very likely explain the shape of these sensorgrams. 
However, an interaction with mass-transport limitations can also generate curves 
with a similar bi-phasic character, where interaction kinetics are faster than the flow 
rate of the cycle is able to deliver or remove material to and from the surface. A 
further complicating factor is the presence of varying amounts of glycerol in the 
samples which may affect the relative viscosities, and thus the refractive index of the 
sample, exacerbating any mass transport problems in the system. However, it should 
be noted that the mass transport coefficient (which relates rate of transfer of mass to 
the surface, through the transition zone and the dextran matrix, in the non-turbulent 
laminar flow-cell to the molecular weight, the diffusion coefficient and flow rate) 
derived from the fitting procedure is significantly higher then the normally 
considered threshold for mass transport problems for protein:ligand interactions of 
>io RU.M'.s', so the data were not affected by mass transport through the 
presence of glycerol. 
Counter to the model used in fitting, there is no evidence in the literature of a 
conformational change in PCNA upon protein or peptide binding, which is supported 
by numerous crystal structures of unliganded and complexed PCNA. Furthermore, 
gel-filtration analysis has already established the general instability of hexa His- and 
untagged Gadd45, so a non-specific interaction between human PCNA and a non-
natively foldedlmisfoldedldenatured and thus non-specifically active Gadd45 
surface, that is just generally 'sticky' is a more likely explanation for the observed 
binding responses. 
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The on-rate is 0.00022 M 1 .s 1 , which is very slow considering that the diffusion 
limited on-rate for average proteins is somewhere in the range of 5 - 10 M 1 .s 1 and 
one would have expected somewhere between 0.1 - 5 M' .s 1 for two protein of this 
size, with little conformational complexity involved in their binding, from SPR 
analysis. This is likely a further reflection of the stability/heterogeneity problems 
observed with the Gadd45 surfaces. 
The calculated equilibrium affinity (Lj) 80 .tM (response was measured 5 seconds 
before the end of the injection phase for 5 seconds) suggests a rather low affinity for 
this protein/protein interaction. This value seems at odds with the low nM affinities 
reported for the PCNA:Gadd45 interaction by other researchers (Vairapandi et al., 
2000) and it is hence unlikely to bare any biological relevance in the cell. Even 
considering that a higher localized concentration is possible (e.g. nucleus) in order to 
achieve useful, functional amounts of complex with such a weak affinity, the kinetics 
of the interaction are very slow and would appear not to be chemically sensible for 
check point/DNA regulation functions as this is likely to require rapid kinetics. 
The reverse experiment where human PCNA was immobilized on the surface of a 
sensor chip, using standard amine chemistries on a CM5 chip was attempted, but 
unfortunately proved to be unsuccessful. However, the PCNA was intolerant to the 
drop in pH (below - pH 6) and salt concentration, required to for the weak 
electrostatic interaction with the dextran surface to facilitate covalent coupling with 
the activated surface. Dropping then pH below 6 resulted in PCNA precipitating 
out of solution. 
The Kjs we calculated might be comparable with affinities calculated from ELISA 
binding assays carried out by others (Vairapandi et al., 2000), but they do not seem 
am 
to be due to any specific interactions. To sum up, we have reasons to believe that 
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Figure 4-22 SPR binding assay of hexa His-Gadd45 and PCNA. 
Increasing concentrations of PCNA (195 nM, 390 nM, 781 nM, 3125 nM, 6.25 kiM, 12.5 tM 2 5M 
and 50 .tM) were passed over the Gadd45 surface. The response to increased PCNA concentrations 
can be interpreted as a 2-state binding process with conformational change or, more likely, as non-
specific binding due to misfoldedlsticky protein. 
4.4.5 GST-Gadd45 constructs 
4.4.5.1 Interaction of GST-Gadd45 fragments with human PCNA using 
SPR 
Covalent coupling of GST-Gadd45 fragments provided a stable surface on CM5 
(CM4 for GST-Gadd45 (95-165)). Increasing concentrations of human PCNA were 
applied to the surface, but neither specific nor non-specific binding was observed. 
The lack of stickiness of the GST-Gadd45 surfaces suggest correctly folded and 
stable GST, while the C-terminal parts of Gadd45 do not appear to have an affinity 
for PCNA as even very high concentrations of human PCNA did not seem to have an 
effect. 
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The recently published crystal structure of mouse Gadd45y/CR6 shows that the 
tertiary structure of these GST-constructs is likely to be compromised due to the 
location of those regions in folded protein (Figure 4-23). 
This could explain the lack of binding in the SPR experiments, but would also lead to 




Figure 4-23 The crystal structure of mouse Gadd45y/CR6 (Schrag et al., 2008). 
The regions equivalent to residues 95-137 and residues 137-165 in hGadd45 are marked in red and 
blue, respectively. Grey dotted lines show loops that are not included in the model. The secondary 
structure elements contained in either of the fragments seem to interact with helices or strands located 
in other parts of the structure. It is hence likely that the Gadd45 fragments in our GST constructs 
might not be able to assume the secondary structure elements possibly needed for binding to PCNA. 
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4.5 SUMMARY, CONCLUSION AND FUTURE WORK 
To sum up, despite literature results claiming a direct in vitro interaction between 
recombinantly expressed PCNA and full-length Gadd45 (Vairapandi et al., 2000), 
our data fail to confirm this. While results of both gel filtration and pull-down 
depletion assays suggest no interaction, SPR data point towards a non-specific 
interaction, which is likely to be due to misfolded Gadd45. We believe, in concord 
with previous work, that Gadd45 is unstable with a tendency to aggregate. 
Private communication with Dr. Fomace implied that crystallization of full-length 
Gadd45 has been attempted and failed, which could be explained on the basis of the 
oligomeric state of hexa His-tagged Gadd45 purified using Ni-NTA resin. 
Interaction of PCNA with the C-terminal parts of Gadd45 in vitro could not be 
confirmed by our work either. 
Previously it had been found that the N-terminal residues 1-94 of Gadd45 are 
sufficient for interacting with PCNA (Hall et al., 1995a), which is at odds with the 
findings of Vaiparandi et al. Confirmative experiments could be designed in form of 
making tagged N-terminal Gadd45 constructs to use with SPR. 
Furthermore, it cannot be ruled out that the PCNA:Gadd45 interaction needs some 
sort of co-factor (e.g. DNA) for the formation of a stable complex, which could be 
investigated in the future. 
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CHAPTER 5. Final Summary and Conclusion 
This thesis is based on structural and biochemical work carried out with SpPCNA 
and hPCNA. I have determined the structure of SpPCNA and so added to the 
information available about this model organism. 
As pointed out in Chapter 1 the hydrophobic pocket in PCNA and other sliding 
clamps is highly conserved. This new structure further confirms this notion. 
Having obtained a complex structure of SpPCNA with p21  (141-160) allowed us to 
compare the binding mode of the peptide to the yeast protein with the complex of 
hPCNA and p21  (141-160). This structure has hence yielded information about 
protein-protein interactions. Despite the high degree of conservation between 
hPCNA and SpPCNA and the presence of most hydrogen donors/acceptors observed 
in the human complex structure, the peptide was unable to bind to the DCL in the 
yeast protein and the C-terminal end of the peptide bound to the hydrophobic pocket 
of a nearby second PCNA molecule instead. 
In order to investigate if this is merely an artefact of crystal packing we used various 
techniques to test the affinity of peptides p21  (141-160) and p21  (141-152) for both 
SpPCNA and hPCNA. Since p21  (141-152) is missing the portion that is making the 
contacts to the IDCL in hPCNA it is expected to bind with the same affinity to 
SpPCNA as the full length peptide. Our affinity data suggest that this is the case, but 
for confirmation further experiments using both ITC and SPR should be set up with 
the two different peptides. 
The significance of the p21  (141-160) binding mode in SpPCNA in vivo is difficult 
to predict as fission yeast does not have a p21 homologue. Since the IDCL feature is 
conserved between all areas of life and since other proteins like DNA polymerase 
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seem to make interactions with this loop, it can be assumed that it also plays an 
important role in yeast protein-protein interactions. 
The second interesting feature of this structure is that the C-terminus of p21 (141 
160) is found in the hydrophobic pocket of an adjacent ring. That an untypical ligand 
can bind to the apparently specific pocket beneath the IDCL is also observed in the 
unliganded structure of SpPCNA, where histidine residues from the hexa His-tags 
are located in the pockets of adjacent rings. The unusual feature of His-tags bound to 
the hydrophobic pocket challenges somewhat the concept that this pocket is specific 
for accommodating the PIP-box binding residues found in various PCNA partner 
proteins. This finding, however, may be useful for future work on finding potential 
inhibitors for PCNA, which leads to the second part of this thesis. 
The work for this thesis also involved a search for novel drug-leads that would bind 
specifically to the hydrophobic pocket. A small molecule like that could be used as 
an anti-cancer drug agent by inhibiting DNA synthesis and other PCNA-related 
functions. A number of small drug-like molecules from in silico screening were 
tested using an FP competitive assay and a thermal denaturation assay. None of the 
compounds, however, showed any binding in either assay. 
Designing drugs based on structural information is inherently difficult and there are 
few successful examples. To find a small molecule that mimics in essence the 
interactions formed at a protein:protein interface is tricky as this usually involves a 
large number of both polar and non-polar interactions. A drug molecule, however, is 
supposed to make only a defined maximum number of interactions in order to fulfil 
the Lipinski rules. These rules ensure that the compound remains non-peptide-like, 
which is important for oral activity in humans. 
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So one reason why our selected compounds have not shown any binding may be that 
the interactions predicted by LIDEAUS are actually not enough to mimic the p21 
interaction and to bind tightly enough to be picked up in the assays. 
Furthermore, while LIDEAUS showed good fits for all selected compounds, it does 
not take into consideration rotational bonds. In solution the small molecules may 
assume a preferred conformation different to the one display in the library file. This 
could mean that there are enthalpic and entropic advantages for the molecules to stay 
in solution and to form hydrogen bonds with bulk water molecules, rather than 
replace water from the protein surface. It has been known that water molecules near a 
hydrophobic pocket are forming tighter bonds which would have to be broken up for 
compound binding. In future the use of programmes that can screen compourids 
based on their preferred conformation in solution will give rise to hits that have the 
best chance of binding to a given pocket. 
Another limiting factor is the poor solubility of many compounds in aqueous solution 
despite good logP ratings. The data suggest that this predicted value can not be relied 
on when making decisions on solubility. Hence it is possible that some compounds 
would have shown binding at a higher concentration. 
Failure in finding effective molecules may also have been down to the choice of 
libraries that were screened. AS1NEX and Specs were chosen on grounds of speed of 
delivery and price. Other compounds that would have been harder to obtain might 
have yielded a positive hit in the assays. 
There are a few points to consider when using the assays mentioned above. The FP 
competitive assay relies on a molecule to compete with the labelled PL peptide, 
which has a high affinity for PCNA. While a shift in polarization could be seen with 
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p21  (141-152) none of the compounds showed an effect. One reason may be that the 
compounds are not binding to that pocket for reasons discussed above. It is also 
possible, however, that some of the small molecules can bind to the pocket, but with 
a much lower affinity than that of the model inhibitor peptide. At maximum 
concentrations that could be obtained in the experimental buffer the compounds may 
not have been able to compete successfully with the labelled probe as their affinity 
may be fairly weak. 
The thermal denaturation assay looks at the stabilizing effect of compounds when the 
protein is exposed to increasing temperatures. The onset of unfolding starts only at 
about 40°C for most proteins and only from that point any effects of a compound on 
the protein stability can be observed. While a molecule might have a reasonable 
affinity at 25°C, at 40°C this will have potentially reduced significantly. Another 
point to consider is that even if a compound bound specifically to the pocket, the 
number of interactions with PCNA might be too few to have a stabilizing effect 
under the given conditions. 
Since PCNA does not have a specific enzymatic activity it is fairly difficult to 
develop binding assays that are both specific and sensitive. A functional assay that 
monitors DNA replication would give the opportunity to check for binding at a lower 
temperature and avoid the need for competition against high concentrations of tightly 
binding peptides. 
Finally, in an attempt to learn more about how proteins lacking the PIP-box motif 
interact with PCNA, we tried to further characterize the direct in vitro interaction 
between PCNA and Gadd45, which had been previously observed by Vaiparandi et 
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al. However, our data fail to confirm what was shown before which leads to 
questioning these previous results. 
One possible reason for failing to observe a direct interaction between PCNA and 
Gadd45 is the inherent instability of recombinantly expressed Gadd45. Although the 
method of purification has a slight effect on oligomerization states, it is possible that 
all of the protein that was used in this study was mis-folded or partially aggregated 
which would lead to a loss of function and impair its ability to bind to partner 
proteins i.e. PCNA. The instability of Gadd45 has been reported by other groups. 
Previously published Gadd45/PCNA binding results were based amongst others on 
an ELISA assay that used a method of immobilizing PCNA on the plates that may 
have deteriorating effects on it. The affinity data that this group derived from that 
assay are may be based on non-specific binding due to suboptimal quality of proteins 
used. 
Most interaction studies between Gadd45 and PCNA carried out by other groups 
involved the use of yeast-two-hybrid assays. Gadd45 is likely to be more stable in the 
cell and hence able to bind to PCNA. It is also possible that this interaction might 
need another factor freely present in yeast cells for stabilization. 
While p21 and Gadd45 compete for association with PCNA their mode of binding is 
different as Gadd45 does not contain a PIP-box motif. Gadd45 'S suppressive 
checkpoint effect is mainly due to disrupting the Cdc2-cyclin B 1 complex important 
for G2IM transition, whereas p21 can act as a Cdk-cyclin inhibitor. By developing a 
drug that mimics the interaction of Gadd45 with PCNA cell division could possibly 
be stopped by disrupting the Cdc2-cyclin BI complex which also contains PCNA 
during G2IM transition. 
176 
Finally, it may be necessary to turn to another example of the non-PIP PCNA 
partners to discover the basis of these interactions as working with Gadd45 has 
proven to be problematic. 
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